3 - Brain imaging investigation of chemotherapy-induced neurocognitive changes  pp. 19-32

Brain imaging investigation of chemotherapy-induced neurocognitive changes

By Brenna C. McDonald, Andrew J. Saykin and Tim A. Ahles

Image View Previous Chapter Next Chapter



Introduction

Structural and functional neuroimaging techniques provide a unique opportunity to examine the neural basis for cognitive changes related to cancer and its treatment. While the link between cognitive dysfunction and central nervous system (CNS) cancers (e.g., primary brain tumors, primary CNS lymphoma, brain metastases of cancer in other organ systems, etc.) or non-CNS cancers treated with prophylactic whole-brain radiation seems clear, our understanding of the causes for cognitive changes following chemotherapy for other non-CNS cancers remains much more limited. Research using a variety of neuroimaging modalities has begun to delineate the brain mechanisms for cognitive changes related to cancer and chemotherapy, across a number of cancer subtypes. This chapter will briefly summarize the cognitive domains most likely to be affected following chemotherapy, review the available data relating cognitive performance and structural and functional neuroimaging changes in various cancer populations, and suggest avenues for future work in this area.

As clinical efficacy of cancer treatment has improved survivorship, increased awareness has arisen of issues critical to the functioning and quality of life of cancer survivors. Specifically, cognitive impairment related to cancer and its treatment, including radiation, chemotherapy, and hormone therapies, has been a topic of increasing study for 20 years. While more detailed discussion of cognitive studies of changes in function related to cancer treatment can be found elsewhere in this volume, these issues will be briefly summarized here, as they form a major component from which subsequent neuroimaging research has grown.

3

Reference Title: REFERENCES

Reference Type: reference-list

Dropcho EJ (2005). Update on paraneoplastic syndromes. Curr Opin Neurol 18(3): 331–336.
Lee BN, Dantzer R, Langley KE et al. (2004). A cytokine-based neuroimmunological mechanism of cancer-related symptoms. Neuroimmunomodulation 11: 279–292.
Meyers CA, Kudelka AP, Conrad CA, Gelke CK, Grove W, Pazdur R (1997). Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res 3: 419–422.
Meyers CA, Albitar M, Estey E (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104: 788–793.
Scheibel RS, Valentine AD, O'Brien S, Meyers CA (2004). Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 16: 185–191.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004). The cognitive sequelae of standard dose adjuvant chemotherapy in women with breast cancer: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292–2299.

Reference Title: REFERENCES

Reference Type: reference-list

Adams RL, Parsons OA, Culbertson JL, Nixon SJ (1996). Neuropsychology for Clinical Practice: Etiology, Assessment, and Treatment of Common Neurological Disorders. Washington, DC: American Psychological Association.
Beck AT, Steer RA (1990). Beck Anxiety Inventory. San Antonio, TX: Psychological Corporation.
Beck AT, Steer RA, Brown GK (1996). Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
Benedict RHB (1997). Brief Visuospatial Memory Test-Revised. Lutz, FL: Psychological Assessment Resources.
Benton A (2000). Exploring the History of Neuropsychology: Selected Papers. New York: Oxford University Press.
Benton AL, Joynt RJ (1960). Early descriptions of aphasia. Arch Neurol 3: 205–222.
Benton AL, Hamsher K de S, Varney NR, Spreen O (1983). Contributions to Neuropsychological Assessment: A Clinical Manual. New York: Oxford University Press.
Bouillaud JB (1825). Recherches cliniques propres à démontrer que la perte de la parole correspond à la lésion des lobules antérieurs du cerveau, et à confirmer l'opinion de M. Gall sur le siège de l'organe du langage articulé. Arch Generales Med 8: 25∓45.
Bradshaw JL, Mattingley JB (1995). Clinical Neuropsychology: Behavioral and Brain Science. San Diego, CA: Academic Press.
Brandt J, Benedict RHB (2001). Hopkins Verbal Learning Test-Revised. Lutz, FL: Psychological Assessment Resources.
Burgess PW, Shallice T (1997). The Hayling and Brixton Tests. Bury St. Edmunds: Thames Valley Test Company.
Butcher JN, Dahlstrom WG, Graham JR, et al. (1989). Minnesota Multiphasic Personality Inventory-2 [Manual]. Minneapolis, MN: University of Minnesota Press.
Delis DC, Kramer JH, Kaplan E, et al. (2000). California Verbal Learning Test-II. New York: Psychological Corporation.
Delis DC, Kaplan E, Kramer JH (2001). Delis-Kaplan Executive Function System. New York: Psychological Corporation.
Dunn LM, Dunn LM (1997). Peabody Picture Vocabulary Test – III. Circle Pines, MN: American Guidance Service.
Folstein MF, Folstein SE, McHugh PR (1975). “Mini-mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198.
Gibson WC (1969). The early history of localization in the nervous system. In PJ Vinken & GW Bruyn (eds.) Handbook of Clinical Neurology (Vol. 2, pp. 4–14). Amsterdam: North-Holland Publishing Co.
Golden CJ (1978). Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Chicago, IL: Stoelting Company.
Goodglass H, Kaplan E (1972). The Assessment of Aphasia and Related Disorders. Philadelphia, PA: Lea & Febiger.
Goodwin DM (1989). A Dictionary of Neuropsychology. New York: Springer-Verlag.
Grant I, Adams KM (eds.) (1996). Neuropsychological Assessment of Neuropsychiatric Disorders (2nd edn.). New York: Oxford University Press.
Gronwall DMA (1977). Paced Auditory Serial-Addition task: a measure of recovery from concussion. Percept Motor Skills 44: 367–373.
Heaton RK, Chelune GJ, Talley JL, et al. (1993). Wisconsin Card Sorting Test (WCST) Manual Revised and Expanded. Odessa, FL: Psychological Assessment Resources.
Heilman KM, Valenstein E (eds.) (2003). Clinical Neuropsychology (4th edn.). New York: Oxford University Press.
Kaplan EF, Goodglass H, Weintraub S (1983). The Boston Naming Test (2nd edn.) Philadelphia, PA: Lea & Febiger.
Kløve H (1963). Clinical neuropsychology. Med Clin North Am 47: 1647–1658.
Kolb B, Whishaw IQ (2003). Fundamentals of Human Neuropsychology (5th edn.). New York: Worth Publishers.
Leach L, Kaplan E, Richards B, et al. (2000). Kaplan-Baycrest Neurocognitive Assessment. San Antonio, TX: Psychological Corporation.
Lezak MD, Howieson DB, Loring DW (2004). Neuropsychological Assessment (4th edn.). New York: Oxford University Press.
Mattis S (2001). Dementia Rating Scale-2 (Manual). Odessa, FL: Psychological Assessment Resources.
Money J (1976). A Standardised Road-Map Test of Direction Sense Manual. San Rafael, CA: Academic Therapy Publications.
Morey LC (1991). Personality Assessment Inventory. Odessa, FL: Psychological Assessment Resources.
Ogden JA (1996). Fractured Minds: A Case-Study Approach to Clinical Neuropsychology. New York: Oxford University Press.
Randolph C, Tierney MC, Mohr E, et al. (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20: 310–319.
Reitan RM, Wolfson D (1993). Halstead-Reitan Neuropsychological Battery. Tucson, AZ: Neuropsychology Press.
Robertson IH, Ward T, Ridgeway V, et al. (1994). The Test of Everyday Attention. Bury St Edmunds: Thames Valley Test Company.
Roid GH (2003). Stanford-Binet Intelligence Scale (5th edn.) Itasca, IL: Riverside Publishing.
Ruff RM, Allen CC (1996). Ruff 2 & 7 Selective Attention Test. Lutz, FL: Psychological Assessment Resources.
Scoville WE, Milner B (1957). Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 20: 11–21.
Shallice T (1982). Specific impairments of planning. Philosoph Trans Soc London B 298: 199–209.
Snaith RP, Zigmond AS (1994). The Hospital Anxiety and Depression Scale. Windsor: NFER-Nelson.
Stern RA, Javorsky DJ, Singer EA, et al. (1999). The Boston Qualitative Scoring System for the Rey-Osterrieth Complex Figure. Odessa, FL: Psychological Assessment Resources.
Strauss E, Sherman EM, Spreen O (2006). A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary (3rd edn.). New York: Oxford University Press.
Stroop JR (1935). Studies of interference in serial verbal reaction. J Exp Psychol 18: 643–662.
Walsh KW (1978). Neuropsychology: A Clinical Approach. New York: Churchill Livingstone.
Warrington EK, James M (1991). Visual Object and Space Perception Battery. Bury St Edmunds: Thames Valley Test Company.
Wechsler D (1997a). The Wechsler Adult Intelligence Scale – III. San Antonio, TX: Psychological Corporation.
Wechsler D (1997b). The Wechsler Memory Scale – III. San Antonio, TX: Psychological Corporation.
Wechsler D (1999). The Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Psychological Corporation.

Reference Title: REFERENCES

Reference Type: reference-list

Ahles TA, Saykin AJ (2002). Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3(3): 84–90.
Ahles TA, Saykin AJ (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Rev 7(3): 192–201.
Ahles TA, Silberfarb PM, et al. (1998). Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 16(5): 1954–60.
Ahles TA, Saykin AJ, et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20(2): 485–493.
Allen JC, Rosen G, et al. (1980). Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64(12): 1261–73.
Anderson-Hanley C, Sherman ML, et al. (2003). Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9(7): 967–982.
Ashburner J, Friston KF (2000). Voxel-based morphometry – the methods. NeuroImage 11(6 Pt 1): 805–821.
Ashburner J, Friston KJ (2001). Why voxel-based morphometry should be used. NeuroImage 14(6): 1238–1243.
Bandettini PA, Wong EC (1997). Magnetic resonance imaging of human brain function. Principles, practicalities, and possibilities. Neurosurg Clin North Am 8(3):345–371.
Bandettini PA, Jesmanowicz A, et al. (1993). Processing strategies for time-course data sets in functional MRI of the human brain. Magn Res Med 30(2): 161–173.
Basser PJ, Mattiello J, et al. (1994). MR diffusion tensor spectroscopy and imaging. Biophys J 66(1): 259–267.
Belliveau JW, Kwong KK, et al. (1992). Magnetic resonance imaging mapping of brain function. Human visual cortex. Invest Radiol 27(Suppl 2): S59–S65.
Brezden CB, Phillips KA, et al. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18(14): 2695–2701.
Brown MS, Simon JH, et al. (1995). MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. AJNR Am J Neuroradiol 16(10): 2013–2020.
Brown MS, Stemmer SM, et al. (1998). White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol 19(2): 217–221.
Castellon SA, Ganz PA, et al. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26(7): 955–969.
Castellon SA, Silverman DHS, et al. (2005). Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 92(3): 199–206.
Ciesielski KT, Lesnik PG, et al. (1999). MRI morphometry of mammillary bodies, caudate nuclei, and prefrontal cortices after chemotherapy for childhood leukemia: multivariate models of early and late developing memory subsystems. Behav Neurosci 113(3): 439–450.
D'Esposito M, Zarahn E, et al. (1999). The effect of normal aging on the coupling of neural activity to the bold hemodynamic response. NeuroImage 10(1): 6–14.
Donovan KA, Small BJ, et al. (2005). Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104(11):2499–2507.
Ebner F, Ranner G, et al. (1989). MR findings in methotrexate-induced CNS abnormalities. Am J Roentgenol 153(6): 1283–1288.
Eichbaum MHR, Schneeweiss A, et al. (2007). Smaller regional volumes of gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109(1): 146–156.
Ferguson RJ, Ahles TA (2003). Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 3: 215–222.
Ferguson RJ, McDonald BC, et al. (2007). Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 25(25): 3866–3870.
Fritsch G, Urban C (1984). Transient encephalopathy during the late course of treatment with high-dose methotrexate. Cancer 53(9): 1849–1851.
Glass JP, Lee YY, et al. (1986). Treatment-related leukoencephalopathy. A study of three cases and literature review. Medicine 65(3): 154–162.
Good CD, Johnsrude IS, et al. (2001). A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14: 21–36.
Harila-Saari AH, Paakko EL, et al. (1998). A longitudinal magnetic resonance imaging study of the brain in survivors in childhood acute lymphoblastic leukemia. Cancer 83(12): 2608–2617.
Heflin LH, Meyerowitz BE, et al. (2005). Re: Cancer as a risk factor for dementia: a house built on shifting sand. J Nat Cancer Inst 97(20): 1550–1551.
Hook CC, Kimmel DW, et al. (1992). Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 31(3): 262–267.
Inagaki M, Yoshikawa E, et al. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109(1): 146–156.
Jenkins V, Shilling V, et al. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94(6): 828–834.
Johnson SC, Saykin AJ, et al. (2001). Similarities and differences in semantic and phonological processing with age: patterns of functional MRI activation. Aging, Neuropsychol Cogn 8(4): 307–320.
Kanard A, Frytak S, et al. (2004). Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management. J Support Oncol 2(2): 127–132.
Kimmel DW, Wijdicks EF, et al. (1995). Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology 45(2): 374–376.
Kingma A, van Dommelens RI, et al. (2001). Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 139(3): 413–420.
Klunk WE, Engler H, et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55(3): 306–319.
Komaki R, Meyers CA, et al. (1995). Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol, Biol Physics 33(1): 179–182.
Kwong KK, Belliveau JW, et al. (1992). Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Nat Acad Sci USA 89(12): 5675–5679.
Lai S, Hopkins AL, et al. (1993). Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T: preliminary results. Magn Reson Imaging Med 30: 387–392.
Le Bihan D, Mangin JF, et al. (2001). Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 13(4): 534–546.
Lesnik PG, Ciesielski KT, et al. (1998). Evidence for cerebellar-frontal subsystem changes in children treated with intrathecal chemotherapy for leukemia: enhanced data analysis using an effect size model. Arch Neurol 55(12): 1561–1568.
Lien HH, Blomlie V, et al. (1991). Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 179(2): 547–550.
Logothetis NK, Pauls J, et al. (2001). Neurophysiological investigation of the basis of the fMRI signal. Nature 412: 150–157.
Mazziotta JC, Toga AW, et al. (2000). Brain Mapping: The Disorders. San Diego, CA: Academic Press.
McAllister TW, Sparling MB, et al. (2001). Differential working memory load effects after mild traumatic brain injury. NeuroImage 14(5): 1004–1012.
Meyers CA, Byrne KS, et al. (1995). Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12(3): 231–235.
Meyers CA, Albitar M, et al. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104(4): 788–793.
Moonen CTW, Bandettini PA (eds.) (2000). Functional MRI. Berlin: Springer.
Ogawa S, Menon RS, et al. (1998). On the characteristics of functional magnetic resonance imaging of the brain. Annu Rev Biophys Biomol Struct 27: 447–474.
Packer RJ, Grossman RI, et al. (1983). High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol 11(3): 159–161.
Pierpaoli C, Jezzard P, et al. (1996). Diffusion tensor MR imaging of the human brain. Radiology 201(3): 637–648.
Reddick WE, Shan ZY, et al. (2006). Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer 106(4): 941–949.
Reddick WE, Laningham FH, Glass JO, Pui CH (2007). Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia. Neuroradiology 49: 889–904.
Rosen BR, Buckner RL, et al. (1998). Event-related functional MRI: past, present, and future. Proc Natl Acad Sci USA 95(3): 773–780.
Ross MH, Yurgelun-Todd DA, et al. (1997). Age-related reduction in functional MRI response to photic stimulation. Neurology 48(1): 173–176.
Saykin AJ, Ahles TA, et al. (2003a). Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8(4): 201–216.
Saykin AJ, Ahles TA, et al. (2003b). Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc 9: 246.
Saykin AJ, Wishart HA, et al. (2004). Cholinergic enhancement of frontal lobe activity in Mild Cognitive Impairment. Brain 127(7): 1574–1583.
Saykin AJ, McDonald BC, et al. (2007). Alterations in Brain Activation during Working Memory in Patients with Breast Cancer: Relation to Treatment Modality, Cancer Status and Task Performance. Available on CD-Rom in NeuroImage, Chicago, IL.
Schagen SB, van Dam FSAM, et al. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85(3): 640–650.
Shilling V, Jenkins V, et al. (2005). The effects of adjuvant chemotherapy on cognition in women with breast cancer – preliminary results of an observational longitudinal study. The Breast 14: 142–150.
Silverman DHS, Dy CJ, et al. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103(3): 303– 311.
Stemmer S, Stears J, et al. (1994). White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol 15(7): 1267–1273.
Tannock IF, Ahles TA, et al. (2004). Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22(11): 2233–2239.
Tchen N, Juffs HG, et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21(22): 4175–4183.
Toga AW, Mazziotta JC (1996). Brain Mapping: The Methods. San Diego, CA: Academic Press.
Van Dam FSAM, Schagen SB, et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Nat Cancer Inst 90(3): 210–218.
Van Oosterhout AG, Ganzevles PG, et al. (1996). Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Physics 34(5): 1037–1044.
Wagner LI, Sweet JJ, et al. (2004). Performance of Cognitively Impaired Oncology Patients and Normal Controls on Functional MRI Tasks. American Society of Clinical Oncology Annual Meeting, New Orleans, LA.
Wagner L, Sweet J, et al. (2006). Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. J Clin Oncol Suppl 24: 8500.
Wefel JS, Lenzi R, et al. (2004a). “Chemobrain” in breast carcinoma?: a prologue. Cancer 101(3): 466–475.
Wefel JS, Lenzi R, et al. (2004b). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292–2299.
Werring DJ, Clark CA, et al. (1998). The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in traumatic injury of the internal capsule. J Neurol Neurosurg Psychiatry 65: 863–869.
Werring DJ, Clark CA, et al. (1999). A direct demonstration of both structure and function in the visual system: combining diffusion tensor imaging with functional magnetic resonance imaging. NeuroImage 9(3): 352–361.
Wieneke MH, Dienst ER (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4: 61–66.
Wishart HA, Saykin AJ, et al. (2004). Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology 62: 234–238.
Yoshikawa E, Matsuoka Y, et al. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 92(1): 81–84.

Reference Title: REFERENCES

Reference Type: reference-list

Aaronson N, Ahmedzai S, Bergman V, et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85: 365–376.
Ahles TA, Silberfarb PM, Herndon J, 2nd, et al. (1998). Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 16: 1954–1960.
Ahles TA, Saykin AJ, Furstenberg CT, et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485–493.
Anderson SW, Damasio H, Tranel D (1990). Neuropsychological impairments associated with lesions caused by tumor or stroke. Arch Neurol 47: 397–405.
Archibald YM, Lunn D, Ruttan LA, et al. (1994). Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80: 247–253.
Arfken CL, Lichtenberg PA, Tancer ME (1999). Cognitive impairment and depression predict mortality in medically ill older adults. J Gerontol Series A-Biol Sci Med Sci 54: M152–M156.
Armstrong CL, Goldstein B, Shera D, et al. (2003). The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer 97: 649–656.
Baile WF (1996). Neuropsychiatric disorders in cancer patients. Curr Opin Oncol 8: 182–187.
Barona A, Reynolds CR, Chastain R (1984). A demographically based index of premorbid intelligence for the WAIS-R. J Consult Clin Psychol 52: 885–887.
Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL (2001). Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 21: 407–424.
Bezjak A, Taylor KM, Ng P, et al. (1998). Quality-of-life information and clinical practice: the oncologist's perspective. Cancer Prevent Control 2: 230–235.
Bick PA (1983). Obsessive-compulsive behavior associated with dexamethasone treatment. J Nerv Mental Dis 171: 253–254.
Brezden CB, Phillips, KA, Abdolell M, et al. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18: 2695–2701.
Cairncross JG, Kim JH, Posner JB (1980). Radiation therapy for brain metastases. Ann Neurol 7: 529–541.
Capuron L, Ravaud A, Gualde N, et al. (2001). Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26: 797–808.
Carney DN (1999). Prophylactic cranial irradiation and small-cell lung cancer [editorial; comment]. New Engl J Med 341: 524–526.
Chidel MA, Suh JH, Barnett GH (2000). Brain metastases: presentation, evaluation, and management. Clevel Clin J Med 67: 120–127.
Cummings J (1990). Introduction. In: Cummings J (ed.) Subcortical Dementia. New York, Oxford University Press.
DeAngelis LM (1994). Management of brain metastases. Cancer Invest 12: 156–165.
DeAngelis LM, Delattre JY, Posner JB (1989). Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789–796.
DiMatteo MR, Lepper HS, Croghan TW (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160: 2101–2107.
Farace E, Shaffrey ME (2000). Relationship of neurocognitive impairment to QOL in malignant brain tumor patients [abstract]. J Neuropsychiatry Clin Neurosci 13: 1.
Farace E, Turkheimer E, Wilkniss S (1995). Utility of analyzing lesion location in an outcome study of traumatic brain injury [abstract]. International Neuropsychological Society. Seattle, WA. J Int Neuropsychol Soc 1.
Ferrell B, Rhiner M, Rivera LM (1993). Development and evaluation of the family pain questionnaire. J Psychosocial Oncol 10: 21–35.
Friedman MA, Meyers CA, Sawaya R (2003). Neuropsychological effects of third ventricle tumor surgery. Neurosurgery 52: 791–798; discussion 798.
Ganz PA (1998). Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? [letter; comment]. J Natl Cancer Inst 90: 182–183.
Ganz PA, Desmond KA, Leedham B, et al. (2002). Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94: 39–49 [erratum in: J Natl Cancer Inst 94:463].
Hahn CA, Dunn RH, Logue PE, et al. (2003). Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55: 992–999.
Hecaen H (1962). Clinical symptomatology in right and left hemisphere lesions. In Mountcastle VB (ed.) Interhemispheric Relations and Cerebral Dominance in Man: Baltimore, MD: Johns Hopkins University Press.
Heilman KM, Bowers D, Valenstein E (1993). Emotional disorders associated with neurological diseases. In Heilman KM, Valenstein E (eds.) Clinical Neuropsychology, 3rd edn. New York: Oxford University Press.
Hewitt M, Greenfield S, Stovall E (eds.) (2006). From Cancer Patient to Cancer Survivor: Lost in Transition. Washington DC: National Academies Press.
Hirsch FR, Paulson OB, Hansen HH, et al. (1982). Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer 50: 2433–2437.
Hochberg FH, Slotnick B (1980). Neuropsychologic impairment in astrocytoma survivors. Neurology 30: 172–177.
Hom J, Reitan RM (1984). Neuropsychological correlates of rapidly vs. slowly growing intrinsic cerebral neoplasms. J Clin Neuropsychol 6: 309–324.
Imperato JP, Paleologos NA, Vick NA (1990). Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28: 818–822.
Irle E, Peper M, Wowra B, et al. (1994). Mood changes after surgery for tumors of the cerebral cortex. Arch Neurol 51: 164–174.
Jelic V, Johansson SE, Almkvist O, et al. (2000). Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging 21: 533–540.
Keime-Guibert F, Napolitano M, Delattre JY (1998). Neurological complications of radiotherapy and chemotherapy. J Neurol 245: 695–708.
Klein M, Taphoorn MJB, Heimans JJ, et al. (2001). Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol 19: 4037–4047.
Laws ER, Shaffrey ME, Morris A, et al. (2003). Surgical management of intracranial gliomas – does radical resection improve outcome? Acta Neurochir Suppl 85: 47–53.
Lezak MD, O'Brien KP (1988). Longitudinal study of emotional, social, and physical changes after traumatic brain injury. J Learn Disabil 21:456–463.
Lezak MD, Howieson DB, Loring DW (2004). Neuropsychological Assessment (4th edn.). New York: Oxford University Press.
Lieberman AN, Foo SH, Ransohoff J, et al. (1982). Long term survival among patients with malignant brain tumors. Neurosurgery 10: 450–453.
Litofsky NS, Farace E, Anderson F Jr., et al. (2004). Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54: 358–366; discussion 366–367.
Loberiza FR Jr., Rizzo JD, Bredeson CN, et al. (2002). Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 20: 2118–2126.
Mechanick JI, Hochberg FH, Larocque A (1986). Hypothalamic dysfunction following whole-brain irradiation. J Neurosurg, 65: 490–494.
Meyers CA (2000). Quality of life of brain tumor patients. In Bernstein M, Berger, MS (eds.) Neuro-Oncology: The Essentials. New York: Thieme Medical Publishers.
Meyers CA, Brown PD (2006). The role and relevance of neurocognitive assessment in clinical trials of patients with central nervous system tumors. J Clin Oncol 24: 1305–1309.
Meyers CA, Hess KR (2003). Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neurooncology 5: 89–95.
Meyers CA, Geara F, Wong PF, et al. (2000a). Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys 46: 51–55.
Meyers CA, Hess KR, Yung WKA, et al. (2000b). Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18: 646–650.
Meyers CA, Mehta MP, Rodrigus P, et al. (2002). Motexafin gadolinium (MGD) delays neurocognitive progression in patients with brain metastases from lung cancer: results of a randomized phase III trial. Neurooncology 4: 372.
Meyers CA, Smith JA, Bezjak A, et al. (2004). Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22: 157–165.
Murray KJ, Scott C, Zachariah B, et al. (2000). Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91–04. Int J Radiat Oncol Biol Phys 48: 59–64.
Olin JJ (2001). Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park) 15: 613–618; discussion 618: 621–624.
Packer RJ, Miller DC, Shaffrey MS, et al. (1998). Intracranial neoplasms. In Rosenberg RN, Pleasure DE (eds.) Comprehensive Neurology (2nd edn.) New York: John Wiley & Sons.
Paganini-Hill A, Clark LJ (2000). Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64: 165–176.
Patchell RA (1995). Metastatic brain tumors. Neurol Clin 13: 915–925.
Patchell R, Tibbs P (1990). A randomised trial of surgery in the treatment of single metastases to the brain. New Engl J Med 22: 494–500.
Peyser JM, Rao SM, Larocca NG, et al. (1990). Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol 47: 94–97.
Pignatti F, Van Den Bent M, Curran D, et al. (2002). Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20: 2076–2084.
Price BH, Mesulam M (1985). Psychiatric manifestations of right hemisphere infarctions. J Nerv Mental Dis 173: 610–614.
Robinson B (1983). Validation of a caregiver strain index. J Gerontol 38: 344–388.
Rohling ML, Green P, Allen LM, et al. (2002). Depressive symptoms and neurocognitive test scores in patients passing symptoms validity tests. Arch Clin Neuropsychol 17: 205–222.
Roman GC, Tatemichi TK, Erkinjuntti T, et al. (1993). Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250–260.
Routh A, Khansur T, Hickman BT, et al. (1994). Management of brain metastases: past, present, and future. Southern Med J 87: 1218–1226.
Salander P, Karlsson T, Bergenheim T, et al. (1995). Long-term memory deficits in patients with malignant gliomas. J Neurooncol 25: 227–238.
Sawaya R, Rambo WM Jr., Hammoud MA, et al. (1995). Advances in surgery for brain tumors. Neurol Clin 13: 757–771.
Schagen SB, Van Dam FS, Muller MJ, et al. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85: 640–650.
Scheibel RS, Meyers CA, Levin VA (1996). Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 30: 61–69.
Sheline GE, Wara WM, Smith V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phy 6: 1215–1228.
Spiegel D (1996). Cancer and depression. Br J Psychiatry Suppl 30: 109–116.
Sundaresan N, Galicich JH, Deck MD, et al. (1981). Radiation necrosis after treatment of solitary intracranial metastases. Neurosurgery 8: 329–333.
Surma-Aho O, Niemela M, Vilkki J, et al. (2001). Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56: 1285–1290.
Taphoorn MJ, Schiphorst AK, Snoek FJ, et al. (1994). Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36: 48–54.
Tashiro M, Itoh M, Kubota K, et al. (2001). Relationship between trait anxiety, brain activity and natural killer cell activity in cancer patients: a preliminary PET study. Psychooncology 10: 541–546.
Tucha O, Smely C, Preier M, et al. (2000). Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47: 324–333; discussion 333–334.
Van Dam FS, Schagen SB, Muller MJ, et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90: 210–218.
Van De Pol M, Ten Velde GP, Wilmink JT, et al. (1997). Efficacy and safety of prophylactic cranial irradiation in patients with small cell lung cancer. J Neurooncol 35: 153–160.
Van Oosterhout AG, Ganzevles PG, Wilmink JT, et al. (1996). Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 34: 1037–1044.
Vecht CJ, Hovestadt A, Verbiest HB, et al. (1994). Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44: 675–680.
Vermeulen SS (1998). Whole brain radiotherapy in the treatment of metastatic brain tumors. Sem in Surg Oncol 14: 64–69.
Walker LG, Heys SD, Walker MB, et al. (1999). Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer. Eur J Cancer 35: 1783–1788.

Reference Title: REFERENCES

Reference Type: reference-list

Aaronson NK, Ahmedzai S, Bergman B et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international cancer trials in oncology. J Natl Cancer Inst 85(5): 365–376.
Acquadro C, Berzon R, Dubois D et al. for the PRO Harmonization Group. (2003). Incorporating the patient's perspective into drug development and communication: an ad hoc force report of the Patient-reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 6(5): 522–531.
Airaksinen E, Larsson M, Lundberg I et al. (2004). Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med 34(1): 83–91.
Airaksinen E, Larsson M, Forsell Y (2005). Neuropsychological functions in anxiety disorders in population-based samples: evidence of episodic memory dysfunction. J Psychiatr Res 39(2): 207–214.
Archibald YM, Lunn D, Ruttan LA et al. (1994). Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80: 247–253.
Beyenburg S, Bauer J, Reuber M (2004). New drugs for the treatment of epilepsy: a practical approach. Postgrad Med J 80: 581–587.
Bremner JD, Narayan M, Anderson ER et al. (2000). Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115–117.
Brown WE, Marsh J, Wolcott D et al. (1991). Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients. Neuropsychologia 29: 35–45.
Castello MA, Clerico A, Deb G et al. (1990). High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 12(3): 297–300.
Cella DF, Tulsky DS, Gray G et al. (1993). The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 11: 570–579
Chamberlain MC (1997). Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 54(5): 554–558.
Chamberlain MC, Kormanik PA (1997). Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 17(3): 230–234.
Christensen H, Griffiths K, MacKinnon A et al. (1997). A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Int Neuropsychol Soc 3: 631–651.
Crossen JR, Garwood D, Glatstein E et al. (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627–642.
Cull A, Hay C, Love SB et al. (1996). What do cancer patients mean when they complain of memory problems? Br J Cancer 74(10): 1674–1679.
Dawson-Hughes B (2001). Bone loss accompanying medical therapies. N Engl J Med 354(13): 989–991.
Derogatis LR, Morrow GR, Fetting J et al. (1983). The prevalence of psychiatric disorders among cancer patients. J Am Med Assoc 249: 751–757.
Ferguson RJ, Ahles TA (2003). Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 3(3): 215–222.
Fliessbach K, Urbach H, Helmstaedter C et al. (2003). Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60: 563–568.
Folstein MF, Folstein SE, McHugh PR (1975). A mini mental state: a practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 12: 189–198.
Geller HM, Cheng KY, Goldsmith NK et al. (2001). Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J Neurochem 78(2): 265–275.
Gregor A, Cull A, Traynor E et al. (1996). Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol 41: 55–59.
Grimm G, Stockenhuber F, Schneeweiss B et al. (1990). Improvement in brain function in hemodialysis patients treated with erythropoietin. Kidney Int 38: 480–486.
Groopman JE, Itri LM (1999). Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634.
Helfre S, Pierga J (1999). Cerebral metastases: radiotherapy and chemotherapy. Neuro-Chirurgie 45(5): 382–392.
Hochberg FH, Slotnick B (1980). Neuropsychologic impairment in astrocytoma survivors. Neurology 30: 172–177.
Huang ME, Wartella JE, Kreutzer JS (2001). Functional outcomes and quality of life in patients with brain tumors: a preliminary report. Arch Phys Med Rehabil 82: 1540–1546.
Hutchinson TA, Boyd NF, Feinstein AR et al. (1979). Scientific problems in clinical scales, as demonstrated in the Karnofsky Index of performance status. J Chronic Dis 32(9–10): 661–666.
Hwang TL, Yung WK, Estey EH et al. (1985). Central nervous system toxicity with high dose Ara-C. Neurology 35: 1475–1479.
Imperato JP, Paleologos NE, Vich NA (1990). Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28: 818–822.
Iop A, Manfredi AM, Bonura S (2004). Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 15: 712–720.
Jacobsen L, Garland M, Booth-Jones K et al. (2004). Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 28(1): 7–18 P.
Jacobson NS, Truax P (1991). Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59(1): 12–19.
Karnofsky DA, Burchenal JH (1949). The clinical evaluation of chemotherapeutic agents in cancer. In Macleod CM (ed.) Evaluation of Chemotherapeutic Agents (pp. 191–205). New York: Columbia University Press.
Kayl AE, Seabrooke LF, Meyers CA (2001). Neurobehavioral changes due to metastatic brain tumors [abstract]. Neurooncology 3(4): 339.
Keime-Guibert F, Napolitano M, Delattre J-Y (1998). Neurological complications of radiotherapy and chemotherapy. J Neurol 245: 695–708.
Lang FF, Wildrick DM, Sawaya R (2000). Metastatic brain tumors. In Bernstein M, Berger MS (eds.) Neuro-Oncology: The Essentials (pp. 329–337). New York: Thieme Medical Publishers.
Lee AW, Kwong DLW, Leung S-F et al. (2002). Factors affecting risk of symptomatic temporal lobe necrosis: Significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53: 75–82.
Lesage P, Portenoy RK (2002). Management of fatigue in the cancer patient. Oncology 16(3): 373–378.
Lewis DA, Smith RE (1983). Steroid induced psychiatric syndromes. J Affect Disord 5: 319.
Lezak MD, Howieson DB, Loring DW (2004). Neuropsychological Assessment, (4th edn.). New York: Oxford University Press.
Lieberman AN, Foo SH, Ransohoff J et al. (1982). Long term survival among patients with malignant brain tumors. Neurosurgery 10: 450–453.
Lipp HP (1999). Neurotoxicity (including sensory toxicity) induced by cytostatics. In Lipp HP (ed.) Anticancer DrugToxicity. Prevention, Management, and Clinical Pharmacokinetics (pp. 431–454). New York: Marcel Dekker Inc.
Litofsky NS, Farace E, Anderson F, Meyers CA, Huang W, Laws ER (2004). Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54(2): 358–366.
Littlewood TJ, Bajetta E, Nrtier JWR et al. (2002). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874.
Logothetis CJ, Wu KK, Finn LD et al. (2001). Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7: 1198–1203.
Loring DW, Meador KJ (2004). Cognitive side effects of antiepileptic drugs in children. Neurology 62: 872–877.
Madhyastha S, Somayaji SN, Raoe MS et al. (2002). Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 80(11): 1076–1084.
Marsh J, Brown WE, Wolcott D et al. (1991). RhuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39: 155–163.
Martignoni E, Costa A, Sinforiani E et al. (1992). The brain as a target for adrenocortical steroids: cognitive implications. Psychoneuroendocrinology 17: 343.
Meador KJ, Baker GA (1997). Behavioral and cognitive effects of lamotrigine. J Child Neurol 12 [Suppl 1]: S44–47.
Meyers CA (1997). Issues of quality of life in neuro-oncology. In Vecht CJ (ed.) Handbook of Clinical Neurology, Neuro-Oncology (Part 1) (pp. 389–409). New York: Elsevier Science.
Meyers CA, Abbruzzese JL (1992). Cognitive functioning in cancer patients: effect of previous treatment. Neurology 42: 434–436.
Meyers CA, Hess KR (2003). Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neurooncology 5(2): 89–95.
Meyers CA, Wefel JS (2003). The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: no ifs ands, buts, or sensitivity. J Clin Oncol 21(19): 3557–3558.
Meyers CA, Obbens EAMT, Scheibel RS et al. (1991a). Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68: 88–92.
Meyers CA, Scheibel RS, Forman AD (1991b). Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41: 672–676.
Meyers CA, Byrne KS, Komaki R (1995). Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12: 231–235.
Meyers CA, Kudelka AP, Conrad CA et al. (1997). Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res 3: 419–422.
Meyers CA, Geara F, Wong P-F et al. (2000). Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys 46: 51–55.
Mulhern RK, Wasserman Al, Fairclough D et al. (1988). Memory function in disease-free survivors of childhood acute lymphoblastic leukemia given central nervous system prophylaxis with or without 1800 cGy cranial irradiation. J Clin Oncol 6: 315–320.
Nerenz DR, Leventhal H, Love RR (1982). Factors contributing to emotional distress during chemotherapy. Cancer 50: 1020–1027.
Ochs J, Mulhern RK, Fairclough D et al. (1991). Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial irradiation or parenteral methotrexate: a prospective study. J Clin Oncol 9(1): 145–151.
Ortinski P, Meador KL (2004). Cognitive side effects of antiepileptic drugs. Epilepsy Behav 5: S60–S65.
Osoba D, Brada M, Yung WKA et al. (2000). Health-related quality of life patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18(7): 1481–1491.
Pavol MA, Meyers CA, Rexer JL et al. (1995). Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology 45: 947–950.
Respini D, Jacobsen PB, Thors C et al. (2003). The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 47: 273–279.
Salander P, Karlsson T, Bergenheim T et al. (1995). Long-term memory deficits in patients with malignant gliomas. J Neurooncol 25: 227–238.
Salinsky MC, Levine RL, Aubuchon JP et al. (1983). Acute cerebellar dysfunction with high-dose Ara-C therapy. Cancer 51: 426–429.
Saykin AJ, Ahles TA, McDonald BC (2003). Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8(4): 201–216.
Scheibel RS, Meyers CA, Levin VA (1996). Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 30: 61–69.
Schwartz J, Alster Y, Ben-Tal O et al. (2000). Visual loss following high-dose cytosine-arabinoside (ARA-C). Eur J Haematol 64(3): 208–209.
Steffens DC, Byrum CE, McQuoid DR et al. (2000). Hippocampal volume in geriatric depression. Biol Psychiatry 48: 301–309.
Stoudemire A, Anfinson T, Edwards J (1996). Corticosteroid-induced delirium and dependency. Gen Hosp Psychiatry 18: 196–202.
Straus DJ (2002). Epoetin alfa as a supportive measure in hematologic malignancies. Semin Hematol 39 [4 Suppl 3]: 25–31.
Taphoorn MJB, Klein M (2004). Cognitive deficits in adult patients with brain tumors. Lancet 3: 159–168.
Taphoorn MJB, Heimans JJ, Snoek FJ et al. (1992). Assessment of quality of life in patients treated for low grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 55: 372–376.
Taphoorn MJB, Schiphorst CP, Snoek JF et al. (1994). Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36: 48–54.
Tarbuck AF, Paykel ES (1995). Effects of major depression on the cognitive function of younger and older patients. Psychol Med 25: 285–296.
Tarter RE, Butters M, Beers SR (2001). Medical Neuropsychology (2nd edn.). New York: Kluwer Academic/Plenum Publishers.
Temple RM, Deary IJ, Winney RJ (1995). Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Nephrol Dial Transplant 10: 1733–1738.
Tierney A, Leonard R, Taylor J et al. (1991). Side effects expected and experienced by women receiving chemotherapy for breast cancer. Br Med J 302:272.
Troy L, McFarland K, Littman-Power S et al. (2000). Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology 9: 29–39.
Tucha O, Smely C, Preier M et al. (2000). Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47: 324–333.
Valentine AD, Passik SD, Massie MJ (2002). Psychiatric and psychosocial issues. In Levin VA (ed.) Cancer in the Nervous System (2nd edn.) (pp. 572–589). New York: Oxford University Press.
Vanderploeg RD (2000). Interview and testing: the data collection phase of neuropsychological evaluations. In Vanderploeg RD (ed.) Clinician's Guide to Neuropsychological Assessment (2nd edn.) (pp. 3–38). New Jersey: Lawrence Erlbaum Associates.
Varney NR, Alexander B, Macindoe JH (1984). Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry 141: 369–372.
Videbech P, Ravnkilde B (2004). Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 161(11): 1957–1966.
Wefel JS, Lenzi R, Theriault RL et al. (2004a). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trial. Cancer 100(11): 2292–2299.
Wefel JS, Kayl AE, Meyers CA (2004b). Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 90(9): 1691–1696.
Wefel JS, Meyers CA (2004). Tamoxifen associated neurotoxicity in women with breast cancer [abstract]. Final program 32nd Annual International Neuropsychological Society Conference: 185–186.
Wiklund I (2004). Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 18: 351– 363.
Willke RJ, Burke LB, Erickson P (2004). Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 25: 535–552.
Wolkowitz OM, Reus VI, Weingartner H et al. (1990). Cognitive effects of corticosteroids. Am J Psychiatry 147: 1297–1303.
Yaffe K, Grady D, Pressman A et al. (1998). Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 46(7): 918–920.

Reference Title: REFERENCES

Reference Type: reference-list

Ames E (1997). The Development of Romanian Orphanage Children Adopted to Canada [Final Report to the National Welfare Grants Program: Human Resources Development Canada]. Burnaby, British Columbia: Simon Fraser University.
Anderson DM, Rennier KM, Ziegler RS et al. (2001). Medical and neurocognitive late effects among survivors of childhood central nervous system tumors. Cancer 92: 2709–2719.
Anderson V (2001). Assessing executive functions in children: biological, psychological, and developmental considerations. Pediatr Rehabil 4: 119–136.
Anderson V, Moore C(1995). Age at injury as a predictor of outcome following pediatric head injury. Child Neuropsychol 1: 187–202.
Baddeley A (1993). Working memory or working attention? In: Baddeley A, Weiskrantz L (eds.) Attention: Selection, Awareness, and Control (pp. 152–170). New York: Oxford University Press.
Baddeley AD, Hitch G (1974). Working memory. In Bower GA (ed.) The Psychology of Learning and Motivation. New York: Academic Press.
Baron IS (2004). Neuropsychological Evaluation of the Child. Oxford: Oxford University Press.
Beglinger LJ, Gaydos B, Tangphao-Daniels O et al. (2005). Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 20: 517–529.
Berger K (2005). The Developing Person Through the Lifespan (6th edn.). New York: Worth Publishers.
Bleyer WA, Fallavollita J, Robison L et al. (1990). Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from Children's Cancer Study Group. Pediatric Hematol Oncol 7: 329–338.
Broca P (1865). Sur le siege de la faculte du langage articule. Bull Soc Anthropol 6: 377–396.
Brown RT, Maden-Swain A (1993). Cognitive, neuropsychological, and academic sequelae in children with leukemia. J Learn Disabil 26: 74–90.
Brown RT, Maden-Swain A, Pais R et al. (1992). Chemotherapy for acute lymphocytic leukemia: cognitive and academic sequelae. J Pediatr 121: 885–889.
Brown RT, Maden-Swain A, Walco GA et al. (1998). Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J Pediatr Psychol 23: 333–340.
Butler RW (1998). Attentional processes and their remediation in childhood cancer. Pediatr Oncol Suppl 1: 75–78.
Butler RW, Copeland DR (2002). Attentional processes and their remediation in children treated for cancer: a literature review and the development of a therapeutic approach. J Int Neuropsychol Soc 8: 115–124.
Buzier AI, de Sonneville LMJ, Van Den Heuvel-Eibrink MM et al. (2005). Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer 45: 281–290.
Chelune GJ, Baer RA (1986). Developmental norms for the Wisconsin Card Sorting Test. J Clin Exp Neuropsychol 8: 219–228.
Children's Oncology Group (2004). Long-Term Follow-up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, version 1.2. Retrieved March 20, 2008, from http://www.survivorshipguidelines.org.
Conners CK (2001). Conners' Rating Scales – Revised (CRS-R). Toronto, ON: Multi-Health Systems, Inc.
Cousens P, Waters F, Said J et al. (1988). Cognitive effects of cranial irridation in leukemia: a survey and meta-analysis. J Child Psychol Psychiatry 29: 839–852.
Dennis M, Hetherington R, Spiegler B (1998). Memory and attention after childhood brain tumors. Med Pediatr Oncol Suppl 1: 25–33.
Drachtman RA, Cole PD, Golden CB et al. (2002). Dextromethorphan is effective in the treatment of subacute methotrexate toxicity. Pediatr Hematol Oncol 19: 319–327.
Duffner PK (2004). Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10: 293–310.
Finger S (1999). Margaret Kennard on sparing and recovery of function: a tribute on the 100th anniversary of her birth. J Historical Neurosci 8: 269–285.
Finger S, Wolf C (1988). The “Kennard effect” before Kennard. The early history of age and brain lesions. Arch Neurol 45: 1136–1142.
Fletcher JM, Copeland DR (1988). Neurobehavioral effects of central nervous system prophylactic treatment of cancer in children. J Clin Exp Neuropsychol 10: 495–538.
Franzen MD, Paul D, Iverson GL (1996). Reliability of alternate forms of the Trail Making Test. Clin Neuropsychol 10: 125–129.
Fuster JM (1980). The Prefrontal Cortex. New York: Raven Press.
Fuster JM (1993). Frontal lobes. Curr Opin Neurobiol 3: 160–165.
Goldman-Rakic PS (1992). Working memory and the mind. Sci Am 267: 111–117.
Gunnar ME (2001). Effects of early deprivation: findings from orphanage reared-infants and children. In Nelson CA, Luciana M (eds.) Developmental Cognitive Neuroscience (pp. 617–629). Cambridge, MA: MIT Press.
Halstead WC (1947). Brain and Intelligence: A Quantitative Study of the Frontal Lobes. Chicago, IL: University of Chicago Press.
Hopewell JW (1998). Radiation injury to the central nervous system. Med Pediatr Oncol Suppl 1: 1–9.
Hoppe-Hirsch E, Brunet L, Laroussinie F et al. (1995). Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv Syst 11: 340–346.
Hughlings-Jackson J (1931). In Taylor J (ed.) Selected Writings of John Hughlings-Jackson. London: Hodder.
Kaplan E (1988). A process approach to neuropsychological assessment. In Boll T, Bryant BK (eds.) Clinical Neuropsychology and Brain Function: Research, Measurement, and Practice (pp. 143–155). Washington DC: American Psychological Association.
Kolb B (1995). Brain Plasticity and Behavior. New Jersey: Lawrence Erlbaum Associates.
Kolb B, Wishaw IQ (2003). Fundamentals of Human Neuropsychology (5th edn.). New York: Worth Publishers.
Langer T, Martus P, Ottensmeier H et al. (2002). CNS late-effects after ALL therapy in childhood. Part III. Neuropsychological performance in long-term survivors of childhood ALL: impairments in concentration, attention, and memory. Med Pediatr Oncol 38: 320–328.
Lashley KD (1950). In search of the engram. Symp Soc Exp Biol 4: 454–482.
Lehtinen SS, Huuskonen UE, Harila-Saari AH et al. (2002). Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer 94: 2466–2473.
Levin HS, Culhane KA, Hartmann J et al. (1991). Developmental changes in performance on tests of purported frontal lobe functioning. Dev Neuropsychol 7: 377–395.
Lezak M, Howieson DB, Loring DW (2004). Neuropsychological Assessment (4th edn.). New York: Oxford University Press.
Luria AR (1973). The Working Brain. New York: Basic Books.
Mirsky AF, Anthony BJ, Duncan CC et al. (1991). Analysis of the elements of attention: a neuropsychological approach. Neuropsychol Rev 2: 109–145.
Moleski M (2000). Neuropsychological, neuroanatomical and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15: 603–630.
Moore BD (2005). Neurocognitive outcomes in survivors of childhood cancer. J Pediatr Psychol 30: 51–63.
Mulhern RK, Butler RW (2004). Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Rehabil 7: 1–14.
Mulhern RK, Butler RW (2005). Neuropsychological late effects. In Brown RT (ed.). Pediatric Hematology/ Oncology: A Biopsychosocial Approach. New York: Oxford University Press.
Mulhern RK, Kepner JL, Thomas PR et al. (1998). Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a pediatric oncology group study. J Clin Oncol 16: 1723–1728.
Packer RJ, Goldwein J, Nicholson HS et al. (1999). Treatment of children with medulloblastoma with reduced-dose cranial spinal radiation and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17: 2127–2136.
Passler MA, Isaac W, Hynd GW (1985). Neuropsychological development of behavior attributed to frontal lobe functioning in children. Dev Neuropsychol 1: 349–370.
Penkman LC (2004). Remediation of attention deficits in children: a focus on childhood cancer, traumatic brain injury and attention deficit disorder. Pediatr Rehabil 7: 111–123.
Penkman LC, Scott-Lane L (2007). Prophylactic academic intervention for children treated with cranial radiation therapy. Dev Neurorehabil 10: 19–26.
Picard EM, Rourke BP (1995). Neuropsychological consequences of prophylactic treatment for acute lymphocytic leukemia. In Rourke BP (ed.). Syndrome of Nonverbal Learning Disabilities (pp. 282–330). New York: Guilford Press.
Posner MI, Petersen SE (1990). The attention system of the brain. Annu Rev Neurosci 13: 25–42.
Reddick WE, Glass JO, Palmer SL et al. (2005). Atypical white matter volume development in children following craniospinal irradiation. Neurooncology 7: 12–19.
Reitan RM (1974). Methodological problems in clinical neuropsychology. In Reitan RM, Davison LA (eds.) Clinical Neuropsychology: Current Status and Applications (pp. 19–46). Washington, DC: Hemisphere Publishing Corporation.
Reynolds CR, Kamphaus RW (2004). Behavior Assessment System for Children (2nd edn.). Circle Pines, MN: AGS Publishing.
Ries LAG, Eisner MP, Kosary CL et al. (eds.) (2005). SEER Cancer Statistics Review, 1975–2002, NCI. Bethesda, MD, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to SEER website 2005.
Ris MD, Noll RB (1994). Long-term neurobehavioral outcome in pediatric brain tumor patients: review and methodological critique. J Clin Exp Neuropsychol 16: 21–42.
Ris MD, Packer R, Goldwein J et al. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a children's cancer group study. J Clin Oncol 19: 3470–3476.
Rowland JH, Glidewell OJ, Sibley RF et al. (1984). Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia. J Clin Oncol 12: 1327–1355.
Rutter M (1998). Developmental catch up, and deficit, following adoption after severe global early privation. J Child Psychol Psychiatry 39: 465–476.
Schatz J, Kramer JH, Ablin A et al. (2000). Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy. Neuropsychology 14: 189–200.
Shallice T (1988). From Neuropsychology to Mental Structure. Cambridge, UK: Cambridge University Press.
Smith MA, Ries LA, Gurney JG et al. (eds.) (1999). SEER Cancer Statistics Review, 1973–1995. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. NCI. Bethesda, MD: National Institutes of Health NIH Pub. No. 99–4649.
Sohlberg M, Mateer C (1987). Attention Process Training (APT). Washington, DC: Association for Neuropsychological Research and Development.
Speechley KN, Barrera ME, Shaw A et al. (2002). Health related quality of life (HRQL) in childhood cancer survivors (<17): survivor-control comparisons and impact of age, gender and cancer type. Poster presented at the sixth World Congress of Psycho-Oncology; 2002; Banff, Alberta.
Spiegler BJ, Kennedy K, Maze R et al. (2006). Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 24: 3858–3864.
Sternberg RJ, Grigorenko EL, Bundy DA (2001). The predictive value of IQ. Merrill Palmer Q 47: 1–41.
Strother D, Pollack I, Fisher PG et al. (2002). Tumors of the central nervous system. In Pizzo PA, Poplack DG (eds.) Principles and Practice of Pediatric Oncology (4th edn.) (pp. 751–824). Philadelphia, PA: Lippincott Williams & Wilkins.
Stuss DT, Alexander MP (2000). Executive functions and the frontal lobes: a conceptual review. Psychol Res 63: 289–298.
Stuss DT, Anderson V (2004). The frontal lobes and theory of mind: developmental concepts from adult focal lesion research. Brain Cogn 55: 69–83.
Thompson RF (2000). The Brain (3rd edn.). New York: Worth Publishers.
Todd JA, Anderson VA, Lawrence J (1996). Planning skills in head injured adolescents and their peers. Neuropsychol Rehabil 6: 81–99.
Von der Weid N, Mosimann I, Hirt A et al. (2003). Intellectual outcome in children and adolescents with acute lymphoblastic leukemia treated with chemotherapy alone: Age and sex-related differences. Eur J Cancer 39: 353–365.
Walter AW, Mulhern RK, Gajjar A et al. (1999). Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol 17: 3720–3728.
Welsh MC, Pennington BF, Grossier DB (1991). A normative-developmental study of executive function: a window on prefrontal function in children. Dev Neuropsychol 7: 131–149.
Wernicke C (1874). Der aphasische Symptomenkomplex. Breslau, Poland: M. Cohn and Weigert.

Reference Title: List of Tests

Reference Type: further-reading

Abidin RR (1995). Parent Stress Index (3rd edn.). Odessa, FL: Psychological Assessment Resources.
Achenbach T (2001). Child Behavior Checklist (CBCL). Burlington, VT: ASEBA.
Beery KE, Beery NA (2004). The Beery-Buktenica Developmental Test of Visual-Motor Integration. Minneapolis, MN: NCS Pearson, Inc.
Benton AL, Hamsher KD, Vanery NR, Spreen O (1983). Contributions to Neuropsychological Assessment: A Clinical Manual. New York: Oxford University Press.
Benton AL, Sivan AB, Hamsher KD, Vanery NR, Spreen O (1994). Contributions to Neuropsychological Assessment: A Clinical Manual (2nd edn.). New York: Oxford University Press.
Brownell R (2000). Receptive One-Word Picture Vocabulary Test–2000 Edition. Novato, CA: Academic Therapy Publications.
Cohen MJ (1997). Children's Memory Scale (CMS). New York: The Psychological Corporation.
Conners CK (2001). Conners' Rating Scales – Revised (CRS-R). Toronto, ON: Multi-Health Systems, Inc.
Conners CK, Staff of Multi-Health Systems (2000). Conners' Continuous Performance Test (CPT-II). North Tonawanda, NY: Multi-Health Systems, Inc.
Corwin J, Bylsma FW (1993). Translations of excerpts from Andre Rey's Psychological Examination of Traumatic Encephalopathy and PA Osterreith's The Complex Figure Copy Test. Clin Neuropsychol 7: 3–21.
De Renzi E, Faglioni P (1978). Development of a shortened version of the Token Test. Cortex 14: 42–49.
Delis D, Kramer JH, Kaplan E, Ober BA (1994). California Verbal Learning Test – Children's Version (CVLT-C). San Antonio, TX: The Psychological Corporation.
Delis D, Kaplan E, Kramer J (2001). Delis-Kaplan Executive Function System (D-KEFS). San Antonio, TX: The Psychological Corporation.
Dunn LM, Dunn LM (1997). Examiner's Manual for the Peabody Picture Vocabulary Test (3rd edn.) (PPVT-III). Circle Pines, MN: American Guidance Service.
Elliott CD (1990). Differential Ability Scales (DAS). San Antonio, TX: The Psychological Corporation.
Gardner MF (2000). Expressive One-Word Picture Vocabulary Test–2000 Edition. Novato, CA: Academic Therapy Publications.
Gioia G, Isquith PK, Guy SC, Kenworthy L (2000). Behavior Rating Inventory of Executive Function. Odessa, FL: Psychological Assessment Resources.
Golden JC (1978). Stroop Color and Word Test. Chicago, IL: Stoelting Co.
Halstead WC (1947). Brain and Intelligence: A Quantitative Study of the Frontal Lobes. Chicago, IL: University of Chicago Press.
Harrison PL, Oakland T (2003). Adaptive Behavior Assessment System (2nd edn.) (ABAS-II). San Antonio, TX: Harcourt Assessment, Inc.
Heaton RK (1981). Wisconsin Card Sorting Test (WCST). Odessa, FL: Psychological Assessment Resources.
Hooper HE (1983). Hooper Visual Orientation Test. Los Angeles, CA: Western Psychological Services.
Kaplan EF, Goodglass H, Weintraub S (1983). The Boston Naming Test. Philadelphia, PA: Lea & Febiger.
Keller FR, Davis CM, Davis HP (1999). Memory Cards Test. Colorado Springs, CO: Colorado Assessment Tests.
Klove H (1963). Clinical neuropsychology. In Foster FM (ed.) The Medical Clinics of North America. New York: Saunders.
Knights RM, Tymchuk AJ (1968). An evaluation of the Halstead-Reitan Category Test for children. Cortex 4: 403–414.
Korkman M, Kirk U, Kemp S (1997). NEPSY: A Developmental Neuropsychological Assessment. San Antonio, TX: The Psychological Corporation.
Manly T, Robertson IH, Anderson V, Nimmo-Smith I (1999). The Test of Everyday Attention for Children: Manual (TEA-Ch). Bury St. Edmunds: Thames Valley Test Company, Ltd.
McGrew KS, Woodcock RW, Maher N (2001). The Woodcock-Johnson III Tests of Achievement (WJ3). Itsaca, IL: Riverside Publishing.
Reynolds CR, Kamphaus RW (2004). Behavior Assessment System for Children (2nd edn.) (BASC-II). Circle Pines, MN: AGS Publishing.
Roid GH (2003). Stanford-Binet Intelligence Scales (5th edn.) (SB5). Itsaca, IL: Riverside Publishing.
Shallice T (1982). Specific impairments of planning. Philos Trans R Soc Lond 298: 199–209.
Sheslow D, Adams W (2004). Wide Range Assessment of Memory and Learning (2nd edn.) (WRAML-II). Lutz, FL: Psychological Assessment Resources.
Simon HA (1975). The functional equivalence of problem solving skills. Cogn Psychol 7: 268–288.
Tiffin J, Asher EJ (1948). The Purdue Pegboard: norms and studies of reliability and validity. J Appl Psychol 32: 234–247.
Varni JW, Seid M, Rode CA (1999). The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 37(2): 126–139.
Wagner RK, Toregensen JK, Rashotte CA (1999). Examiner's Manual: The Comprehensive Test of Phonological Processing. Austin, TX: PRO-ED, Inc.
Wechsler D (1945). A standardized memory scale for clinical use. J Psychol 19: 87–95.
Wechsler D (1991). Wechsler Intelligence Scale for Children (3rd edn.) (WISC-III). San Antonio, TX: The Psychological Corporation.
Wechsler D (1997). Wechsler Adult Intelligence Scale (3rd edn.) (WAIS-III). San Antonio, TX: The Psychological Corporation.
Wechsler D (1999). Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio, TX: The Psychological Corporation.
Wechsler D (2001). Wechsler Individual Achievement Test (2nd edn.) (WIAT-II). San Antonio, TX: Harcourt Assessment, Inc.
Wechsler D (2002). Wechsler Preschool and Primary Scale of Intelligence (3rd edn.) (WPPSI-III). San Antonio, TX: The Psychological Corporation.
Wechsler D (2003). Wechsler Intelligence Scale for Children (4th edn.) (WISC-IV). San Antonio, TX: The Psychological Corporation.
Wilkinson GS (1993). WRAT-3: The Wide Range Achievement Test Administration Manual (3rd edn.). Wilmington, DE: Wide Range.

Reference Title: REFERENCES

Reference Type: reference-list

Abayomi OK (1996). Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncol 35: 659–663.
Anderson VA, Godber T, Smibert E et al. (2000). Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer 82: 255–262.
Andratschke NH, Nieder C, Price RE et al. (2005). Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 32 [2 Suppl. 3]: S67–70.
Armstrong CL, Gyato K, Awadalla AW et al. (2004). A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of the controversy. Neuropsychol Rev 14: 65–86.
Banisadr G, Quéraud-Lesaux F, Boutterin MC et al. (2002). Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 81: 257–269.
Bassant MH, Court L (1978). Effect of whole-body gamma irradiation on the activity of rabbit hippocampal neurons. Radiat Res 75: 595–606.
Bellinzona M, Gobbel GT, Shinohara C et al. (1996). Apoptosis is induced in the subependyma of young adult rats by ionizing irradiation. Neurosci Lett 208: 163–166.
Bordet R, Gelé P, Duriez P et al. (2006). PPARs: a new target for neuroprotection. J Neurol Neurosurg Psychiatry 77: 285–287.
Brown WR, Thore CR, Moody DM et al. (2005). Vascular damage after fractionated whole-brain irradiation in rats. Radiat Res 164: 662–668.
Calvo W, Hopewell JW, Reinhold HS et al. (1988). Time- and dose-related changes in the white matter of the rat brain after single doses of X rays. Br J Radiol 61: 1043– 1052.
Chiang C-S, McBride WH, Withers HR (1993). Radiation-induced astrocytic and microglial cellular hyperplasia. Radiother Oncol 29: 60–68.
Cooper JS, Fu K, Marks J et al. (1995). Late effects of radiation in the head and neck region. Int J Radiat Oncol Biol Phys 31: 1141–1164.
Cox JD, Stetz J, Pajak TF (1995). Toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 31: 1341–1346.
Crossen JR, Garwood D, Glatstein E et al. (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627–642.
El-Agamawi AY, Hopewell JW, Plowman PN et al. (1996). Modulation of normal tissue responses to radiation. Br J Radiol 69: 374–375.
Ellis F (1969). Dose, time fractionation: a clinical hypothesis. Clin Radiol 20: 1–7.
Emami B, Lyman J, Brown A et al. (1991). Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21: 109–122.
Esik O, Csere T, Stefantis K et al. (2003). A review on radiogenic Lhermitte's sign. Pathol Oncol Res 9: 115–120.
Feinstein DL (2003). Therapeutic potential of peroxisomal proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5: 67–73.
Fike JR, Goebbel GT, Martob J et al. (1994). Radiation brain injury is reduced by the polyamine inhibitor alpha-difluoromethylornithine. Radiat Res 138: 99–106.
Fowler JF (1992). Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol 2: 16–21.
Fukuda H, Fukuda A, Zhu C et al. (2004). Irradiation-induced progenitor cell death in the developing brain is resistant to erythropoietin treatment and caspase inhibition. Cell Death Differ 11: 1166–1178.
Gage FH, Kempermann G, Palmer TD et al. (1998). Multipotent progenitor cells in the adult dentate gyrus. J Neurobiol 36: 249–266.
Gordon KB, Char DH, Sagerman RH (1995). Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys 31: 1123–1140.
Grommes C, Landreth GE, Heneka MT (2004). Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 5: 419–429.
Hopewell JW, Van Den Aardweg GJMJ, Morris GM et al. (1993). Unsaturated lipids as modulators of radiation damage in normal tissues. In Horrobin DF (ed.). New Approaches to Cancer Treatment (pp. 88–106). London: Churchill Communications Europe.
Horner PJ, Palmer TD(2003). New roles for astrocytes: the nightlife of an “astrocyte”. La vida loca! Trends Neurosci 26: 597–603.
Hornsey S, Myers R, Coultas PG et al. (1981). Turnover of proliferative cells in the spinal cord after X irradiation and its relation to time-dependent repair of radiation damage. Br J Radiol 54: 1081–1085.
Hornsey S, Myers R, Jenkinson T (1990). The reduction of radiation damage to the spinal cord by postirradiation administration of vasoactive drugs. Int J Radiat Oncol Biol Phys 18: 1437–1442.
Jaenke RS, Robbins MEC, Bywaters T et al. (1993). Capillary endothelium: target site of renal radiation injury. Lab Invest 57: 551–565.
Kim JH, Brown SL, Kolozsvary A et al. (2004). Modification of radiation injury by Ramipril, inhibitor of the angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat Res 161: 137–142.
Leibel SA, Sheline GE (1991). Tolerance of the brain and spinal cord to conventional irradiation. In Gutin P, Liebel SA, Sheline GE (eds.) Radiation Injury to the Nervous System (1st edn.) (pp. 211–238). New York: Raven Press.
Limoli CL, Rola R, Giedzinski E et al. (2004). Cell-density-dependent regulation of neural precursor cells function. Proc Natl Acad Sci USA 101: 16052–16057.
Limoli CL, Giedzinski E, Baure J et al. (2006). Altered growth and radiosensitivity in neural precursor cells subjected to oxidative stress. Int J Radiat Biol 82: 640–647.
Lynch CD, Sonntag WE, Wheeler KT (2002). Radiation-induced dementia in aged rats: effects of growth hormone and insulin-like growth factor 1 [Abstract]. Neuro-Oncology 4: 354.
Macbeth FR, Wheldon TE, Girling DJ et al. (1996). Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 8: 176–181.
McCunniff AJ, Liang AJ (1989). Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys 16: 675–678.
Mildenberger M, Beach TG, McGeer EG et al. (1990). An animal model of prophylactic cranial irradiation: histologic effects at acute, early and delayed stages. Int J Radiat Oncol Biol Phys 18: 1051–1060.
Mizumatsu S, Monje ML, Morhardt DR et al. (2003). Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 63: 4021–4027.
Monje ML, Mizumatsu S, Fike JR et al. (2002). Irradiation induced neural precursor-cell dysfunction. Nature Med 8: 955–961.
Monje ML, Toda H, Palmer TD (2003). Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760–1764.
Moore BD, Copeland DR, Ried H et al. (1992). Neurophysiological basis of cognitive deficits in long-term survivors of childhood cancer. Arch Neurol 49: 809–817.
Morris GM, Coderre JA, Bywaters A et al. (1996). Boron neutron capture irradiation of the rat spinal cord: histopathological evidence of a vascular-mediated pathogenesis. Radiat Res 146: 313–320.
Moulder J, Robbins MEC, Cohen EP et al. (1998). Pharmacologic modification of radiation-induced late normal tissue injury. In Mittal BB, Purdy JA, Ang KK (eds.) Radiation Therapy (pp. 129–151). Norwell, MA: Kluwer.
Mulhern RK, Merchant TE, Gajjar A et al. (2004). Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5: 399–408.
Muller HW, Junghans U, Kappler J (1995). Astroglial neurotrophic and neurite-promoting factors. Pharmacol Ther 65: 1–18.
Nakagawa M, Bellinzona M, Seilhan TM et al. (1996). Microglial responses after focal radiation-induced injury are affected by alpha-difluoromethylornithine. Int J Radiat Oncol Biol Phys 36: 113–123.
Nakaya K, Hasegawa T, Flickinger JC et al. (2005). Sensitivity to radiation-induced apoptosis and neuron loss declines rapidly in the postnatal mouse neocortex. Int J Radiat Biol 81: 545–554.
Nieder C, Price RE, Rivera B et al. (2000). Both early and delayed treatment with growth factors can modulate the development of radiation myelopathy (RM) in rats [Abstract]. Radiother Oncol 56 [Suppl. 1]: S15.
Noel F, Gumin GJ, Raju U et al. (1998). Increased expression of prohormone convertase-2 in the irradiated rat brain. FASEB J 12: 1725–1730.
Palmer TD, Takahashi J, Gage FH (1997). The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci 8: 389–404.
Palmer TD, Willhoite AR, Gage FH (2000). Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425: 479–494.
Pekny M, Nilsson M (2005). Astrocyte activation and reactive gliosis. Glia 50: 427–434.
Pellmar TC, Lepinski DL (1993). Gamma radiation (5–10 Gy) impairs neuronal function in the guinea pig hippocampus. Radiat Res 136: 255–261.
Raff MC, Miller RH, Noble M (1983). A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303: 390–396.
Reinhold HS, Calvo W, Hopewell JW et al. (1990). Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys 18: 37–42.
Rezvani M, Birds DA, Hodges H et al. (2002). Modification of radiation myelopathy by the transplantation of neural stem cells in the rat. Radiat Res 156: 408–412.
Robbins MEC, Zhao W (2004). Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol 80: 251–259.
Rola R, Raber J, Rizk A et al. (2004). Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol 188: 316–330.
Rola R, Sarkissian V, Obenaus A et al. (2005). High-LET radiation induces inflammation and persistent changes in markers of hippocampal neurogenesis. Radiat Res 164: 556–560.
Roman DD, Sperduto PW (1995). Neuropsychological effects of cranial radiation: current knowledge and future directions. Int J Radiat Oncol Biol Phys 31: 983–998.
Rubin P, Casarett GW (1968). Clinical Radiation Pathology (Vols 1 and 2). Philadelphia, PA: WB Saunders.
Sarkissian V (2005). The sequelae of cranial irradiation on human cognition. Neurosci Lett 382: 118–123.
Schultheiss TE, Stephens LC (1992). Permanent radiation myelopathy. Br J Radiol 65: 737–753.
Schultheiss TE, Kun LE, Ang KK et al. (1995). Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 31: 1093–1112.
Shaw E, Arusell R, Scheithauer B et al. (2002). A prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a NCCTG-RTOG-ECOG Study. J Clin Oncol 20: 2267–2276.
Sheline GE, Wara WM, Smith V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6: 1215–1218.
Siegal T, Pfeffer MR, Meltzer A et al. (1996). Cellular and secretory mechanisms related to delayed radiation-induced microvessel dysfunction in the spinal cord of rats. Int J Radiat Oncol Biol Phys 36: 649–659.
Sklar CA, Constine LS (1995). Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys 31: 1113–1122.
Sminia P, Van Der Kleij AJ, Carl UM et al. (2003). Prophylactic hyperbaric oxygen treatment and rat spinal cord irradiation. Cancer Lett 191: 59–65.
Snyder JS, Kee N, Wojtowicz JM (2003). Effects of adult neurogenesis on synaptic plasticity in the rat dentate gyrus. J Neurophysiol 85: 2423–2431.
Song H, Stevens CF, Gage FH (2002). Astroglia induce neurogenesis from adult neural stem cells. Nature 417: 39–44.
Spence AM, Krohn KA, Edmonson SW et al. (1986). Radioprotection in rat spinal cord with WR-2721 following cerebral lateral intraventricular injection. Int J Radiat Oncol Biol Phys 12: 1479–1482.
Stoll G, Jander S (1999). The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 58: 233–247.
Surma-aho O, Niemalä M, Vilkki J et al. (2001). Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56: 1285–1290.
Tofilon PJ, Fike JR (2000). The radioresponse of the central nervous system: a dynamic process. Radiat Res 153: 357–370.
Van Der Maazen RWM, Kleiboer BJ, Verhagen I et al. (1991a). Irradiation in vitro discriminates between different O-2A progenitor cell subpopulations in the perinatal central nervous system of rats. Radiat Res 128: 64–72.
Van Der Maazen RWM, Verhagen I, Kleiboer BJ et al. (1991b). Radiosensitivity of glial progenitor cells of the prenatal and adult rat optic nerve studies by an in vitro clonogenic assay. Radiother Oncol 20: 258–264.
Van Den Maazen RWM, Kleiboer BJ, Berhagen I et al. (1993). Repair capacity of adult rat glial progenitor cells determined by an in vitro clonogenic assay after in vitro or in vivo fractionated irradiation. Int J Radiat Biol 63: 661–666.
Van Rossum D, Hanisch UK (2004). Microglia. Metab Brain Dis 19: 393–411.
Vaughan DW, Peters A (1974). Neuroglial cells in the cerebral cortex of rats from young adulthood to old age: an electron microscopic study. J Neurocytol 3: 405–429.
Volterra A, Meldelosi J (2005). Astrocytes from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6: 626–640.
Weitzner MA, Meyers CA, Gelke CK et al. (1995). The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75: 1151–1161.
Zhao W, Payne V, Tommasi E et al. (2007). Administration of the peroxisomal proliferator-activated receptor β agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 67: 6–9.

Reference Title: REFERENCES

Reference Type: reference-list

Ahles TA, Saykin AJ, Noll WW et al. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12: 612–619.
Alcaraz A, Rey C, Concha A et al. (2002). Intrathecal vincristine: fatal myeloencephalopathy despite cerebrospinal fluid perfusion. J Toxicol Clin Toxicol 40: 557–561.
Anderson-Hanley C, Sherman ML, Riggs R et al. (2003). Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9: 967–982.
Barton D, Loprinzi C (2002). Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer 3 [Suppl. 3]: S121–S127.
Bender CM, Yasko JM, Kirkwood JM et al. (2000). Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 9: 352–363.
Bender CM, Sereika SM, Berga SL et al. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15: 422–430.
Birgegård G, Aapro MS, Bokemeyer C et al. (2005). Cancer-related anemia: pathogenesis, prevalence, and treatment. Oncology 68 [Suppl. 1], 3–11.
Blalock JE, Smith EM (1980). Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormones and endorphins. Proc Natl Acad Sci USA 77: 5972–5974.
Blalock JE, Stanton JD (1980). Common pathways of interferon and hormonal action. Nature 283: 406–408.
Brown MS, Stemmer SM, Simon JH et al. (1998). White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am J Neuroradiol 19: 217–221.
Brown WS, Marsh JT, Wolcott D et al. (1991). Cognitive function, mood and p3 latency: effects of the amelioration of anemia in dialysis patients. Neuropsychologia 29: 35–45.
Büntzel J, Küttner K (1998). Chemoprevention with interferon alfa and 13-cis retinoic acid in the adjunctive treatment of head and neck cancer. Auris Nasus Larynx 25: 413–418.
Capuron L, Ravaud A, Miller AH et al. (2004). Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18: 205–213.
Caraceni A, Gangeri L, Martini C et al. (1998). Neurotoxicity of interferon-α in melanoma therapy: results from a randomized clinical trial. Cancer 83: 482–489.
Castellon SA, Ganz PA, Bower JE et al. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26: 955–969.
Chen Y, Lomnitski L, Michaelson DM et al. (1997). Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80: 1255–1262.
Cirelly R, Tyring SK (1995). Major therapeutic uses of interferons. Clin Immunother 3: 27–87.
Clark JW (1996). Biological response modifiers. Cancer Chemother Biol Response Modif 16: 239–273.
Crandall J, Sakai Y, Zhang J et al. (2004). 13-cis-Retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice. Proc Natl Acad Sci USA 101: 5111–5116.
Cunningham RS (2003). Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 26: 38S–42S.
Delattre JY, Posner JB (1995). Neurological complications of chemotherapy and radiation therapy. In Aminoff MJ (ed.). Neurology and General Medicine (2nd edn.) (pp. 421–445). New York: Churchill Livingstone.
Dieperink E, Willenbring M, Ho SB (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 157: 867–876.
Doolittle ND, Peereboom DM, Christoforidis GA et al. (2006). Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol 81: 81–91.
Eberling JL, Wu C, Tong-Turnbeaugh R et al. (2004). Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21: 364–371.
Egan MF, Goldberg TE, Kolachana BS et al. (2001). Effect of COMT Val108/158 met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98: 6917–6922.
Egan MF, Kojima M, Callicott JH et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257–269.
Farkkila M, Iivanainen M, Roine R et al. (1984). Neurotoxic and other side effects of high dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 70: 42–46.
Fliessbach K, Urbach H, Helmstaedter C et al. (2003). Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60: 563–568.
Garcia-Tena J, Lopez-Andreu JA, Ferris J et al. (1995). Intrathecal chemotherapy related myeloencephalopathy in a young child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 12: 377–385.
Gilbert MR, Armstrong TS (1996). Neurotoxicities. In Kirkwood J, Lotze M, Yasko J (eds.) Current Cancer Therapeutics (2nd edn.) (pp. 364–371). Philadelphia, PA: Current Medicine.
Goldman LS (1994). Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 35: 412–413.
Green HJ, Pakenham KI, Headley BC et al. (2002). Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90: 427–432.
Groopman JE, Itri LM (1999). Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634.
Haykin ME, Gorman M, van Hoff J et al. (2006). Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 76: 153–157.
Heflin LH, Meyerowitz BE, Hall P et al. (2005). Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 97: 854–856.
Honigsberger L, Fielding JW, Priestman TJ (1983). Neurological effects of recombinant human interferon. Br J Med 286: 719.
Jansen C, Miakowski C, Dodd M et al. (2005). Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum 32: 1151–1163.
Jenkins VA, Shilling V, Fallowfield L et al. (2004). Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13: 61–66.
Jenkins VA, Bloomfield DJ, Shilling VM et al. (2005). Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96: 48–53.
Jenkins V, Shilling V, Deutsch G et al. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94: 828–834.
Jensen BV (2006). Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33 [Suppl. 8]: S15–S21.
Johnson SA (2006). Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin Oncol 33 [Suppl. 8]: S22–S27.
Joshi G, Sultana R, Tangpong J et al. (2005). Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 39: 1147–1154.
Juengling FD, Ebert D, Gut O et al. (2000). Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 152: 383–389.
Kayl AE, Wefel JS, Meyers CA (2006). Chemotherapy and cognition: effects, potential mechanisms and management. Am J Ther 13: 362–369.
Keime-Guibert F, Napolitano M, Delattre JY (1998). Neurological complications of radiotherapy and chemotherapy. J Neurol 245: 695–708.
Kim YA, Chung HC, Choi HJ et al. (2006). Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36: 55–59.
Knobf MT (2006). Reproductive and hormonal sequelae of chemotherapy in women. Am J Nurs 106 [Suppl. 3]: 60–65.
Krajinovic M, Robaey P, Chiasson S et al. (2005). Polymorphisms of genes controlling homocysteine levels and IQ score following treatment for childhood ALL. Pharmacogenomics 6: 293–302.
Krause I, Valesini G, Scrivo R et al. (2003). Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115: 390–397.
Kreukels BPC, Schagen SB, Ridderinkhof KR et al. (2006). Effects of high-dose and conventional-dose adjuvant chemotherapy in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 7: 67–78.
Lacosta S, Merali Z, Anisman H (2000). Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 8: 83–90.
Largillier R, Etienne-Grimaldi MC, Formento JL et al. (2006). Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 12: 5496–5502.
Lee BN, Dantzer R, Langley KE et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11: 279–292.
Linnebank M, Pels H, Klecza N et al. (2005). MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 64: 912–913.
Lipp HP (1999). Neurotoxicity (including sensory toxicity) induced by cytostatics. In Lipp HP (ed.). Anticancer Drug Toxicity: Prevention, Management, and Clinical Pharmacokinetics (pp. 431–453). New York: Marcel Dekker, Inc.
Lipshultz SE (2006). Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 33 [Suppl. 8]: 8–14.
Madhyastha S, Somayaji SN, Rao MS et al. (2002). Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 80: 1076–1084.
Malek-Ahmadi P, Ghandour E (2004). Bupropion for treatment of interferon-induced depression. Ann Pharmacother 38: 1202–1205.
Malik UR, Makower DF, Wadler S (2001). Interferon-mediated fatigue. Cancer 92 [Suppl]: 1664–1668.
Massa E, Madeddu C, Lusso MR et al. (2006). Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57: 175–182.
Mayr N, Zeitlhofer J, Deecke L et al. (1999). Neurological function during long-term therapy with recombinant interferon alpha. J Clin Neurosci 11: 343–348.
McAllister TW, Ahles TA, Saykin AJ et al. (2004). Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatr Rep 6: 364–371.
McEwen BS, Alves SE (1999). Estrogen actions in the central nervous system. Endocr Rev 20: 279–307.
Menzies R, Phelps C, Wiranowska M et al. (1996). The effect of interferon-alpha on the pituitary-adrenal axis. J Interferon Cytokine Res 16: 619–629.
Meyers CA, Valentine AD (1995). Neurological and psychiatric effects of immunological therapy. CNS Drugs 3: 56–68.
Meyers CA, Scheibel RS, Forman AD (1991). Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41: 672–676.
Meyers CA, Kudelka AP, Conrad CA et al. (1997). Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res 3: 419–422.
Meyers CA, Weitzner MA, Valentine AD et al. (1998). Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16: 2522–2527.
Meyers JN, Whiteside TL (1996). Immunotherapy of squamous cell carcinoma of the head and neck. In Meyers EN, Suen JY (eds.). Cancer of the Head and Neck (pp. 805–817). Philadelphia, PA: WB Saunders Company.
Mihich E (2000). Historical overview of biologic response modifiers. Cancer Invest 18: 456–466.
Moleski M (2000). Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15: 603–630.
Molina JR, Barton DL, Loprinzi CL (2005). Chemotherapy-induced ovarian failure. Drug Safety 28: 401–416.
Moor BD (2005). Neurocognitive outcomes in survivors of childhood cancer. J Pediatr Psychol 30: 51–63.
Mottet N, Prayer-Galetti T, Hammerer P et al. (2006). Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98: 20–27.
Musselman DL, Lawson DH, Gumnick JF et al. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med 344: 961–966.
National Institutes of Health (2003). Biological Therapy. Treatments that use your Immune System to Fight Cancer. [Brochure]. NIH Publication No. 03–5406.
Nemeroff CB, Krishnan KR, Reed D et al. (1992). Adrenal gland enlargement in major depression: a computed tomographic study. Arch Gen Psychiatry 49: 384–387.
Okcu MF, Selvan M, Wang L et al. (2004). Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10: 2618–2625.
O'Shaughnessy JA, Svetislava JV, Holmes FA et al. (2005). Feasibility of quantifying the effects of epoetin alpha therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5: 439–446.
Pavol MA, Meyers CA, Rexer JL et al. (1995). Pattern of neurobehavioral deficits associated with interferon alpha therapy for leukemia. Neurology 45: 947–950.
Penson RT, Kronish K, Duan Z et al. (2000). Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF-alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 1: 33–41.
Pusztai L, Mendoza TR, Reuben JM et al. (2004). Changes in plasma level of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25: 94–102.
Quinn CT, Kamen BA (1996). A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med 44: 522–530.
Roe CM, Behrens MI, Xiong C et al. (2005). Alzheimer disease and cancer. Neurology 64: 895–898.
Rottenberg DA (ed.) (1991). Neurological Complications of Cancer Treatment. Boston, MA: Butterworth-Heinemann.
Saykin AJ, Ahles TA, McDonald BC (2003). Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8: 201–216.
Schaefer M, Engelbrecht MA, Gut O et al. (2002). Interferon alpha (IFN-α) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26: 731–746.
Schaefer M, Schwiger M, Pich M et al. (2003). Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 [Suppl. 3]: S203–S206.
Schagen SB, Muller MJ, Boogerd W et al. (2002). Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective. Clin Breast Cancer 3 [Suppl]: S100–S108.
Scheibel RS, Valentine AD, O'Brien S et al. (2004). Cognitive dysfunction and depression during treatment with interferon alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 16: 1–7.
Schneiderman B (2004). Hippocampal volumes smaller in chemotherapy patients. Lancet Oncol 5: 202.
Shah RR (2005). Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules. Expert Opinion Drug Safety 4: 103–128.
Shapiro CL, Recht A (2001). Drug therapy – side effects of adjuvant treatment of breast cancer. New Engl J Med 344: 1997–2008.
Sheline GE, Wara WM, Smith V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6: 1215–1228.
Shilling V, Jenkins V, Morris R et al. (2005). The effects of adjuvant chemotherapy on cognition in women with breast cancer – preliminary results of an observational longitudinal study. Breast 14: 142–150.
Shin DM, Khuri FR, Murphy B et al. (2001). Combined interferon-alpha, 13-cis-retinoic acid, and alpha tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19: 3010–3017.
Shin DM, Glisson BS, Khuri FR et al. (2002). Phase II and biological study of interferon alpha, retinoic acid, and cisplatin in advanced squamous cell skin cancer. J Clin Oncol 20: 364–370.
Shuper A, Stark B, Kornreich L et al. (2000). Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 15: 573–580.
Silverman DH, Dy CJ, Castellon SA et al. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103(3): 303–311.
Smedley H, Katrak M, Sikora K et al. (1983). Neurological effects of recombinant interferon alpha. Br Med J 286: 262–264.
Smith A, Tyrrell D, Coyle K et al. (1988). Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology 96: 414–416.
Spiegel RJ (1989). The alpha interferons: clinical overview. Urology 34: 75–79.
Staat K, Segatore M (2005). The phenomenon of chemo brain. Clin J Oncol Nurs 9: 713–721.
Steinherz LJ, Yahalom J (1993). Cardiac complications of cancer therapy. In DeVita VT, Jr., Hellman S, Rosenberg SA (eds.) Cancer Principles and Practice of Oncology (4th edn.) (pp. 2370–2385). Philadephia, PA: J.B. Lippincott Company.
Strite D, Valentine AD, Meyers CA (1997). Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry 9: 273–276.
Sul JK, DeAngelis LM (2006). Neurologic complications of cancer chemotherapy. Semin Oncol 33: 324–332.
Taphoorn MJB, Klein M (2004). Cognitive deficits in adult patients with brain tumors. Lancet Neurol 3: 159–168.
Taylor JL, Grossberg SE (1998). The effects of interferon-α on the production and action of other cytokines. Semin Oncol 25 [Suppl. 1]: S3–S29.
Tompkins WA (1999). Immunomodulation and therapeutic effects of the oral use of interferon-α: mechanism of action. J Interferon Cytokine Res 19: 817–828.
Tsavaris N, Kosmas C, Vadiaka M et al. (2002). Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21–27.
Valentine AD, Meyers CA (2005). Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 7: 391–395.
Valentine AD, Meyers CA, Talpaz M (1995). Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 13: 561–566.
Valentine AD, Meyers CA, Kling MA et al. (1998). Mood and cognitive side effects of interferon-α therapy. Semin Oncol 25: 39–47.
Wagner LI, Sweet JJ, Desa J et al. (2005). Prechemotherapy hemoglobin (Hgb) and cognitive impairment among breast cancer patients. J Clin Oncol 23: 760S.
Wefel JS, Meyers CA (2005). Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 97: 788–789.
Wefel JS, Lenzi R, Theriault R et al. (2004a). “Chemobrain” in breast cancer? A prologue. Cancer 101: 466–475.
Wefel JS, Lenzi R, Theriault R et al. (2004b). The cognitive sequelae of standard dose adjuvant chemotherapy in women with breast cancer: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292–2299.
Weiss RB, Vogelzang NJ (1993). Miscellaneous toxicities. In DeVita VT, Jr., Hellman S, Rosenberg SA (eds.) Cancer Principles and Practice of Oncology (4th edn.) (pp. 2349–2358). Philadelphia, PA: JB Lippincott Company.
Wood LJ, Nail LM, Gilster A et al. (2006). Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33: 535–542.
Yaffe K, Sawaya G, Lieberburg I et al. (1998). Estrogen therapy in postmenopausal women effects of cognitive function and dementia. J Am Med Assoc 279: 688–695.
Yoshikawa E, Matsuoka Y, Inagaki M et al. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 92: 81–84.
Zaloga GP, Bhatt B, Marik P (2001). Critical illness and systemic inflammation. In Becker KL (ed.) Endocrinology and Metabolism (3rd edn.) (pp. 2068–2076). Philadelphia, PA: Lippincott Williams & Wilkins.

Reference Title: REFERENCES

Reference Type: reference-list

Almeida OP, Waterreus A, Spry N et al. (2004). One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29: 1071–1081.
Azad N, Pitale S, Barnes WE et al. (2003). Testosterone treatment enhances regional brain perfusion in hypogonadal men. J Clin Endocrinol Metab 88: 3064–3068.
Barrett-Connor E, Kritz-Silverstein D (1993). Estrogen replacement therapy and cognitive function in older women. J Am Med Assoc 269: 2637–2641.
Beer TM, Bland LB, Bussiere JR et al. (2006). Testosterone loss and estradiol administration modify memory in men. J Urol 175: 130–135.
Bender CM, Paraska KK, Sereika SM et al. (2001). Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manag 21: 407–424.
Benson JR (2002). Re: The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94: 1336–1337.
Bowen RL, Martins RN, Gregory CW et al. (2005). Dementia and testosterone levels in men. J Am Med Assoc 293: 551.
Chen D, Wu CF, Shi B et al. (2002a). Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav 71: 269–276.
Chen D, Wu CF, Shi B et al. (2002b). Tamoxifen and toremifene impair retrieval, but not acquisition, of spatial information processing in mice. Pharmacol Biochem Behav 72: 417–421.
Cherrier MM, Asthana S, Plymate S et al. (2001). Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57: 80–88.
Cherrier MM, Rose AL, Higano C (2003). The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170: 1808– 1811.
Cholerton B, Gleason CE, Baker LD et al. (2002). Estrogen and Alzheimer's disease: the story so far. Drugs Aging 19: 405–427.
Cook IA, Morgan ML, Dunkin JJ et al. (2002). Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study. Int J Geriatr Psychiatry 17: 610– 618.
Drake EB, Henderson VW, Stanczyk FZ et al. (2000). Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 54: 599–603.
Eberling JL, Reed BR, Coleman JE et al. (2000). Effect of estrogen on cerebral glucose metabolism in postmenopausal women. Neurology 55: 875–877.
Eberling JL, Wu C, Tong-Turnbeaugh R et al. (2004). Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21: 364–371.
Ernst T, Chang L, Cooray D et al. (2002). The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94: 592–597.
Espeland MA, Rapp SR, Shumaker SA et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 291: 2959–2968.
Fonda SJ, Bertrand R, O'Donnell A et al. (2005). Age, hormones, and cognitive functioning among middle-aged and elderly men: cross-sectional evidence from the Massachusetts Male Aging Study. J Gerontol A Biol Sci Med Sci 60: 385–390.
Ganz PA, Castellon SA, Silverman DH (2002). Estrogen, tamoxifen, and the brain. J Natl Cancer Inst 94: 547–549.
Gleason CE, Cholerton B, Carlsson CM et al. (2005). Neuroprotective effects of female sex steroids in humans: current controversies and future directions. Cell Mol Life Sci 62: 299–312.
Goss PE, Strasser K (2001). Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881–894.
Green HJ, Pakenham KI, Gardiner RA (2000). Effects of luteinizing hormone releasing hormone analogs on cognition in women and men: a review. Psychol Health Med 5: 407–418.
Green HJ, Pakenham KI, Headley BC et al. (2002). Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90: 427–432.
Hampson E (1990). Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 14: 26–43.
Haren MT, Wittert GA, Chapman IM et al. (2005). Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 50: 124–133.
Hausmann M, Slabbekoorn D, Van Goozen SH et al. (2000). Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci 114: 1245–1250.
Hellerstedt BA, Pienta KJ (2002). The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154–179.
Henderson VW, Guthrie JR, Dudley EC et al. (2003). Estrogen exposures and memory at midlife: a population-based study of women. Neurology 60: 1369–1371.
Herr HW, O'Sullivan M (2000). Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163: 1743–1746.
Hogervorst E, Williams J, Budge M et al. (2001). Serum total testosterone is lower in men with Alzheimer's disease. Neuroendocrinol Lett 22: 163–168.
Hogervorst E, De Jager C, Budge M et al. (2004). Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology 29: 405–421.
Janowsky JS, Chavez B, Orwoll E (2000). Sex steroids modify working memory. J Cogn Neurosci 12: 407–414.
Jenkins VA, Bloomfield DJ, Shilling VM et al. (2005). Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96: 48–53.
Juul A, Skakkebaek NE (2002). Androgens and the ageing male. Hum Reprod Update 8: 423–433.
Kenny AM, Bellantonio S, Gruman CA et al. (2002). Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 57: M321–M325.
Luoto R, Manolio T, Meilahn E et al. (2000). Estrogen replacement therapy and MRI-demonstrated cerebral infarcts, white matter changes, and brain atrophy in older women: the Cardiovascular Health Study. J Am Geriatr Soc 48: 467–472.
Maki PM (2004). Hormone therapy and risk for dementia: where do we go from here? Gynecol Endocrinol 19: 354–359.
Maki PM, Resnick SM (2000). Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 21: 373–383.
Maki PM, Rich JB, Rosenbaum RS (2002). Implicit memory varies across the menstrual cycle: estrogen effects in young women. Neuropsychologia 40: 518–529.
Meyer PM, Powell LH, Wilson RS et al. (2003). A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology 61: 801–806.
Miller WR (1996). Estrogens and Endocrine Therapy for Breast Cancer. Estrogen and Breast Cancer. Heidelberg: Springer Verlag.
Moffat SD, Zonderman AB, Metter EJ et al. (2004). Free testosterone and risk for Alzheimer disease in older men. Neurology 62: 188–193.
Muller M, Aleman A, Grobbee DE et al. (2005). Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level? Neurology 64: 866–871.
Newton C, Slota D, Yuzpe AA et al. (1996). Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril 65: 1253–1255.
Nickelsen T, Lufkin EG, Riggs BL et al. (1999). Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24: 115–128.
Norbury R, Cutter WJ, Compton J et al. (2003). The neuroprotective effects of estrogen on the aging brain. Exp Gerontol 38: 109–117.
Nystedt M, Berglund G, Bolund C et al. (2000). Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer – self-rated physiological effects and symptoms. Acta Oncol 39: 959–968.
O'Connor DB, Archer J, Hair WM et al. (2001). Activational effects of testosterone on cognitive function in men. Neuropsychologia 39: 1385–1394.
Osborne CK, Zhao H, Fuqua SA (2000). Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172–3186.
Owens JF, Matthews KA, Everson SA (2002). Cognitive function effects of suppressing ovarian hormones in young women. Menopause 9: 227–235.
Paganini-Hill A, Clark LJ (2000). Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64: 165–176.
Phillips SM, Sherwin BB (1992). Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17: 485–495.
Rapp SR, Espeland MA, Shumaker SA et al. (2003). Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 289: 2663–2672.
Resnick SM, Maki PM, Golski S et al. (1998). Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 34: 171–182.
Rosario ER, Chang L, Stanczyk FZ et al. (2004). Age-related testosterone depletion and the development of Alzheimer disease. J Am Med Assoc 292: 1431–1432.
Salminen E, Portin R, Korpela J et al. (2003). Androgen deprivation and cognition in prostate cancer. Br J Cancer 89: 971–976.
Salminen EK, Portin RI, Koskinen A et al. (2004). Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10: 7575–7582.
Salminen EK, Portin RI, Koskinen AI et al. (2005). Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103: 1381–1387.
Sanders G, Sjodin M, de Chastelaine M (2002). On the elusive nature of sex differences in cognition: hormonal influences contributing to within-sex variation. Arch Sex Behav 31: 145–152.
Schagen SB (2002). Cognitive function following chemotherapy: a study in breast cancer patients. Ph.D Thesis. University of Amsterdam.
Schmidt R, Fazekas F, Reinhart B et al. (1996). Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc 44: 1307–1313.
Sharifi N, Gulley JL, Dahut WL (2005). Androgen deprivation therapy for prostate cancer. J Am Med Assoc 294: 238–244.
Shaywitz SE, Shaywitz BA, Pugh KR et al. (1999). Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. J Am Med Assoc 281: 1197–1202.
Sherwin BB (1988). Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 13: 345–357.
Sherwin BB (2000). Oestrogen and cognitive function throughout the female lifespan. Novartis Found Symp 230: 188–196.
Sherwin BB (2003). Steroid hormones and cognitive functioning in aging men: a mini-review. J Mol Neurosci 20: 385–393.
Sherwin BB (2005). Estrogen and memory in women: how can we reconcile the findings? Horm Behav 47: 371–375.
Sherwin BB, Tulandi T (1996). “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 81: 2545–2549.
Shilling V, Jenkins V, Fallowfield L et al. (2003). The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 86: 405–412.
Shumaker SA, Legault C, Rapp SR et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 289: 2651–2662.
Shumaker SA, Legault C, Kuller L et al. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 291: 2947–2958.
Simpson ER, Dowsett M (2002). Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 57: 317–338.
Tannock IF, Ahles TA, Ganz PA et al. (2004). Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22: 2233–2239.
Taxel P, Stevens MC, Trahiotis M et al. (2004). The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc 52: 269– 273.
Tripathy D, Benz CC (2001). Hormones and cancer. In Greenspan FS, Gardner DG (eds.) Basic and Clinical Endocrinology. New York: Lange Medical Books.
Verghese J, Kuslansky G, Katz MJ et al. (2000). Cognitive performance in surgically menopausal women on estrogen. Neurology 55: 872–874.
Visvanathan K, Davidson NE (2003). Aromatase inhibitors as adjuvant therapy in breast cancer. Oncology (Huntingt) 17: 335–342, 347.
Wolf OT, Kirschbaum C (2002). Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Horm Behav 41: 259–266.
Wolf OT, Neumann O, Hellhammer DH et al. (1997). Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 82: 2363–2367.
Yaffe K, Sawaya G, Lieberburg I et al. (1998). Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J Am Med Assoc 279: 688–695.
Yaffe K, Krueger K, Sarkar S et al. (2001). Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344: 1207–1213.
Yaffe K, Lui LY, Zmuda J et al. (2002). Sex hormones and cognitive function in older men. J Am Geriatr Soc 50: 707–712.
Yaffe K, Krueger K, Cummings SR et al. (2005). Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 162: 683–690.

Reference Title: REFERENCES

Reference Type: reference-list

Anderson SI, Taylor R, Whittle IR (1999). Mood disorders in patients after treatment for primary intracranial tumours. Br J Neurosurg 13: 480–485.
Anderson SW, Damasio H, Tranel D (1990). Neuropsychological impairments associated with lesions caused by tumor or stroke. Arch Neurol 47: 397–405.
Armstrong CL, Hunter JV, Ledakis GE et al. (2002). Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59: 40–48.
Armstrong CL, Goldstein B, Shera D et al. (2003). The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer 97: 649–656.
Ashby LS, Shapiro WR (2004). Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr Neurol Neurosci Rep 4: 211–217.
Béhin A, Delattre JY (2003). Neurologic sequelae of radiotherapy of the nervous system. In Schiff D, Wen PY (eds.) Cancer Neurology in Clinical Practice (pp. 173–192). Totowa: Humana Press.
Bondy ML, Wrensch MR (1996). Epidemiology of primary malignant brain tumours. In Yung WKA (ed.) Cerebral Gliomas (pp. 251–270). London: Ballière Tindall.
Brown PD, Buckner JC, O'Fallon JR et al. (2003). Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J Clin Oncol 21: 2519–2524.
Brown PD, Buckner JC, O'Fallon JR et al. (2004). Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 59: 117–125.
Buckner JC, Gesme D, O'Fallon JR et al. (2003). Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma and oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21: 251–255.
Cairncross JG (2000). Understanding low-grade glioma: a decade of progress. Neurology 54: 1402–1403.
Cairncross JG, Ueki K, Zlatescu MC et al. (1998). Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473–1479.
Choucair AK, Scott C, Urtasun R et al. (1997). Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91–14. Int J Radiat Oncol Biol Phys 38: 9–20.
Christensen HC, Schüz J, Kosteljanetz M et al. (2005). Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology 64: 1189–1195.
Constine LS, Konski A, Ekholm S et al. (1988). Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 15(2): 319–330.
Corn BW, Yousem DM, Scott CB et al. (1994). White matter changes are correlated significantly with radiation dose. Obervations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer 74 (10): 2828–2835.
Drane LD, Meador KJ (2002). Cognitive and behavioural effects of antiepileptic drugs. Epilepsy Behav 3: 49–53.
Dropcho EJ (2004). Low-grade gliomas in adults. Curr Treat Options Neurol 6: 265–271.
Duffau H (2006). New concepts in surgery of WHO grade II glioma: functional brain mapping, connectionism and plasticity – a review. J Neurooncol 79: 77–115.
Duffau H, Capelle L, Denvil D et al. (2003a). Functional recovery after surgical resection of low grade gliomas in eloquent brain: hypothesis of brain compensation. J Neurol Neurosurg Psychiatry 74(7): 901–907.
Duffau H, Capelle L, Denvil D et al. (2003b). Usefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions: functional results in a consecutive series of 103 patients. J Neurosurg 98(4): 764–778.
Duffau H, Khalil I, Gatignol P et al. (2004). Surgical removal of corpus callosum infiltrated by low-grade glioma: functional outcome and oncological considerations. J Neurosurg 100: 431–437.
Efird JT, Friedman GD, Sidney S et al. (2004). The risk for malignant primary adult-onset glioma in a large multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors. J Neurooncol 68: 57–69.
Fuller GN, Hess KR, Rhee CH et al. (2002). Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival and reveals clinically relevant novel glioma subsets. Brain Pathol 12: 108–116.
Ginsberg LE, Fuller GN, Hashni M et al. (1998). The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49: 436–440.
Godard S, Getz G, Delorenzi M et al. (2003). Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63: 6613–6625.
Hahn CA, Dunn RH, Logue PE et al. (2003). Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55: 992–999.
Hardell L, Carlberg M, Söderqvist F, Mild KH, Morgan (2007). Long-term use of cellular phones and brain tumours: increased risk associated with use for ≥10 years. Occup Environ Med 64: 626–632.
Hemminki K, Li X (2003). Familial risks in nervous system tumors. Cancer Epidemiol Biomarkers Prev 12: 1137–1142.
Herholz K, Hölzer T, Bauer B et al. (1998). 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 50: 1316–1322.
Hirose Y, Aldape KD, Chang S et al. (2003). Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet 142: 1–7.
Hoang-Xuan K, Capelle L, Kujas M et al. (2004). Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22: 3133–3138.
Huncharek M, Kupelnick B, Wheeler L (2003). Dietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studies. J Environ Pathol Toxicol Oncol 22: 129–137.
Idbaih A, Omuro A, Ducray F, Hoang-Xuan K (2007). Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 19: 606–611.
Iwadate Y, Sakaida T, Hiwasa T et al. (2004). Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64: 2496–2501.
Jackson RJ, Fuller GN, Abi-Said D et al. (2001). Limitations of stereotactic biopsy in the initial management of gliomas. Neurooncology 3: 193–200.
Johannesen TB, Langmark F, Lote K (2003). Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg 99: 854–862.
Jokeit H, Ebner A (1999). Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study. J Neurol Neurosurg Psychiatry 67: 44–50.
Kaloshi G, Benouaich-Amiel A, Diakite F et al. (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68: 1831–1836.
Karim ABMF, Maat B, Hatlevoll R et al. (1996). A randomised trial on dose response in radiation therapy of low grade cerebral glioma: EORTC study 22844. Int J Radiat Oncol Biol Phys 36: 549–556.
Karim ABMF, Afra D, Cornu P et al. (2002). Randomized trial on efficacy of radiotherapy for cerebral low-grade glioma in the adult. EORTC study 22845 with the MRC study BR04: an interim analysis. Int J Radiat Oncol Biol Phys 52: 316–324.
Keles GE, Lamborn KR, Berger MS (2001). Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95: 735–745.
Kiebert GM, Curran D, Aaronson NK et al. (1998). Quality of life after radiation therapy of low-grade glioma of the adult: results of a randomised phase III trial on dose response (EORTC 22844). Eur J Cancer 34: 1902–1909.
Kleihues P, Cavenee WK (eds.) (2000). World Health Organization Classification of Tumours of the Nervous System. Lyon: WHO/ARC Press.
Klein M Heimans JJ, Aaronson NK et al. (2002). Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360: 1361–1368.
Klein M, Engelberts NH, Van Der Ploeg HM et al. (2003). Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54: 514–520.
Klein M, Fagel S, Taphoorn MJB, Postma TJ, Heimans JJ (2006). Neurocognitive function in long-term low-grade glioma. Survivors: a six-year follow-up study. Neurooncology 8(4): 321 (abstract).
Knopp EA, Cha S, Johnson G et al. (1999). Glial neoplasms: dynamic contrast-enhanced T2-weighted imaging. Radiology 211: 791–798.
Komine C, Watanabe T, Katayama Y et al. (2003). Promotor hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13: 176–184.
Kono K, Inoue Y, Nakayama K et al. (2001). The role of diffusion-weighted imaging in patients with brain tumors. Am J Neuroradiol 22: 1081–1088.
Laack NN, Brown PD, Ivnik RJ et al. (2005). Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63: 1175–1183.
Leighton C, Fisher B, Bauman G et al. (1997). Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15: 1294–1301.
Levin N, Lavon I, Zelikovitsch B et al. (2006). Progressive low-grade oligobendrogliomas: response to temozolomide and correlation between genetic profile and O-6-methyguanine DNA methyltransferase protein expression. Cancer 106: 1759–1765.
Maia AC Jr., Malheiros SM, da Rocha AJ et al. (2005). MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26: 777–783.
Mandonnet E, Delattre JY, Tnaguy ML et al. (2003). Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53: 524–528.
Meador KJ (2002). Cognitive outcomes and predictive factors in epilepsy. Neurology 58: 21–26.
Meyers CA, Hess KR (2003). Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neurooncology 5: 89–95.
Monje ML, Palmer T (2003). Radiation injury and neurogenesis. Curr Opin Neurol 16: 129–134.
Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD (2007). Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 62: 515–520.
Murphy PS, Viviers L, Abson C et al. (2004). Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 90: 781–786.
Nagesh Y, Tsien CI, Chevenert TL et al. Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys 70(4): 1002–1010.
Niël CGJH, Struikmans H, van Santvoort J (2005). Radiotherapy for primary brain tumors: clinical potential of novel treatment techniques. Neurooncology 7(3): 391 (abstract).
Olson JD, Riedel E, DeAngelis LM (2000). Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54: 1442–1448.
Pace A, Vidiri A, Galie E et al. (2003). Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14: 1722–1726.
Pahlson A, Ek L, Ahlstrom G et al. (2003). Pitfalls in the assessment of disability in individuals with low-grade gliomas. J Neurooncol 65: 149–158.
Peterson K, Rosenblum MK, Powers JM et al. (1993). Effect of brain irradiation on demyelinating lesions. Neurology 43: 2105–2112.
Pignatti F, van den Bent MJ, Curran D et al. (2002). Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20: 2076–2084.
Postma TJ, van Groeningen CJ, Witjes RJ et al. (1998). Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38: 69–75.
Postma TJ, Klein M, Verstappen CC et al. (2002). Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 59: 121–123.
Quinn JA, Reardon DA, Friedman AH et al. (2003). Phase II trial of temozolomide in patients with progressive low grade glioma. J Clin Oncol 21: 646–651.
Rasheed BK, Wiltshire RN, Bigner SH et al. (1999). Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11: 162–167.
Recht LD, Lew R, Smith TW (1992). Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31: 431–436.
Rees JH (2002). Low-grade gliomas in adults. Curr Opin Neurol 15: 657–661.
Reijneveld JC, Sitskoorn MM, Klein M et al. (2001). Cognitive status and quality of life in patients with suspected versus proven low-grade glioma. Neurology 56: 618–623.
Rogers LR, Morris HH, Lupica K (1993). Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 43: 1599–1601.
Sanai N, Berger MS (2008). Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4): 753–764.
Salvati M, Artico M, Caruso R et al. (1991). A report on radiation-induced gliomas. Cancer 67: 392–397.
Scheibel RS, Meyers CA, Levin VA (1996). Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 30(1): 61–69.
Scott JN, Brasher PM, Sevick RJ et al. (2002). How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59: 947–949.
Shaw EG, Daumas-Duport C, Scheithauer BW et al. (1989). Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70: 853–861.
Shaw E, Arusell R, Scheithauer B et al. (2002). Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a NCCTG/RTOG/ECOG study. J Clin Oncol 20: 2267–2276.
Sheline GE, Wara WM, Smith V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6: 1215–1228.
Smith JS, Perry A, Borell TJ et al. (2000). Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytoma. J Clin Oncol 18: 636–645.
Smith JS, Chang EF, Lamborn KR et al. (2008). Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26: 1338–1345.
Stege EM, Kros JM, de Bruin HG et al. (2005). Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103: 802–809.
Surma-Aho O, Niemela M, Vilkki J et al. (2001). Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56: 1285–1290.
Swennen MHJ, Bromberg JEC, Witkamp TD et al. (2004). Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. J Neurooncol 66: 333–339.
Takebayashi T, Varsier N, Kikuchi Y et al. (2008). Mobile phone use, exposure to radiofrequency electromagnetic field, and brain tumour: a case–control study. Br J Cancer 98: 652–659.
Taphoorn MJB, Klein M (2004). Cognitive deficits in adult brain tumour patients. Lancet Neurol 3: 159–168.
Taphoorn MJB, Heimans JJ, Snoek FJ et al. (1992). Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 55: 372–376.
Torres JJ, Mundt AJ, Sweeney PJ et al. (2003). A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60: 1113–1118.
Tucha O, Smely C, Preier M, Lange KW (2000). Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47: 324–333.
Van den Bent MJ, Kros JM, Heimans JJ et al. (1998). Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51: 1140–1145.
Van den Bent MJ, Taphoorn MJB, Brandes AA et al. (2003). Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: EORTC Brain Tumor Group Study 26971. J Clin Oncol 21: 2525–2528.
Van den Bent MJ, Afra D, de Witte O et al. (2005). Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366: 985–990.
Vecht CJ (1993). Effect of age on treatment decisions in low-grade glioma. J Neurol Neurosurg Psychiatry 56: 1259–1264.
Vigliani MC, Sichez N, Poisson M, Delattre JY (1996). A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 35: 527–533.
Vigliani MC, Duyckaerts C, Hauw JJ et al. (1999). Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study. J Neuro Oncol 41: 137–149.
Vuori K, Kankaanranta L, Hakkinen AM et al. (2004). Low-grade gliomas and focal cortical developmental malformations: differentation with proton MR spectroscopy. Radiology 230: 703–708.
Watanabe T, Nakamura M, Kros JM et al. (2002). Phenotype versus genotype correlation in oligodendroglioma and low-grade diffuse astrocytoma. Acta Neuropathol 103: 267–275.
Wen PY (2003). Central nervous system complications of cancer therapy. In Schiff D, Wen PY (eds.) Cancer Neurology in Clinical Practice (pp. 215–231. Totowa: Humana Press.

Reference Title: REFERENCES

Reference Type: reference-list

Abdallah NM-BB, Slomianka L, Lipp H-P (2007). Reversible effect of X-irradiation on proliferation, neurogenesis, and cell death in the dentate gyrus of adult mice. Hippocampus 17(12): 1230–1240.
Archibald YM, Lulnn D, Ruttan LA et al. (1994). Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80: 247–253.
Armstrong C, Ruffer J, Corn B, DeVires K, Mollman J (1995). Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: neuropsychologic outcome and proposed mechanisms. J Clin Oncol 13: 2263–2271.
Bartolomei F, Bosma I, Klein M et al. (2006). How do brain tumors alter functional connectivity? A magnetoencephalography study. Ann Neurol 59: 128–138.
Beck AT, Steer RA (1993). Beck Depression Inventory. San Antonio, TX: Psychological Corp.
Beck AT, Brown G, Epstein N, Steer RA (1990). An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893–897.
Belka C, Budach W, Kortmann RD et al. (2001). Radiation induced CNS toxicity – molecular and cellular mechanisms. Br J Cancer 85: 1233–1239.
Benedict RHB, Schretlen D, Groninger L et al. (1998). Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12: 43–55.
Benton AD (1968). Differential behavioral effects in frontal lobe disease. Neuropsychologia 6: 53–60.
Benton AL, Hamsher K de S (1989). Multilingual Aphasia Examination. Iowa City, IA: AJA Associates.
Bhat SR, Goodwin TL, Burwinkle TM et al. (2005). Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23: 5493–5500.
Bosma I, Vos MJ, Heimans JJ et al. (2007). The course of neurocognitive functioning in high-grade glioma patients. Neurooncology 9: 53–62.
Brown PD, Buckner JC, O'Fallon JR et al. (2003). Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J Clin Oncol 21: 2519–2524.
Brown PD, Jensen AW, Felten SJ et al. (2006). Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 24: 5427–5433.
Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K (1991). The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliative Care 7: 6–9.
Bruera E, Valero V, Driver L et al. (2006). Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24: 2073–2078.
Bruera E, Osta BE, Valero V et al. (2007). Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 25: 3475–3481.
Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S (2006). Effect of high-dose cortisol on memory functions. Ann N Y Acad Sci 1071: 434–437.
Carson KA, Grossman SA, Fisher JD, Shaw EG (2007). Prognostic factors for survival in adult patients with recurrent gliomas enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25: 2601–2606.
Cavaliere R, Schiff D (2006). Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep 6: 218–226.
Cella DF, Tulsky DS, Gray G et al. (1993). The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11: 570–577.
Central Brain Tumor Registry of the United States (2005). Primary Brain Tumors in the United States Statistical Report 1998–2002 (pp. 8–50). Chicago, IL: Central Brain Tumor Registry of the United States.
Crossen JR, Garwood D, Glatstein E et al. (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627–642.
Cull A, Hay C, Love SB et al. (1996). What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer 74: 1674–1679.
Curran WJ Jr., Scott CB, Horton J et al. (1993). Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant gliomas trials. J Natl Cancer Inst 85: 704–710.
Davies E, Clarke C (2005). Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. J Neurol Neurosurg Psychiatry 76: 555–561.
DeAngelis LM, Delattre J-Y, Posner JB (1989). Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789–796.
Folstein MF, Folstein SE, McHugh PR (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.
Fries JF (1980). Aging, natural death, and the compression of morbidity. N Engl J Med 303: 130–135.
Gill D, Hatcher S (2000). Antidepressants for depression in medical illness. Cochrane Database Syst Rev 4: CD001312.
Hamilton M (1959). The assessment of anxiety state by rating. Br J Med Psychol 32: 50–55.
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
Hildebrand J (2006). Neurological complications of cancer chemotherapy. Curr Opin Oncol 18: 321–324.
Hochberg FH, Slotnick B (1980). Neuropsychologic impairment in astrocytoma survivors. Neurology 30: 172–177.
Imperato JP, Palelogos NA, Vick NA (1990). Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28: 818–822.
Jagaroo V, Rogers MP, Black PM (2000). Allocentric visuospatial processing in patients with cerebral gliomas: a neurocognitive assessment. J Neurooncol 49: 235–248.
Jemal A, Siegel R, Ward E et al. (2007). Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
Johnson MR, Hageboutros A, Wand K, High L, Smith JB, Diasio RB (1999). Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5: 2006–2011.
Kaleita TA, Wellich DK, Graham CA et al. (2006). Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. Proc ASCO 24(18S): 58S, [abstract 1503].
Karnofsky DA, Abelmann WH, Craver LF (1948). The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634–656.
Kayl AE, Meyers CA (2003). Does brain tumor histology influence cognitive function? Neurooncology 5: 255–260.
Klein M, Heimans JJ (2004). The measurement of cognitive functioning in low-grade glioma patients after radiotherapy [Letter]. J Clin Oncol 22: 966–967.
Klein M, Taphoorn MJB, Heimans JJ et al. (2001). Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol 19: 4037–4047.
Klein M, Engelberts NHJ, van der Ploeg HM et al. (2003a). Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54: 514–520.
Klein M, Postma TJ, Taphoorn MJB et al. (2003b). The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61: 1796–1798.
Lannering B, Marky I, Lundberg A et al. (1990). Long-term sequelae after pediatric brain tumors: their effect on disability and quality of life. Med Pediatr Oncol 18: 304–310.
Lezak MD. (1995). Neuropsychological Assessment (3rd edn.). New York: Academic Press.
Lezak MD, Howieson DB, Loring DW (1994). Neuropsychological Assessment. New York: Oxford University Press.
Levin VA, Yung WK, Bruner J et al. (2002). Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 53: 58–66.
Levine DW, Kripke DF, Kaplan RM et al. (2003). Reliability and validity of the Women's Health Initiative Insomnia Rating Scale. Psychol Assess 15: 137–148.
Lilja A, Brun A, Salford LG et al. (1992). Neuropsychological indexes of a partial frontal syndrome in patients with nonfrontal gliomas. Neuropsychology 6: 315–326.
Lupien SJ, Gillin CJ, Hauger RL (1999). Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 113: 420–430.
Maldjian JA, Detre JA, Killgore WES et al. (2001). Neuropsychologic performance after resection of an activation cluster involved in cognitive memory function. AJR Am J Roentgenol 176: 541–544.
Marin RS (1991). Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3: 243–254.
Marin RS (1996). Apathy: concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry 1: 304–314.
Mattson RH (2004). Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis 1 [Suppl 1]: S10–S17.
Mauer M, Stupp R, Taphoorn MJ et al. (2007). The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer 97: 302–307.
McNair DM, Lorr M, Droppleman LF (1992). Profile of Mood States Manual. San Diego, CA: Educational and Industrial Testing Service.
Mendoza TR, Wang XS, Cleeland CS et al. (1999). The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85: 1186–1196.
Mesulam M (2000). Attentional networks, confusional states, and neglect syndromes. In Mesulam M (ed.) Principles of Behavioral and Cognitive Neurology (pp. 174–256). New York: Oxford University Press.
Meyers CA, Boake C (1993). Neurobehavioral disorders in brain tumor patients: rehabilitation strategies. Cancer Bull 45: 362–364.
Meyers CA, Brown PD (2006). Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24: 1305–1309.
Meyers CA, Wefel JS (2003). The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21: 3357–3358.
Meyers CA, Kudelka AP, Conrad CA et al. (1997). Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res 3: 419–422.
Meyers CA, Weitzner MA, Valentine AD, Levin VA (1998). Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16: 2522–2527.
Meyers CA, Hess KR, Yung WKA, Levin VA (2000). Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18: 646–650.
Meyers CA, Smith JA, Bezjak A et al. (2004). Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22: 157–165.
Monje ML, Mizumatsu S, Fike JR, Palmer TD (2002). Irradiation induces neural precursor-cell dysfunction. Nat Med 8: 955–962.
Monje ML, Toda H, Palmer TD (2003). Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760–1765.
Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD (2007). Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 62(5): 515–520.
Moulder JE, Robbins ME, Cohen EP et al. (1998). Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treat Res 93: 129–151.
Mulhern RK, Khan RB, Kaplan S et al. (2004). Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 22: 4795–4803.
Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830–1835.
Murray KJ, Scott C, Zachariah B et al. (2000). Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91–04. Int J Radiat Oncol Biol Phys 48: 59–64.
O'Connor NM, Mayberrg MR (2000). Effects of radiation on cerebral vasculature: a review. Neurosurgery 46: 138–151.
O'Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M (2005). Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 65: 331–332.
Oken MM, Creech RH, Tormey DC et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655.
Okuyama T, Akechi T, Kugaya A et al. (2000). Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 19: 5–14.
Packer RJ, Gurney JG, Punyko JA et al. (2003). Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 21: 3255–3261.
Patchell RA, Tibbs PA, Regine WF et al. (1998). Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. J Am Med Assoc 280: 1485–1489.
Raida M, Schwabe W, Hausler P et al. (2001). Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7: 2832–2839.
Report of the Brain Tumor Progress Review Group (2005). National Institute of Neurologic Disorders and Stroke. Accessed 27 March, 2008 from http://www.ninds.nih.gov/find_people/groups/brain_tumor_prg/btprgreport.htm.
Rozental JM Levine RL, Nickles RJ, Dobkin JA, Hanson JM (1990). Cerebral diaschisis in patients with malignant glioma. J Neurooncol 8: 153–161.
Salander P, Karlsson T, Bergenheim T et al. (1995). Long-term memory deficits in patients with malignant gliomas. J Neurooncol 25: 227–238.
Scheibel RS, Meyers CA, Levin VA (1996). Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 30: 61–69.
Shaw E, Arusell R, Scheithauer B et al. (2002). Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20: 2267–2276.
Shaw EG, Rosdhal R, D'Agostino RB Jr et al. (2006). Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24: 1415–1420.
Shehata N, Pater A, Tang SC (1999). Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Cancer Invest 17: 201–205.
Sherer M, Meyers CA, Bergloff P (1997). Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer 80: 250–257.
Sherman AM, Jaeckle K, Meyers CA (2002). Pre-treatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer 95: 1311–1316.
Sohlberg MM, Maateer CA (1989). Introduction to Cognitive Rehabilitation. New York: Guilford.
Spielberger C, Gorsuch R, Lushene R (1970). State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists.
Steinbach JP, Blaicher H-P, Herrlinger U et al. (2006). Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 66: 239–242.
Stupp R, Mason WP, van den Bent MJ et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352: 987–996.
Taphoorn MJ, Klein M (2004). Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3: 159–168.
Taphoorn MJ, Heimans JJ, Snoek FL et al. (1992). Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 55: 372–376.
Taphoorn MJ, Stupp R, Coens C et al. (2005). Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol 6: 937–944.
Taylor BV, Buckner JC, Cascino TL et al. (1998). Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 16: 2195–2201.
Tofilon PJ, Fike JR (2000). The radioresponse of the central nervous system: a dynamic process. Radiat Res 153: 357–370.
Torres IJ, Mundt AJ, Sweeney PJ et al. (2003). A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60: 1113–1118.
Ulrich CM, Yasui Y, Storb R et al. (2001). Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98: 231–234.
Ulrich CM, Robien K, Sparks R (2003). Pharmacogenetics and folate metabolism – a promising direction. Pharmacogenomics 3: 299–313.
Varni JW, Limbers CA, Burnwinkle TM (2007). How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes 5: 1–13.
Wade DT, Collin C (1988). The Barthel ADL Index: a standard measure of physical disability. Int Disabil Stud 10: 64–67.
Ware JE, Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30: 473–483.
Wechsler D (1981). Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: The Psychological Corporation.
Wei CW, Gui G, Mikulis DJ (2007). Tumor effects on cerebral white matter as characterized by diffusion tensor tractography. Can J Neurol Sci 34: 62–68.
Weitzner MA, Meyers CA, Gelke CK et al. (1995). The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75: 1151–1161.
Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J (2002). Predicting major depression in brain tumor patients. Psychooncology 11: 230–238.
Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L (2006). Medical management of patients with brain tumors. J Neurooncol 80: 313–332.
Young AH, Sahakian BJ, Robbns TW et al. (1999). The effects of chronic administration of hydrocortisone on cognitive functioning normal male volunteers. Psychopharmacology 145: 260–266.
Young GS (2007). Advanced MRI of adult brain tumors. Neurol Clin N Am 25: 947–973.

Reference Title: REFERENCES

Reference Type: reference-list

Abrey LE, Olson JD, Raizer JJ et al. (2001). A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53: 259–265.
Agboola O, Benoit B, Cross P et al. (1998). Prognostic factors derived from recursive partitioning analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys 42: 155–159.
Ahles TA, Saykin AJ, Furstenberg CT et al. (2002). Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485–493.
Alexander E, Loeffler JS (1999). The case for radiosurgery. Clin Neurosurg 45: 32–40.
Andrews DW, Scott CB, Sperduto PW et al. (2004). Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet 363(9422): 1665–1672.
Antonadou D, Coliarakis N, Paraskevaidis M et al. (2002a). Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A phase III study [abstract]. Int J Radiat Oncol Biol Phys 54: 93–94.
Antonadou D, Paraskevaidis M, Sarris G et al. (2002b). Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20: 3644–3650.
Aoyama H, Shirato H, Tago M et al. (2006). Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. J Am Med Assoc 295(25): 2483–2491.
Arriagada R, LeChevalier T, Borie F et al. (1995). Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. J Natl Cancer Inst 87: 183–190.
Bambakidis NC, Miller RH (2004). Transplantation of oligodendrocyte precursors and sonic hedgehog results in improved function and white matter sparing in the spinal cords of adult rats after contusion. Spine J 4(1):16–26.
Blakemore WF, Gilson JM, Crang AJ (2003). The presence of astrocytes in areas of demyelination influences remyelination following transplantation of oligodendrocyte progenitors. Exp Neurol 184(2): 955–963.
Boldrey E, Sheline G (1967). Delayed transitory clinical manifestation after radiation treatment of intracranial tumors. Acta Radiol 5: 5–10.
Borgelt B, Gelber R, Kramer S et al. (1980). The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6: 1–9.
Borgelt B, Gelber R, Larson M et al. (1981). Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7: 1633–1638.
Bradley KA, Mehta MP (2004). Management of brain metastases. Semin Oncol 31: 693–701.
Breneman JC, Warnick RE, Albright REJ et al. (1997). Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series. Cancer 79: 551–557.
Brezden CB, Phillips KA, Abdolell M (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18: 2695–2701.
Burger PC, Mahaley MS Jr., Dudka L et al. (1979). The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer 44: 1256–1279.
Cammer W (2000). Effects of TNFalpha on immature and mature oligodendrocytes and their progenitors invitro. Brain Res 864(2): 213–219.
Cappuzo F, Mazzoni F, Maestri A et al. (2000). Medical treatment of brain metastases from solid tumors. Forum (Genova) 10: 137–148.
Chatani M, Teshima T, Hata K et al. (1986). Prognostic factors in patients with brain metastases from lung carcinoma. Strahlenther Onkol 162: 157–161.
Chatani M, Matayoshi Y, Masaki N et al. (1994). Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 170: 155–161.
Chougule PB, Burton-Williams M, Saris S et al. (2000). Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both [abstract]. Int J Radiat Oncol Biol Phys 48: 114
Chow BM, Li YQ, Wong CS. (2000). Radiation-induced apoptosis in the adult central nervous system is p53-dependent. Cell Death Differ 7(8): 712–720.
Christodoulou C, Bafaloukos D, Kosmidis P et al. (2001). Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249–254.
Crossen JR, Garwood D, Glatstein E et al. (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation induced encephalopathy. J Clin Oncol 12: 627–642.
Curran W, Mehta MP, Terhaard C et al. (2002). Predictors of Survival for Patients with Brain Metastases: Results of a Randomized Phase III Trial [abstract 155]. Int J Radiat Oncol Biol Phys 54: 93.
Danysz W, Parsons CG, Mobius JH et al. (2000). Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2: 85–97.
DeAngelis LM, Delattre JY, Posner JB (1989). Radiation induced dementia in patients cured of brain metastases. Neurology 39: 789–796.
Dropcho EJ (2005). Paraneoplastic disorders of the nervous system. In Black PM, Loeffler JS (eds.) Cancer of the Nervous System, (pp. 691–714). Philadelphia, PA: Lippincott Williams & Wilkins.
Ellis R, Gregor A (1998). The treatment of brain metastases from lung cancer. Lung Cancer 20: 81–84.
Feldman H, Gauthier S, Hecker J et al. (2005). Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized placebo-controlled trial. Int J Geriatr Psychiatry 20(6): 559–569.
Fontanella M, Perozzo P, Ursone R et al. (2003). Neuropsychological assessment after microsurgical clipping or endovascular treatment for anterior communicating artery aneurysm. Acta Neurochir 145: 867–872.
Freidman MA, Meyers CA, Sawaya R (2003). Neuropsychological effects of third ventricular tumor surgery. Neurosurgery 52: 791–798.
Gaspar L, Scott C, Rotman M et al. (1997). Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4): 745–751.
Gottwald B, Wilde B, Mihajlovic Z et al. (2004). Evidence for distinct cognitive deficits after focal cerebellar lesions. J Neurol Neurosurg Psychiatry 75: 1524–1531.
Graus F, Walker RW, Allen JC (1983). Brain metastases in children. J Pediatr 103(4): 558–561.
Green HJ, Pakenham KI, Headley BC et al. (2002). Altered cognitive function in men treated for prostate cancer with luteinising hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. Br J Urol 90: 427–432.
Greenberg H, Chandler WF, Sandler HM (1999). Brain metastases. In: Greenberg H, Chandler WF, Sandler HM (eds.) Brain Tumors, (pp. 299–317, Vol. 54). New York: Oxford University Press.
Gregor A, Cull A, Stephens RJ et al. (1997). Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicenter randomized trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organisation for Research and Treatment of Cancer (EORTC). Eur J Cancer 33: 1752–1758.
Grill J, Viguier D, Kieffer V et al. (2004). Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. J Neurosurg 101: 152–158.
Groves AK, Barnett SC, Franklin RJ et al. (1993). Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 362(6419): 453–455.
Haie-Meder C, Pellae-Cosset B, Laplanche A et al. (1993). Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26: 111–116.
Harwood AR, Simson WJ (1977). Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int J Radiat Oncol Biol Phys 2: 1091–1094.
Herman MA, Tremont-Lukats I, Meyers CA et al. (2003). Neurocognitive and functional assessment of patients with brain metastases. Am J Clin Oncol 26(3): 273–279.
Hoerr R (2003). Behavioral and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry 36 [Suppl. 1]: S56–S61.
Hulshof MC, Stark NM, van der Kleij A et al. (2002). Hyperbaric oxygen therapy for cognitive disorders after irradiation of the brain. Strahlenther Onkol 178(4): 192–198.
Hutter BO, Spetzger U, Bertalanffy H et al. (1997). Cognition and quality of life in patients after transcallosal microsurgery for midline tumors. J Neurosurg Sci 41: 123–129.
Izquierdo I, da Cunha C, Rosat R et al. (1992). Neurotransmitter receptors involved in post-training memory processing by the amygdala, medial septum, and hippocampus of the rat. Behav Neural Biol 58(1): 16–26.
Jatoi A, Kahanic SP, Frytag S et al. (2005). Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 13(1): 66–69.
Juengling FD, Ebert D, Gut O et al. (2000). Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 152: 383–389.
Karatekin C, Lazareff JA, Asarnow RF (2000). Relevance of cerebellar hemispheres for executive functions. Pediatr Neurol 22: 106–112.
Kauer JA, Manlenka RC, Nicoll RA (1988). NMDA application potentiates synaptic transmission in the hippocampus. Nature 334(6179): 250–252.
Kelly K, Bunn PAJ (1998). Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 20: 85–91.
Kelley KW, Bluthé RM, Dantzer R et al. (2003). Cytokine-induced sickness behavior. Brain Behav Immun 17: S112–S118.
Kershner P, Wang-Cheng R (1989). Psychiatric side-effects of steroid therapy. Psychosomatics 30: 135–139.
Klein M, Engelberts NHJ, van der Ploeg HM et al. (2003). Epilepsy in low grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54: 514–520.
Knighton DR, Hunt TK, Schenestuhl H et al. (1983). Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 221: 1283–1289.
Kohshi K, Imada H, Nomoto S et al. (2003). Successful treatment of radiation-induced brain necrosis by hyperbaric oxygen therapy. J Neurol Sci 209(1–2): 115–117.
Komaki R, Meyers CA, Shin DM et al. (1995). Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 33(1): 179–182.
Kondzoilka D, Patel A, Lunsford LD et al. (1999). Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45(2): 427–434.
Kramer S (1968). The hazards of therapeutic irradiation of the central nervous system. Clin Neurosurg 15: 301–318.
Kurtz JM, Gelber R, Brady LW et al. (1981). The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7: 891–895.
Lassman AB, DeAngelis LM (2003). Brain metastases. Neurol Clin 21(I): I,vii.
LeBars PL (2003). Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry Jun; 36 [Suppl 1]: S44–S49.
Lee AW, Kwong DLW, Leung SF et al. (2002). Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53: 75–85.
Levin ED, Sledge D, Baruah A et al. (2003). Ventral hippocampal NMDA blockade and nicotinic effects on memory function. Brain Res Bull 61(5): 489–495.
Leyland-Jones B, Semiglazov V, Pawlicki M et al. (2005). Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960–5972.
Li J, Bentzen SM, Renschler M, Mehta MP (2006). Improvement in neurocognitive function (NCF) correlates with tumor regression after whole brain radiation therapy (WBRT) for brain metastases (BM) [abstract]. Proc Am Soc Clin Oncol 24 [Suppl. 18S]: 1504.
Lilja A, Smith GJ, Salford LG (1992). Microprocesses in perception and personality. J Nerv Ment Dis 180: 82–88.
Lim LC, Rosenthal MA, Maartens N et al. (2004). Management of brain metastases. Intern Med J 34: 270–278.
Magy L, Mertens C, Avellana-Adalid V et al. (2003). Inducible expression of FGF2 by a rat oligodendrocyte precursor cell line promotes CNS myelination in vitro. Exp Neurol 184(2): 912–922.
Marx RE, Johnson RP, Kline SN (1985). Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc 111; 49–54.
McEwen BS, Alves SE (1999). Estrogen actions in the central nervous system. Endocr Rev 20: 279–307.
Mehta MP, Tremont-Lukas I (2004). Radiosurgery for single and multiple metastases. In Sawaya R (ed.) Intracranial Metastases: Current Management Strategies, (pp. 139–164). Malden MA: Blackwell.
Mehta MP, Shapiro WR, Glantz M et al. (2002). Lead-in phase to randomized trial of Motexafin Gadolinium and whole brain radiation for patients with brain metastases. Centralized assessment of magnetic resonance imaging, neurocognitive and neurologic end points. J Clin Oncol 20: 3445–3453.
Mehta MP, Rodrigus P, Terhaard CHJ et al: (2003). Survival and neurologic outcomes in a randomized trial of Motexafin Gadolinium and whole brain radiation therapy in brain metastases. J Clin Oncol 21: 2529–2536.
Mehta MP, Gervais R, Chabot P et al. (2006). Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial [abstract]. Proc Am Soc Clin Oncol 24 [Suppl. 18S]: 7014.
Meyers CA, Abbruzzese JL (1992). Cognitive functioning in cancer patients: effect of previous treatment. Neurology 42: 434–436.
Meyers CA, Boake C (1993). Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies. Cancer Bull 45: 362–364.
Meyers CA, Hess KR (2003). Multifaceted endpoints in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neurooncology 5: 89–95.
Meyers CA, Valentine AD, Wong FCL et al. (1994). Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlation of SPECT with neuropsychological testing. J Neuropsychiatry Clin Neurosci 6: 285–288.
Meyers CA, Weitzner MA, Valentine et al. (1998). Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16(7): 2522–2527.
Meyers CA, Smith JA, Bezjak A et al. (2004). Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and Motexafin Gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1): 157–165.
Mix JA, Crews WD (2002). A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17(6): 267–277.
Monje ML, Palmer T (2003). Radiation injury and neurogenesis. Curr Opin Neurol 16: 129–134.
Murray KJ, Scott C, Greenberg HM et al. (1997). A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39: 571–574.
Nieder C, Berberich W, Schnabel K (1997). Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 39: 25–30.
Noordjik EM, Vecht CJ, Haaxma-Reiche H et al. (1994). The choice of treatment of single brain metastases should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29: 711–717.
Nussbaum ES, Djalilian HR, Cho K et al. (1996). Brain metastases: histology, multiplicity, surgery and survival. Cancer 78(8): 1781–1788.
Patchell RA, Tibbs PA, Walsh JW et al. (1990). A randomized trial of surgery in the treatment of single metastases to the brain. N Eng J Med 322(8): 494–500.
Patchell RA, Tibbs PA, Regine WF et al. (1998). Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. J Am Med Assoc 280: 1485–1489.
Peace KA, Orme SM, Thompson AR (1997). Cognitive dysfunction in patients treated for pituitary tumors. J Clin Exp Neuropsychol 19: 1–6.
Peissner W, Kocher M, Treuer H (1999). Ionizing radiation-induced apoptosis of proliferating stem cells in the dentate gyrus of the adult rat hippocampus. Brain Res Mol Brain Res 71(1): 61–68.
Penitzka S, Steinvorth S, Sehlleier S et al. (2002). Assessment of cognitive function after preventive and therapeutic whole brain irradiation using neuropsychological testing. Strahlenther Onkol 178: 252–258.
Pirzkall A, Debus J, Lohr F et al. (1998). Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16: 3563–3569.
Posner JB (1995). Neurologic Complications of Cancer. Philadelphia, PA: FA Davis.
Postmus PE, Haaxma-Reiche H, Smit EF et al. (2000). Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy. A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18: 3400–3408.
Quan AL, Videtic GM, Suh JH (2004). Brain metastases in small cell lung cancer. Oncology 18: 961–72.
Regine WF, Scott C, Murray K et al. (2001). Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs accelerated hyperfractionated radiotherapy: an analysis of RTOG study 91–04. Int J Radiat Oncol Biol Phys 51: 711–717.
Regine WF, Schmitt FA, Scott CB et al. (2004). Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 58(5): 1346–1352.
Renschler M, Mehta MP, Donald DM et al. (2003). Treatment intent for brain metastases: surveys of medical and radiation oncologists indicate that maintaining neurologic and neurocognitive function is more important than prolonging survival. Proc Am Soc Clin Oncol 22: 552 (no. 2222).
Rich JB, Maki P (1999). Estrogen, testosterone and the brain: a review of neuropsychological, aging and neuroimaging studies. J Int Neuropsychol Soc 6: iii.
Riedel G, Reymann KG (1996). Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Acta Physiol Scand 157(1): 1–19.
Roman G (2000). Perspectives in the treatment of vascular dementia. Drugs Today (Barc) 36(9): 641–653.
Salminen E, Porten R, Korpela J et al. (2003). Androgen deprivation and cognition in prostate cancer. Br J Cancer 89: 971–976.
Sanghavi SN, Miranpuri SS, Chappell R et al. (2001). Radiosurgery for patients with brain metastases: a multi-institutional analysis stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 51: 426–434.
Sawaya R, Bindal R (2001). Metastatic brain tumors. In Laws E, Kaye AH (eds.) Brain Tumors: an Encyclopedic Approach (pp. 923–946). Edinburgh: Churchill Livingstone.
Schagen SB, vanDam FS, Muller MJ et al. (1999). Cognitive deficits after postoperative chemotherapy for breast cancer. Cancer 85: 640–650.
Scheibel RS, Meyers CA, Levin VA (1996). Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location and treatment. J Neurooncol 30: 61–69.
Schellinger PD, Meinck HM, Thron A (1999). Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 44(3): 275–281.
Schultheiss TE, Kun LE, Ang KK et al. (1995). Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 31: 1093–1112.
Senzer N (2002). Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. Semin Oncol 6 [Suppl. 19]: 47–52.
Seung SK, Sneed PK, McDermott MW et al. (1998). Gamma Knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am 4: 103–109.
Shaw E, Scott C, Suh J et al. (2003). RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group recursive partitioning analysis brain metastases database. J Clin Oncol 21: 2364–2371.
Sheline GE, Wara WM, Smith V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6: 1215–1228.
Silverman DH, Castellon SA, Abraham L et al. (2003). Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive changes. Proc Am Soc Clin Oncol 22: 12.
Sundstrom JT, Minn H, Lertola KK et al. (1998). Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 30: 296–299.
Taphoorn MJB (2003). Neurocognitive sequelae in the treatment of low grade gliomas. Semin Oncol 30 [6 Suppl. 19] 45–48.
Tucha O, Smely C, Preier M (2003). Preoperative and postoperative cognitive functioning in patients with frontal meningioma. J Neurosurg 98: 21–31.
Turkheimer E, Yeo RA, Jones CL et al. (1990). Quantitative assessment of covariation between neuropsychological function and location of naturally occurring lesions in human. J Clin Exp Neuropsychol 12: 549–565.
Van Der Kogel AJ (1986). Radiation-induced damage in the central nervous system: an interpretation of target cell responses. Br J Cancer 7: 207–217.
Van Oosterhout AG, Boon PJ, Houx PJ et al. (1995). Follow up of cognitive functioning in patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 31: 911–914.
Vannucci RC, Baten M (1974). Cerebral metastatic disease in childhood. Neurology 24(10): 981–985.
Varney NR, Syrop C, Kubu CS et al. (1998). Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet 10: 53–57.
Verger E, Gil M, Yaya R et al. (2003). Concomitant temozolomide (TMZ) and whole brain radiotherapy (WBRT) in patients with brain metastases (BM): randomized multicentric phase II study [abstract]. Proc Am Soc Clin Oncol 22: 101.
Wefel JS, Kayl AE, Meyers CA (2004a). Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 90: 1691–1696.
Wefel JS, Lenzi R, Theriault RL et al. (2004b). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective randomized longitudinal trial. Cancer 100(11): 2292–2299.
Weitzner MA, Meyers CA, Valentine AD (1995). Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 7: 347–350.
Wen PY, Black PM, Loeffler JS (2001). Metastatic brain cancer. In Devita VT Jr., Hellman S, Rosenberg SA (eds.) Cancer: Principles and Practice of Oncology (6th edn.) (pp. 2655–2670). Philadelphia PA: Lippincott Williams & Wilkins.
Wieneke MH, Dienst ER (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4: 61–66.
Wolkowitz OM, Reus VI, Weingartner H et al. (1990). Cognitive aspects of corticosteroids. Am J Psychiatry 147: 1297–1303.
Young RF (1998). Radiosurgery for the treatment of brain metastases. Semin Surg Oncol 14: 70–78.
Zimm S, Wampler GL, Stablein D et al. (1981). Intracerebral metastases in solid tumor patients: natural history and results of treatment. Cancer 48: 384–394.

Reference Title: REFERENCES

Reference Type: reference-list

Abrey LE, DeAngelis LM, Yahalom J (1998). Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859–863.
Abrey LE, Yahalom J, DeAngelis LM (2000). Treatment of primary CNS lymphoma: the next step. J Clin Oncol 18: 3144–3150.
Abrey L, Moskowitz CH, Mason WP et al. (2003). Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21: 4151–4156.
Batchelor T, Loeffler JS (2006). Primary CNS lymphoma. J Clin Oncol 24: 1281–1288.
Behin A, Delattre J-Y (2003). Neurologic sequelae of radiotherapy on the nervous system. In Schiff D, Wen PY (eds.) Cancer Neurology in Clinical Practice (pp. 173–191). Totowa, NJ: Humana Press Inc.
Besell EM, Graus F, Lopez-Guillermo A et al. (2001). CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 50: 457–464.
Blay J-Y, Conroy T, Chevreau C et al. (1998). High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864–871.
Boiardi A, Silvani A, Valentini S et al. (1993). Chemotherapy as a first treatment for primary non-Hodgkin's lymphoma of the central nervous system: preliminary data. J Neurol 241: 96–100.
Cher L, Glass J, Harsh GR et al. (1996). Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred chemotherapy: preliminary results. Neurology 46: 1757–1759.
Constine LS, Konski A, Ekholm S et al. (1988). Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 15: 319–330.
Correa DD, Anderson ND, Glass A et al. (2003). Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin Adv Hematol Oncol 1: 490.
Correa DD, DeAngelis LM, Shi W et al. (2004). Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62: 548–555.
Corry J, Smith JG, Wirth A et al. (1998). Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol 41: 615–620.
Crossen JR, Goldman DL, Dahlborg SA et al. (1992). Neuropsychological asssessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 30: 23–29.
Dahlborg SA, Henner WD, Crossen JR et al. (1996). Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166–174.
Dahlborg SA, Petrillo A, Crossen JR et al. (1998). The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 4(2): 110–124.
DeAngelis LM (1995). Current management of primary central nervous system lymphoma. Oncology 9: 63–71.
DeAngelis LM, Hormigo A (2004). Treatment of primary central nervous system lymphoma. Semin Oncol 31: 684–692.
DeAngelis LM, Shapiro WR (1991). Drug/radiation interactions and central nervous system injury. In Gutin PH, Leibel SA, Sheline GE (eds.) Radiation Injury to the Nervous System (pp. 361–382). New York: Raven Press.
DeAngelis LM, Delattre J-Y, Posner JB (1989). Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789–796.
DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G (1990). Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40(1): 80–86.
DeAngelis LM, Yahalom J, Thaler HT et al. (1992). Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635–643.
Desmond DW (2002). Cognition and white matter lesions. Cerebrovasc Dis 13: 53–57.
Doolittle ND, Miner ME, Siegal T et al. (2000). Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637–647.
Dropcho EJ (1991). Central nervous system injury by therapeutic irradiation. Neurol Clin 9: 69–88.
Eby NL, Grufferman S, Flannelly CM et al. (1988). Increasing incidence of primary brain lymphoma in the U.S. Cancer 62: 2461–2465.
Ferreri AJM, Reni M, Pasini F et al. (2002). A multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513–1520.
Fliessbach K, Urbach H, Helmstaedter C et al. (2003). Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60: 563–568.
Fliessbach K, Helmstaedter C, Urbach H et al. (2005). Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64: 1184–1188.
Freilich RJ, Delattre J-Y, Monjour A, DeAngelis LM(1996). Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435–439.
Glass J, Gruber ML, Cher L, Hochberg F (1994). Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 88–195.
Grant JW, Isaacson PG (1992). Primary central nervous system lymphoma. Brain Pathol 2: 97–109.
Guha-Thakurta N, Damek D, Pollack C et al. (1999). Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259–268.
Harder H, Holtel H, Bromberg JEC et al. (2004). Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62: 544–547.
Herrlinger U, Schabet M, Clemens M et al. (1998). Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 97: 257–264.
Herrlinger U, Schabet M, Brugger W et al. (2002). German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51: 247–252.
Herrlinger U, Kuker W, Uhl M et al. (2005). NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57: 843–847.
Hoang-Xuan K, Taillandier L, Chinot O et al. (2003). Chemotherapy alone as initial treatment for CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Control Group. J Clin Oncol 21: 2726–2731.
Keime-Guibert F, Napolitano M, Delattre JY (1998). Neurological complications of radiotherapy and chemotherapy. J Neurol 245: 695–708.
Kraemer DF, Fortin D, Neuwelt EA (2002). Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Curr Neurol Neurosci Rep 2: 216–224.
Laack NN, Brown PD (2004). Cognitive sequelae of brain radiation in adults. Semin Oncol 31: 702–713.
Lai R, Abrey LE, Rosenblum MK, DeAngelis LD (2004). Treatment-induced leukoencephalopathy in primary CNS lymphoma. Neurology 62: 451–456.
McAllister LD, Doolittle ND, Guastadisegni PE et al. (2000). Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46: 51–61.
Meyers CA, Wefel JS (2003). The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21: 3557–3558.
Nelson DF (1999). Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 43: 241–247.
Neuwelt EA, Goldamn DA, Dahlborg SA et al. (1991). Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580–1590.
Neuwelt EA, Guastadisegni PE, Varallyay P et al. (2005). Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 26: 258–265.
O'Brien P, Roos D, Pratt G et al. (2000). Phase II multicenter study of a brief single agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18: 519–526.
O'Neill BP (2004). Neurocognitive outcomes in primary CNS lymphoma (PCNSL). Neurology 62: 532–533.
O'Neill BP, Illig JJ (1989). Primary central nervous system lymphoma. Mayo Clinic Proc 64: 1005–1020.
Pels H, Schlegel U (2006). Primary central nervous system lymphoma. Curr Treat Options Neurol 8: 346–357.
Pels H, Deckert-Schulter M, Glasmacher A et al. (2000). Primary central nervous system lymphoma: a clinicopathological study of 28 cases. Hematol Oncol 18: 21–32.
Pels H, Schmidt-Wolf IGH, Glasmacher A et al. (2003). Primary central nervous system lymphoma: results of a pilot study and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21: 4489–4495.
Peterson K, DeAngelis LM (1997). Primary cerebral lymphoma. In Vecht CJ (ed.) Handbook of Clinical Neurology (Vol. 24, pp. 257–268). Part II: Neuro-Oncology. Amsterdam: Elsevier Science.
Peterson K, Gordon KB, Heinemann M-H et al. (1993). The clinical spectrum of ocular lymphoma. Cancer 72: 843–849.
Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H et al. (2003). High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II Trial 20962. J Clin Oncol 21: 4483–4488.
Roman-Goldstein SM, Mitchell P, Crossen JR et al. (1995). MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. Am J Neuroradiol 16: 543–553.
Sandor V, Stark-Vancs V, Pearson D et al. (1998). Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000–3006.
Sarazin M, Ameri A, Monjour A et al. (1995). Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. Eur J Cancer 31A: 2003–2007.
Schlegel U, Pels H, Glasmacher A et al. (2001). Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 71: 118–122.
Sheline G (1980). Irradiation injury of the human brain: a review of clinical experience. In Gilbert HA, Kagan AR (eds.) Radiation Damage to the Nervous System (pp. 39–68). New York: Raven Press.
Sheline G, Wara WM, Smith V (1980). Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Physics 6: 1215–1228.
Tofilon PJ, Fike JR (2000). The radioresponse of the central nervous system: a dynamic process. Radiat Res 153: 357–370.
Tullberg M, Fletcher E, DeCarli C et al. (2004). White matter lesions impair frontal lobe function regardless of their location. Neurology 63: 246–253.
Van Der Maazen RW, Kleiboer BJ, Verhagen I et al. (1993). Repair capacity of adult rat glial progenitor cells determined by an in vitro clonogenic assay after in vitro or in vivo fractionated irradiation. Int J Radiat Biol 63: 661–666.
Weitzner MA, Meyers CA (1997). Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology 6: 169–177.

Reference Title: REFERENCES

Reference Type: reference-list

Anderson DM, Rennie KM, Ziegler RS et al. (2001). Medical and neurocognitive late effects among survivors of childhood central nervous system tumors. Cancer 92(10): 2709–2719.
Anderson VA, Godber T, Smibert E et al. (2000). Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer 82(2): 255–262.
Bassal M, Mertens AC, Taylor L et al. (2006). Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24(3): 476–483.
Beebe DW, Ris MD, Armstrong FD et al. (2005). Cognitive and adaptive outcome in low-grade pediatric cerebellar astrocytomas: evidence of diminished cognitive and adaptive functioning in National Collaborative Research Studies (CCG 9891/POG 9130). J Clin Oncol 23(22): 5198–5204.
Bordeaux JD, Dowell RE Jr., Copeland DR et al. (1988). A prospective study of neuropsychological sequelae in children with brain tumors. J Child Neurol 3(1): 63–68.
Bowers DC, Mulne AF, Reisch JS et al. (2002). Nonperioperative strokes in children with central nervous system tumors. Cancer 94: 1094–1101.
Bowers DC, Liu Y, Leisenring W et al. (2006). Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24(33): 5277–5282.
Brownstein CM, Mertens AC, Mitby PA et al. (2004). Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 89(9): 4422–4427.
Buono L, Morris M, Morris R et al. (1998). Evidence for the syndrome of nonverbal learning disabilities in children with brain tumors. Child Neuropsychol 4(2): 144–157.
Butler RW, Copeland DR (2002). Attentional processes and their remediation in children treated for cancer: a literature review and the development of a therapeutic approach. J Int Neuropsychol Soc 8(1): 115–124.
Butler RW, Mulhern RK (2005). Neurocognitive interventions for children and adolescents surviving cancer. J Pediatr Psychol 30(1): 65–78.
Butler RW, Hill JM, Steinherz PG et al. (1994). Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 12(12): 2621–2629.
Carlson-Green B, Morris RD, Krawiecki N (1995). Family and illness predictors of outcome in pediatric brain tumors. J Pediatr Psychol 20(6): 769–784.
Copeland DR, deMoor C, Moore BD 3rd et al. (1999). Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study. J Clin Oncol 17(11): 3476–3486.
Daugaard G, Abildgaard U (1991). Renal Morbidity of Chemotherapy. Oxford: Butterworth-Heinemann.
Donaldson SS, Kaplan HS (1982). Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 66(4): 977–989.
Eiser C (2004). Neurocognitive sequelae of childhood cancers and their treatment: a comment on Mulhern and Butler. Pediatr Rehabil 7(1): 15–16.
Ellenberg L, McComb JG, Siegel SE et al. (1987). Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 21(5): 638–644.
Ergun-Longmire B, Mertens AC, Mitby P et al. (2006). Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91(9): 3494–3498.
Filley CM (2001). The Behavioral Neurology of White Matter. New York: Oxford University Press.
Fletcher JM, Copeland DR (1988). Neurobehavioral effects of central nervous system prophylactic treatment of cancer in children. J Clin Exp Neuropsychol 10(4): 495–537.
Fuemmeler BF, Elkin TD, Mullins LL (2002). Survivors of childhood brain tumors: behavioral, emotional, and social adjustment. Clin Psychol Rev 22(4): 547–585.
Goldstein AM, Pastakia B, DiGiovanna JJ et al. (1994). Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC). Am J Med Genet 50(3): 272–281.
Goldstein AM, Yuen J, Tucker MA (1997). Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8(6): 865–871.
Gurney J, Kadan-Lottick N, Packer R et al. (2003a). Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 97: 663–673.
Gurney JG, Ness KK, Stovall M et al. (2003b). Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab 88(10): 4731–4739.
Hamilton SR, Liu B, Parsons RE et al. (1995). The molecular basis of Turcot's syndrome. N Engl J Med 332(13): 839–847.
Hancock SL, Cox RS, McDougall IR (1991). Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325(9): 599–605.
Heikens J, Ubbink M, van der Pal H et al. (2000). Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer 88: 2116–2121.
Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A et al. (1990). Medulloblastoma in childhood: progressive intellectual deterioration. Childs Nerv Syst 6(2): 60–65.
Hoppe-Hirsch E, Brunet L, Laroussinie F et al. (1995). Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv Syst 11(6): 340–345; discussion 345–346.
Jakacki RI, Goldwein JW, Larsen RL et al. (1993). Cardiac dysfunction following spinal irradiation during childhood. J Clin Oncol 11(6): 1033–1038.
Jakacki RI, Schramm CM, Donahue BR et al. (1995). Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation. J Clin Oncol 13(6): 1478–1485.
Jankovic M, Brouwers P, Valsecchi MG et al. (1994). Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 344(8917): 224–227.
Jannoun L, Bloom HJ (1990). Long-term psychological effects in children treated for intracranial tumors. Int J Radiat Oncol Biol Phys 18(4): 747–753.
Kleinschmidt-DeMasters BK, Lillehei KO (1995). Radiation-induced meningioma with a 63-year latency period. Case report. J Neurosurg 82(3): 487–488.
Kramer S, Lee KF (1974). Complications of radiation therapy: the central nervous system. Semin Roentgenol 9(1): 75–83.
Landier W, Bhatia S, Eshelman DA et al. (2004). Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committe and Nursing Discipline. J Clin Oncol 22(24): 4979–4990.
Lipshultz SE, Colan SD, Gelber RD et al. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324(12): 808–815.
Luban NL (1998). An update on transfusion-transmitted viruses. Curr Opin Pediatr 10(1): 53–59.
Mabbott D, Penkman L, Witol A et al. (2005). Attention, working memory and processing speed in children with posterior fossa tumours. Poster presented at the 2005 International Neuropsychological Society Meeting, Dublin, Ireland, 6–9 July, 2005.
Martins AN, Johnston JS, Henry JM et al. (1977). Delayed radiation necrosis of the brain. J Neurosurg 47(3): 336–345.
Mertens AC, Yasui Y, Neglia JP et al. (2001). Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19(13): 3163–3172.
Mertens AC, Yasui Y, Liu Y et al. (2002). Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 95(11): 2431–2441.
Mostow EN, Byrne J, Connelly RR et al. (1991). Quality of life in long-term survivors of CNS tumors of childhood and adolescence. J Clin Oncol 9(4): 592–599.
Mulhern RK, Butler RW (2004). Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Rehabil 7(1): 1–14; discussion 15–16.
Mulhern R, Butler RW (2005). Neuropsychological late effects. In Brown RT (ed.) Pediatric Hematology/Oncology: A Biopsychosocial Approach. New York: Oxford University Press.
Mulhern RK, Wasserman AL, Friedman AG et al. (1989). Social competence and behavioral adjustment of children who are long-term survivors of cancer. Pediatrics 83(1): 18–25.
Mulhern RK, Hancock J, Fairclough D et al. (1992). Neuropsychological status of children treated for brain tumors: a critical review and integrative analysis. Med Pediatr Oncol 20(3): 181–191.
Mulhern RK, Kepner JL, Thomas PR et al. (1998). Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 16(5): 1723–1728.
Mulhern RK, Reddick WE, Palmer SL (1999). Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol 46(6): 834–841.
Mulhern R, Palmer S, Reddick W et al. (2001). Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 19(2): 472–479.
Mulhern RK, White HA, Glass JO et al. (2004). Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc 10(2): 180–189.
Neglia JP, Robison LL, Stovall M et al. (2006). New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98(21): 1528–1537.
Ness KK, Mertens AC, Hudson MM et al. (2005). Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann Intern Med 143(9): 639–647.
Nicholson HS, Butler R (2001). Late effects of therapy in long-term survivors. In Keating R, Goodrich J, Packer R (eds.) Tumors of the Pediatric Central Nervous System. New York: Thieme.
Nicholson HS, Fears TR, Byrne J (1994). Death during adulthood in survivors of childhood and adolescent cancer. Cancer 73(12): 3094–3102.
Oberfield SE, Soranno D, Nirenberg A et al. (1996). Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 150(6): 589–592.
O'Driscoll BR, Hasleton PS, Taylor PM et al. (1990). Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 323(6): 378–382.
Oeffinger KC, Mertens AC, Hudson MM et al. (2004). Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med 2(1): 61–70.
Oeffinger KC, Mertens AC, Sklar CA et al. (2006). Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355(15): 1572–1582.
Packer RJ, Sutton LN, Atkins TE et al. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 70(5): 707–713.
Packer RJ, Sutton LN, Elterman R et al. (1994). Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81(5): 690–698.
Packer R, Gurney J, Punyko J et al. (2003). Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood Cancer Survivor Study. J Clin Oncol 21: 3255–3261.
Palmer SL, Goloubeva O, Reddick WE et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 19(8): 2302–2308.
Palmer SL, Gajjar A, Reddick WE et al. (2003). Predicting intellectual outcome among children treated with 35–40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 17(4): 548–555.
Penkman L (2004). Remediation of attention deficits in children: a focus on childhood cancer, traumatic brain injury and attention deficit disorder. Pediatr Rehabil 7(2): 111–123.
Peterson K, Shao C, McCarter R et al. (2005). An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors. Pediatric Blood Cancer 47: 83–88.
Pollack IF (1994). Brain tumors in children. N Engl J Med 331(22): 1500–1507.
Radcliffe J, Packer RJ, Atkins TE et al. (1992). Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32(4): 551–554.
Reddick WE, White HA, Glass JO et al. (2003). Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 97(10): 2512–2519.
Reddick WE, Glass JO, Palmer SL et al. (2005). Atypical white matter volume development in children following craniospinal irradiation. Neurooncology 7(1): 12–19.
Reeves CB, Palmer SL, Reddick WE et al. (2006). Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol 31: 272–280.
Reimers TS, Ehrenfels S, Mortensen EL et al. (2003). Cognitive deficits in long-term survivors of childhood brain tumors: identification of predictive factors. Med Pediatr Oncol 40(1): 26–34.
Reinhold HS, Calvo W, Hopewell JW et al. (1990). Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys 18(1): 37–42.
Ries LAG, Eisner M, Kosary C et al. (2005). SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/CSR/1975_2002/, based on November 2004 SEER data submission, posted to the SEER website, 2005.
Ris MD, Noll RB (1994). Long-term neurobehavioral outcome in pediatric brain-tumor patients: review and methodological critique. J Clin Exp Neuropsychol 16(1): 21–42.
Ris MD, Packer R, Goldwein J et al. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19(15): 3470–3476.
Riva D, Pantaleoni C, Milani N et al. (1989). Impairment of neuropsychological functions in children with medulloblastomas and astrocytomas in the posterior fossa. Childs Nerv Syst 5(2): 107–110.
Ronckers CM, Sigurdson AJ, Stovall M et al. (2006). Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. Radiat Res 166(4): 618–628.
Ross L, Johansen C, Dalton S et al. (2003). Psychiatric hospitalizations among survivors of cancer in childhood or adolescence. New Engl J Med 349: 650–657.
Shuper A, Packer RJ, Vezina LG et al. (1995). “Complicated migraine-like episodes” in children following cranial irradiation and chemotherapy. Neurology 45(10): 1837–1840.
Skinner R, Pearson AD, Amineddine HA et al. (1990). Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 61(6): 927–931.
Sklar CA (1995). Growth following therapy for childhood cancer. Cancer Invest 13(5): 511–516.
Sklar CA (1997). Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 44(2): 489–503.
Sklar CA, Constine LS (1995). Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys 31(5): 1113–1121.
Stavrou T, Bromley C, Nicholson HS et al. (2001). Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 23: 431–436.
Strother D, Pollack I, Fisher PG et al. (2002). Tumors of the central nervous system. In Poplack PA (ed.) Principles and Practice of Pediatric Oncology (4th edn.). Philadelphia, PA: Lippincott Williams & Wilkins.
Travis LB, Rabkin CS, Brown LM et al. (2006). Cancer survivorship – genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98(1): 15–25.
Vassilopoulou S, Klein MJ, Moore BD et al. (1995). Efficacy of growth hormone replacement therapy in children with organic growth hormone deficiency after cranial irradiation. Horm Res 43(5): 188–193.
Walter AW, Mulhern RK, Gajjar A et al. (1999). Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 17(12): 3720–3728.
Yeates KO, Swift E, Taylor HG et al. (2004). Short- and long-term social outcomes following pediatric traumatic brain injury. J Int Neuropsychol Soc 10(3): 412–426.

Reference Title: REFERENCES

Reference Type: reference-list

Ablon J (1995). “The Elephant Man” as “self” and “other”: the psycho-social costs of a misdiagnosis. Soc Sci Med 40: 1481–1489.
Alivisatos B, Petrides M (1997). Functional activation of the human brain during mental rotation. Neuropsychologia 35: 111–118.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn.) (Test Revision). DSM-IV-TR. Arlington, VA: American Psychiatric Association.
Aoki S, Barkovich AJ, Nishimura K et al. (1989). Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 172: 527–534.
Bale SJ, Amos CI, Parry DM et al. (1991). Relationship between head circumference and height in normal adults and in the nevoid basal cell carcinoma syndrome and neurofibromatosis type I. Am J Med Genet 40: 206–210.
Balestri P, Vivarelli R, Grosso S et al. (2003). Malformations of cortical development in neurofibromatosis type 1. Neurology 61: 1799–1801.
Billingsley RL, McAndrews MP, Crawley AP et al. (2001). Functional MRI of phonological and semantic processing in temporal lobe epilepsy. Brain 124: 1218–1227.
Billingsley RL, Schrimsher GW, Jackson EF et al. (2002). Significance of planum temporale and planum parietale morphologic features in neurofibromatosis, type I. Arch Neurol 59: 616–622.
Billingsley RL, Jackson EF, Slopis JM et al. (2003a). Functional magnetic resonance imaging of phonologic processing in neurofibromatosis 1. J Child Neurol 18: 731–740.
Billingsley RL, Slopis JM, Swank PR et al. (2003b). Cortical morphology associated with language function in neurofibromatosis, type I. Brain Lang 85: 125–139.
Billingsley RL, Jackson EF, Slopis JM et al. (2004). Functional MRI of visual-spatial processing in neurofibromatosis, type I. Neuropsychologia 42: 395–404.
Booth JR, MacWhinney B, Thulborn KR et al. (2000). Developmental and lesion effects in brain activation during sentence comprehension and mental rotation. Dev Neuropsychol 18: 139–169.
Brewer VR, Moore BD, Hiscock M (1997). Learning disability subtypes in children with neurofibromatosis. J Learn Disabil 30: 521–533.
Cawthon RM, Weiss R, Xu GF et al. (1990). A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations [published erratum appears in Cell 1990 Aug 10:62(3):following 608]. Cell 62: 193–201.
Clark MM, Plante E (1998). Morphology of the inferior frontal gyrus in developmentally language-disordered adults. Brain Lang 61: 288–303.
Costa RM, Federov NB, Kogan JH et al. (2002). Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415: 526–530.
Coude FX, Mignot C, Lyonne S et al. (2004). Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children. Behav Genet 34: 635.
Crump T (1981). Translation of case reports in Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen [On Multiple Fibromas of the Skin and their Relationship to Multiple Neuromas] by F. V. Recklinghausen. In Riccardi VM, Mulvihill J (eds.) Neurofibromatosis (von Recklinghausen Disease): Genetics, Cell Biology, and Biochemistry (Vol. 23, pp. 259–275). New York: Raven Press.
Cutting LE, Koth CW, Denckla MB (2000). How children with neurofibromatosis type 1 differ from “typical” learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 17: 29–47.
De Winter AE, Moore BD, Slopis JM et al. (1999). Brain tumors in children with neurofibromatosis: additional neuropsychological morbidity? Neurooncology 1: 275–281.
Denckla MB, Hofman K, Mazzocco MM et al. (1996). Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 67: 98–102.
Descheemaeker MJ, Ghesquiere P, Symons H et al. (2005). Behavioural, academic and neuropsychological profile of normally gifted neurofibromatosis type 1 children. J Intellect Disabil Res 49: 33–46.
DiPaolo DP, Zimmerman RA, Rorke LB et al. (1995). Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 195: 721–724.
Duffner P, Cohen M, Seidel F et al. (1989). The significance of MRI abnormalities in children with neurofibromatosis. Neurology 39: 373–378.
Dunn DW, Roos KL (1989). Magnetic resonance imaging evaluation of learning difficulties and incoordination in neurofibromatosis. Neurofibromatosis 2: 1–5.
Eden GF, Stein JF, Wood HM et al. (1996a). Differences in visuospatial judgement in reading-disabled and normal children. Percept Motor Skills 82: 155–177.
Eden GF, VanMeter JW, Rumsey JM et al. (1996b). Abnormal processing of visual motion in dyslexia revealed by functional brain imaging [see comments]. Nature 382: 66–69.
Eden GF, VanMeter JW, Rumsey JM et al. (1996c). The visual deficit theory of developmental dyslexia. Neuroimage 4: S108–S117.
Eldridge R, Denckla MB, Bien E et al. (1989). Neurofibromatosis type 1 (Recklinghausen's disease). Neurologic and cognitive assessment with sibling controls. Am J Dis Child 143: 833–837.
Eliason MJ (1986). Neurofibromatosis: implications for behavior and learning. Neurofibromatosis 7: 175–179.
Eliason MJ (1988). Neuropsychological patterns: neurofibromatosis compared to developmental learning disorders. Neurofibromatosis 1: 17–25.
Ferner RE, Chaudhuri R, Bingham J et al. (1993). MRI in neurofibromatosis 1: the nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 56: 492–495.
Ferner RE, Hughes RA, Weinman J (1996). Intellectual impairment in neurofibromatosis 1. J Neurol Sci 138: 125–133.
Fletcher JM, Shaywitz SE, Shankweiler DP et al. (1994). Cognitive profiles of reading disability: comparisons of discrepancy and low achievement definitions. J Educ Psychol 86: 6–23.
Goh WHS, Khong PL, Leung CSY et al. (2004). T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: Their impact on cognitive function. J Child Neurol 19: 853–858.
Greenlee MW, Magnussen S, Reinvang I (2000). Brain regions involved in spatial frequency discrimination: evidence from fMRI. Exp Brain Res 132: 399–403.
Guo HF, Tong JY, Hannan F et al. (2000). A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 403: 895–898.
Gutmann DH, Aylsworth A, Carey JC et al. (1997). The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J Am Med Assoc 278: 51–57.
Hofman KJ, Harris EL, Bryan RN et al. (1994). Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 124: S1–S8.
Itoh T, Magnaldi S, White RM et al. (1994). Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. AJNR Am J Neuroradiol 15: 1513–1519.
Kayl AE, Moore B, Slopis JM et al. (2000). Quantitative morphology of the corpus callosum in children with neurofibromatosis and attention deficit hyperactivity disorder. J Child Neurol 15: 90–96.
Korf BR, Rubenstein AE (2005). Neurofibromatosis: A Handbook for Patients, Families, and Health Care Professionals (2nd edn.). New York: Thieme Medical Publications.
Kortmann RD, Timmermann B, Taylor RE et al. (2003). Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther Onkol 179: 585.
Leonard CM, Eckert MA, Lombardino LJ et al. (2001). Anatomical risk factors for phonological dyslexia. Cerebral Cortex 11: 148–157.
Lindgren SD, Benton AL (1980). Developmental patterns of visuospatial judgment. J Pediatr Psychol 5: 217–225.
Listernick R, Louis DN, Packer RJ et al. (1997). Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41: 143–149.
Margariti PN, Blekas K, Katzioti FG et al. (2007). Magnetization transfer ratio and volumetric analysis of the brain in macrocephalic patients with neurofibromatosis type 1. Eur Radiol 17: 433–438.
Mazzocco MM, Turner JE, Denckla MB et al. (1995). Language and reading deficits associated with neurofibromatosis type 1: evidence for a not-so-nonverbal learning disability. Dev Neuropsychol 11: 503–522.
Moore BD, Denckla MB (1999). Neurofibromatosis. In Yeates K, Ris M, Taylor H (eds.) Pediatric Neuropsychology: Research, Theory, and Practice. New York: Guilford Publications, Inc.
Moore BD, Ater JL, Needle MN et al. (1994). Neuropsychological profile of children with neurofibromatosis, brain tumor, or both. J Child Neurol 9: 368–377.
Moore BD, Slopis JM, Schomer D et al. (1996). Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 46: 1660–1668.
Moore BD, Slopis JM, Jackson EF et al. (2000). Brain volume in children with neurofibromatosis, type 1: relation to neuropsychological status. Neurology 54: 914–920.
Mulvihill JJ, Parry DM, Sherman JL et al. (1990). Neurofibromatosis-1 (Recklinghausen Disease) and neurofibromatosis-2 (bilateral acoustic neurofibromatosis) – an update. Ann Int Med 113: 39–52.
National Insitutes of Health (1988). Consensus development conference: neurofibromatosis conference statement. Arch Neurol 45: 575–578.
North K, Joy, P, Yuille D et al. (1994). Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities [see comments]. Neurology 44: 878–883.
North KN, Riccardi V, Samango-Sprouse C et al. (1997). Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 48: 1121–1127.
Packer RJ, Gutmann DH, Rubenstein A et al. (2002). Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 58(10): 1461.
Paulesu E, Frith U, Snowling M et al. (1996). Is developmental dyslexia a disconnection syndrome? Evidence from PET scanning. Brain 119 (Pt 1): 143–157.
Pavol M, Hiscock M, Massman P et al. (2006). Neuropsychological function in adults with von Recklinghausen's neurofibromatosis. Dev Neuropsychol 29: 509–526.
Pugh KR, Shaywitz BA, Shaywitz SE et al. (1996). Cerebral organization of component processes in reading. Brain 119: 1221–1238.
Riccardi VM (1981). Von Recklinghausen neurofibromatosis. N Engl J Med 305: 1617–1627.
Riccardi V, Eichner J (1986). Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore, MD: Johns Hopkins University.
Rourke BP (1989). Nonverbal Learning Disabilities. New York: Guilford Press.
Said SM, Yeh TL, Greenwood RS et al. (1996). MRI morphometric analysis and neuropsychological function in patients with neurofibromatosis. Neuroreport 7: 1941–1944.
Schrimsher GW, Billingsley RL, Slopis JM et al. (2003). Visual-spatial performance deficits in children with neurofibromatosis type-1. Am J Med Genetics Part A 120A: 326–330.
Sevick RJ, Barkovich AJ, Edwards MS et al. (1992). Evolution of white matter lesions in neurofibromatosis type 1: MR findings. AJR Am J Roentgenol 159: 171–175.
Sharif S, Ferner R, Birch JM et al. (2006). Second primary tumors in neurofibromatosis I patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24: 2570–2575.
Shaywitz SE, Shaywitz BA, Pugh KR et al. (1998). Functional disruption in the organization of the brain for reading in dyslexia. Proc Natl Acad Sci USA 95: 2636–2641.
Silva AJ, Frankland PW, Marowit Z et al. (1997). A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 15: 281–284.
Stanovich KE (1988). Explaining the differences between the dyslexic and the garden-variety poor reader: the phonological-core variable-difference model. J Learn Disabil 21: 590–604.
Temple E, Poldrack RA, Protopapas A et al. (2000). Disruption of the neural response to rapid acoustic stimuli in dyslexia: evidence from functional MRI. Proc Natl Acad Sci USA, 97: 13907–13912.
Temple E, Poldrack RA, Salidis J et al. (2001). Disrupted neural responses to phonological and orthographic processing in dyslexic children: an fMRI study. Neuroreport 12: 299–307.
Uhlmann EJ, Gutmann DH (2001). Tumor suppressor gene regulation of cell growth – recent insights into neurofibromatosis 1 and 2 gene function. Cell Biochem Biophys 34: 61–78.
Viskochil D, Buchberg AM, Xu G et al. (1990). Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62: 187–192.
von Deimling A, Krone W, Menon AG (1995). Neurofibromatosis type 1: pathology, clinical features and molecular genetics. Brain Pathol 5: 153–162.
Wadsby M, Lindehammar H, Eeg-Olofsson O (1989). Neurofibromatosis in childhood: neuropsychological aspects. Neurofibromatosis 2: 251–260.
Wallace MR, Marchuk DA, Andersen LB et al. (1990). Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients [published erratum appears in Science 1990 Dec 21; 250(4988): 1749]. Science 249: 181–186.
Zhu Y, Romero MI, Ghosh P et al. (2001). Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15: 859–876.
Zvulunov A, Weitz R, Metzker A (1998). Neurofibromatosis type 1 in childhood: evaluation of clinical and epidemiologic features as predictive factors for severity. Clin Pediatr (Phila) 37: 295–299.

Reference Title: REFERENCES

Reference Type: reference-list

Ahles TA, Saykin A (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19(8): 812–820.
Ahles TA, Tope DM, Furstenberg C, Hann D, Mills L (1996). Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 14: 1457–1462.
Ahles TA, Saykin AJ, Furstenberg CT et al. (2002). Neuropsychologic impact of standard dose systemic chemotherapy in long term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485–493.
Ahles TA, Saykin AJ, Noll WW et al. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12: 612–619.
Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003). Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9: 967–982.
Andrykowski MA, Schmitt FA, Gregg ME, Brady MJ, Lamb DG, Henslee-Downey PJ (1992). Neuropsychologic impairment in adult bone marrow transplant candidates. Cancer 70: 2288–2297.
Andrykowski MA, Carpenter JS, Greiner CB et al. (1997). Energy level and sleep quality following bone marrow transplantation. Bone Marrow Transplant 20: 669–679.
Antonini G, Ceschin V, Morino S et al. (1998). Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology 50: 1441–1445.
Antunes NL, Small TN, George D, Farid B, Lis E (1999). Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 20: 241–243.
Antunes NL, Boulad FL, Prasad V, Rosenblum M, Lis E, Souweidane M (2000). Rolandic encephalopathy and epilepsia partialis continua following bone marrow transplant. Bone Marrow Transplant 26: 917–919.
Armstrong FD (2001). Acute and long term neurodevelopmental outcomes in children following bone marrow transplantation. Front Biosci 6: 6–12.
Armstrong FD (2005). Thalassemia and learning: neurocognitive functioning in children. Ann N Y Acad Sci 1054: 283–289.
Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A (1984). Cyclosporine associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 38: 34–37.
Bartha AI, Foster-Barber A, Miller SP et al. (2004). Neonatal encephalopathy: association of cytokines with MR spectroscopy and outcome. Pediatr Res 56(6): 960–966.
Brown WS, Marsh JT, Wolcott D et al. (1991). Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients. Neuropsychologia 29: 35–45.
Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J (1996). Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 348: 992–996.
Buizer AI, de Sonneville LMJ, Van Den Heuvel-Eibrink MM, Veerman AJP (2005). Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer 45: 281–290.
Buizer AI, de Sonneville LMJ, Van Den Heuvel-Eibrink MM, Veerman AJP (2006). Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. Cancer 106: 2067–2075.
Butler RW, Copeland DR (2002). Attentional processes and their remediation in children treated for cancer: a literature review and the development of a therapeutic approach. J Int Neuropsychol Soc 8: 115–124.
Capuron L, Gumnick JF, Musselman DL, Lawson DH et al. (2002). Neurobehavioral effects of interferon alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26: 643–652.
De Brabander C. Cornelissen J, Smitt, P, Vecht CJ, van den Bent MJ (2000). Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry 68: 36–40.
Espy KA, Moore IM, Kaufmann PM, Kramer JH, Matthay K, Hutter JJ (2001). Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol 26: 1–9.
Faraci M, Lanino E, Dini G et al. (2002). Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology 59: 1895–1904.
Friedman MA (2001). Neuropsychological functioning in hematopoietic stem cell transplantation. Dissertation Abstracts. Houston, TX: University of Houston.
Gallardo D, Ferra C, Berlanga JJ et al. (1996). Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 18: 1135–1139.
Graus F, Saiz A, Sierra J et al. (1996). Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia. Neurology 46: 1004–1009.
Harder H, Cornelissen JJ, Van Gool AR et al. (2002). Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer 95: 183–192.
Harder H, van Gool AR, Cornelissen JJ et al. (2005). Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. Eur J Cancer 41: 1007–1016.
Harder H, Duivenvoorden HJ, van Good AR et al. (2006). Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a one-year follow-up pilot study. J Clin Exp Neuropsychol 28: 283–293.
Hill DE, Ciesielski KT, Hart BL, Jung RE (2004). MRI morphometric and neuropsychological correlates of long-term memory in survivors of childhood leukemia. Pediatr Blood Cancer 42: 611–617.
Jacobsen PB, Garland LL, Booth-Jones M et al. (2004). Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 28: 7–18.
Kaemingk KL, Carey ME, Moore IM, Herzer M, Hutter JJ (2004). Math weaknesses in survivors of acute lymphoblastic leukemia compared to healthy children. Child Neuropsychol 10: 14–23.
Kim S-D, Kim H-S (2005). Effects of a relaxation breathing exercise on fatigue in haemopoietic stem cell transplantation patieints. J Clin Nurs 14: 51–55.
Kingma A, Van Dommelen RI, Mooyaart EL, Wilmink JT, Deelman BG, Kamps WA (2002). No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol-Oncol 24: 106–114.
Krajinovic M, Robaey P, Chiasson S et al. (2005). Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 6: 293–302.
Kramer JH, Crittenden MR, DeSantes K, Cowan MJ (1997). Cognitive and adaptive behavior one and three years following bone marrow transplantation. Bone Marrow Transplant 19: 607–613.
Kronfol Z, Remick DG (2000). Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157: 683–694.
Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W (2002). CNS late-effects after ALL therapy in childhood. Part III: Neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol 38: 320–328.
Lee BN, Dantzer R, Langley KE et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11: 279–292.
Leukemia and Lymphoma Society (2005). Facts 2005. Available online at www.leukemia-lymphoma.org, accessed 4 April 2008.
Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F (2006). Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17(1): 146–150.
Marsh JT, Brown WS, Wolcott D et al. (1991). rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39: 155–163.
Martin-Lester M (1997). Cognitive function in dialysis patients. ANNA J 24: 359–365.
Mennes M, Stiers P, Vandenbussche E et al. (2005). Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr Blood Cancer 44: 478–486.
Metallinos-Katsaras E, Valassi-Adamn E, Dewey KG, Lonnerdal B, Stamoulakatou A, Pollitt E (2004). Effect of iron supplementation on cognition in Greek preschoolers. Eur J Clin Nutri 58: 1532–1542.
Meyers CA (1999). Mood and cognitive disorders in cancer patients receiving cytokine therapy. In Dantzer R (ed.) Cytokines, Stress and Depression. New York: Kluwer Academic/Plenum Publishers.
Meyers CA, Abbruzzese JL (1992). Cognitive functioning in cancer patients: effect of previous treatment. Neurology 42: 434–436.
Meyers CA, Valentine AD (1995). Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 3: 56–68.
Meyers CA, Scheibel RS, Forman AD (1991). Persistent neurotoxicity of systematically administered interferon alpha. Neurology 41: 672–676.
Meyers CA, Weitzner M, Byrne K, Valentine A, Champlin RE, Przepiorka D (1994). Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol 12: 820–826.
Meyers CA, Albitar M, Estey E (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104: 788–793.
Mulhern RK, Butler RW (2004). Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Rehabit 7: 1–14.
Mulhern RK, Ochs J, Fairclough D (1992) Deterioration of intellect among children surviving leukemia: IQ test changes modify estimates of treatment toxicity. J Consult Clin Psychol 60: 477–480.
Mulhern RK, Khan RB, Kaplan S et al. (2004). Short term efficacy of methylphenidate: a randomized double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 22: 4795–4803.
Nissenson AR (1992). Epoetin and cognitive function. Am J Kidney Dis 20: 21–24.
Oeffinger KC, Hudson MM (2004). Long term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 54: 208–236.
Padovan CS, Yousry TA, Schleuning M, Holler E, Kolb H-J, Straube A (1998). Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation. Ann Neurol 43: 627–633.
Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M (1995). Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 45: 947–950.
Peper M, Steinvorth S, Schraube P et al. (2000). Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors. Int J Radiat Oncol Biol Phys 46(2): 303–311.
Phipps S, Dunavant M, Srivastava DK, Bowman L, Mulhern RK (2000). Cognitive and academic functioning in survivors of pediatric bone marrow transplantation. J Clin Oncol 18 (5): 1004–1011.
Recht L, Mrugala M (2003). Neurologic complications of hematologic neoplasms. Neurol Clin 21: 87–105.
Reichenberg A, Yirmiya R, Schuld A et al. (2001). Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58: 445–452.
Richard F, Amouyel P (2001). Genetic susceptibility factors for Alzheimer's disease. Eur J Pharmacol 412: 1–12.
Ries LAG, Eisner MP, Kosary CL et al. (2005). SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER website, 2005.
Rodgers J, Marckus R, Kearns P, Windebuck K (2003). Attentional ability among survivors of leukaemia treated without cranial irradiation. Arch Dis Child 88: 147–150.
Scheibel RS, Valentine AD, O'Brien S, Meyers CA (2004). Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 16: 185–191.
Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R (1997). Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med 102: 21–28.
Shah AK (1999). Cyclosporine A neurotoxicity among bone marrow transplant recipients. Clin Neuropharmacol 22: 67–73.
Singh NP, Sahni V, Wadhwa A et al. (2006). Effect of improvement in anemia on electroneurophysiological markers (P300) of cognitive dysfunction in chronic kidney disease. Hemodial Int 10(3): 267–273. Erratum in Hemodial Int 2006; 10(4): 408.
Snider S, Bashir R, Bierman P (1994). Neurologic complications after high-dose chemotherapy and autologous bone marrow transplantation for Hodgkin's disease. Neurology 44: 681–684.
Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A (2003). Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 60: 842–848.
Spiegler BJ, Kennedy K, Maze R et al. (2006). Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 24: 3858–3864.
Stalfelt AM, Zettervall O (1997). Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon. Leukemia Res 21(8): 775–783.
Stivelman JC (2000). Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 15(3): 29–35.
Temple RM, Deary IJ, Winney RJ (1995). Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Nephrol Dial Transplant 10: 1733–1738.
Uckan D, Cetin M, Yigitkanli I et al. (2005). Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant 35: 71–76.
Velu T, Debusscher L, Stryckmans PA (1985). Cyclosporin-associated fatal convulsions. Lancet Jan 26; 1(8422): 219.
Vezmer S, Becker A, Bode, U, Jaehde U (2003). Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49: 92–104.
Waber DP, Tarbell NJ, Fairclough D et al. (1995). Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 13: 2490–2496.
Waber DP, Shapiro BL, Carpentieri SC et al. (2001). Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia. Cancer 92: 15–22.
Walter T (1994). Effect of iron-deficiency anaemia on cognitive skills in infancy and childhood. Baillieres Clin Haematol 7: 815–827.
Watkins LR (2000). The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 51: 29–57.
Weiskopf RB, Toy P, Hopf HW et al. (2005). Acute isovolemic anemia impairs central processing as determined by P300 latency. Clin Neurophysiol 116: 1028–1032.
Weiskopf RB, Feiner J, Hopf H et al. (2006). Fresh blood and aged stored blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. Anesthesiology 104: 911–920.
Wilson RW, Taliaferro LA, Jacobsen PB (2006). Pilot study of a self-administered stress management and exercise intervention during chemotherapy for cancer. Support Care Cancer 14: 928–935.

Reference Title: REFERENCES

Reference Type: reference-list

Alamowitch S, Graus F, Uchuya M et al. (1997). Limbic encephalitis and small cell lung cancer: clinical and immunological features. Brain 120: 923–928.
Ances BM, Vitaliani R, Taylor RA et al. (2005). Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128: 1764–1777.
Anderson NE, Budde-Steffen C, Rosenblum MK et al. (1988). Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine 67: 100–109.
Antoine JC, Honnorat J, Anterion CT et al. (1995). Limbic encephalitis and immunological perturbations in two patients with thymoma. J Neurol Neurosurg Psychiatry 58: 706–710.
Antoine JC, Absi L, Honnorat J et al. (1999). Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 56: 172–177.
Antunes NL, Khakoo Y, Matthay KK et al. (2000). Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 22: 315–320.
Aydiner A, Gurvit H, Baral I (1998). Paraneoplastic limbic encephalitis with immature ovarian teratoma. J Neuro-oncol 37: 63–66.
Bak TH, Antoun N, Balan KK, Hodges JR (2001). Memory lost, memory regained: neuropsychological findings and neuroimaging in two cases of paraneoplastic limbic encephalitis with radically different outcomes. J Neurol Neurosurg Psychiatry 71: 40–47.
Bakheit AM, Kennedy PG, Behan PO (1990). Paraneoplastic limbic encephalitis: clinicopathologic correlations. J Neurol Neurosurg Psychiatry 53: 1084–1088.
Bataller L, Wade DF, Graus F et al. (2004). Antibodies to Zic4 in paraneoplastic neurological disorders and small cell lung cancer. Neurology 62: 778–782.
Behin A, Delattre JY (2004). Complications of radiation therapy on the brain and spinal cord. Semin Neurol 24(4): 405–417.
Bell BB, Tognoni PG, Bihrle R (1998). Limbic encephalitis as a paraneoplastic manifestation of renal cell carcinoma. J Urol 160: 828.
Benke T, Wagner M, Pallua AK et al. (2004). Long-term cognitive and MRI findings in a patient with paraneoplastic limbic encephalitis. J Neurooncol 66: 217–224.
Bennett JL, Galetta SL, Frohman LP et al. (1999). Neuro-ophthalmologic manifestations of a paraneoplastic syndrome and testicular carcinoma. Neurology 52: 864–867.
Bernal F, Graus F, Pifarre A et al. (2002). Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol 103: 509–515.
Bien CG, Schulze-Bonjage A, Deckert M et al. (2000). Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology 55: 1823–1828.
Blaes F, Fuhlhuber V, Korfei M et al. (2005). Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 58: 313–317.
Bloch MH, Hwang WC, Baehring JM, Chambers SK (2004). Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnestic syndrome. Obstet Gynecol 104: 1174–1177.
Boltshauser E, Deonna T, Hirt HR (1979). Myoclonic encephalopathy of infants, or “dancing eyes syndrome.” Helv Paediatr Acta 34: 119–133.
Brierley JB, Corsellis JA, Hierons R, Nevin S (1960). Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 83: 357–368.
Buckley C, Oger J, Clover L et al. (2001). Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50: 73–78.
Candler PM, Dale RC, Griffin S et al. (2006). Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 77: 507–512.
Chan KH, Vernino S, Lennon VA (2001). ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 50: 301–311.
Connolly AM, Pestronk A, Mehta S et al. (1997). Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 130: 878–884.
Cooper R, Khakoo Y, Matthay KK et al. (2001). Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features. Med Pediatr Oncol 36: 623–629.
Corsellis JA, Goldberg GJ, Norton AR (1968). “Limbic encephalitis” and its association with carcinoma. Brain 91: 481–496.
Dalmau J, Graus F, Rosenblum MK, Posner JB (1992). Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 71: 59–72.
Dalmau J, Graus F, Villarejo A et al. (2004). Clinical analysis of anti-Ma2-associated encephalitis. Brain 127: 1831–1844.
Deodhare S, O'Connor P, Ghazarian D, Bilbao JM (1996). Paraneoplastic limbic encephalitis in Hodgkin disease. Can J Neurol Sci 23: 138–140.
Dirr LY, Elster AD, Donofrio PD, Smith M (1990). Evolution of brain MRI abnormalities in limbic encephalitis. Neurology 40: 1304–1306.
Dorresteijn LD, Kappelle AC, Renier WO, Gijtenbeek JM (2002). Anti-amphiphysin associated limbic encephalitis: a paraneoplastic presentation of small-cell lung carcinoma. J Neurol 249: 1307–1308.
Dropcho EJ (2002). Remote neurologic manifestations of cancer. Neurol Clin 20 (1): 85–122.
Dropcho EJ (2004). Neurotoxicity of cancer chemotherapy. Semin Neurol 24(4): 419–426.
Dropcho EJ (2005). Immunotherapy for paraneoplastic neurological disorders. Expert Opin Biol Ther 5(10): 1339–1348.
Duyckaerts C, Derouesne C, Signoret JL et al. (1985). Bilateral and limited amygdalohippocampal lesions causing a pure amnestic syndrome. Ann Neurol 18: 314–319.
Dyken P, Kolar O (1968). Dancing eyes, dancing feet: infantile polymyoclonus. Brain 91: 305–320.
Fakhoury T, Abou-Khalil B, Kessler RM (1999). Limbic encephalitis and hyperactive foci on PET scan. Seizure 8: 427–430.
Farrugia ME, Conway R, Simpson DJ, Kurian KM (2005). Paraneoplastic limbic encephalitis. Clin Neurol Neurosurg 107: 128–131.
Fauser S, Talazko J, Wagner K et al. (2005). FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis. Acta Neurol Scand 111: 338–343.
Fisher PG, Wechsler DS, Singer HS (1994). Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol 10: 309–312.
Fujii N, Furuta A, Yamaguchi H et al. (2001). Limbic encephalitis associated with recurrent thymoma: a postmortem study. Neurology 57: 344–347.
Gambini C, Conte M, Bernini G et al. (2003). Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 442: 555–462.
Graus F, Keime-Guibert F, Rene R et al. (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124: 1138–1148.
Graus F, Delattre JY, Antoine JC et al. (2004). Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75: 1135–1140.
Gultekin SH, Rosenfeld MR, Voltz R et al. (2000). Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123: 1481–1494.
Hammer MS, Larsen MB, Stack CV (1995). Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol 13: 21–24.
Hart IK, Maddison P, Newsom-Davis J et al. (2002). Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125: 1887–1895.
Hayward K, Jeremy RJ, Jenkins S et al. (2001). Long-term neurobehavioral outcome in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 139: 552–559.
Henson RA, Hoffman HL, Urich H (1965). Encephalomyelitis with carcinoma. Brain 88: 449–464.
Hersh B, Dalmau J, Dangond F et al. (1994). Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 44: 1754–1755.
Hirayama K, Taguchi Y, Sato M, Tsukamoto T (2003). Limbic encephalitis presenting with topographical disorientation and amnesia. J Neurol Neurosurg Psychiatry 74: 110–112.
Hiyama E, Yokoyama T, Ichikawa T et al. (1994). Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer 74: 1821–1826.
Ingenito GG, Berger JR, David NJ, Norenberg MD (1990). Limbic encephalitis associated with thymoma. Neurology 40: 382.
Kaniecki R, Morris JC (1993). Reversible paraneoplastic limbic encephalitis. Neurology 43: 2418–2419.
Kararizou E, Markou I, Zalonis I et al. (2005). Paraneoplastic limbic encephalitis presenting as acute viral encephalitis. J Neurooncology 75: 229–232.
Keime-Guibert F, Graus F, Broet P et al. (1999). Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 53: 1719–1723.
Kinirons P, Fulton A, Keoghan M et al. (2003). Paraneoplastic limbic encephalitis and chorea associated with CRMP-5 neuronal antibody. Neurology 61: 1623–1624.
Kinsbourne M (1962). Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 25: 271–276.
Kleopa KA, Elman LB, Lang B et al. (2006). Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 129: 1570–1584.
Kodama T, Numaguchi Y, Gellad FE et al. (1991). Magnetic resonance imaging of limbic encephalitis. Neuroradiology 33: 520–523.
Kohler J, Hufschmidt A, Hermle L et al. (1988). Limbic encephalitis: two cases. J Neurooncology 20: 177–178.
Konczak J, Schoch B, Dimitrova A et al. (2005). Functional recovery of children and adolescents after cerebellar tumour resection. Brain 128: 1428–1441.
Korfei M, Fuhlhuber V, Schmidt T et al. (2005). Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 170: 150–157.
Kuban KC, Ephros MA, Freeman RL et al. (1983). Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 13: 69–71.
Lacomis D, Khoshbin S., Schick RM (1990). MR imaging of paraneoplastic limbic encephalitis. J Comput Assist Tomogr 14: 115–117.
Landolfi JC, Nadkarni M (2003). Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study. Neurooncology 5: 214–216.
Lawn ND, Westmoreland BF, Kiely MJ et al. (2003). Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 78: 1363–1368.
Lee AC, Ou Y, Lee WK, Wong YC (2003). Paraneoplastic limbic encephalitis masquerading as chronic behavioural disturbance in an adolescent girl. Acta Paediatr 92: 506–509.
Lee EK, Maselli RA, Agius MA (1998). Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 65: 857–862.
Liguori R, Vincent A, Clover L et al. (2001). Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124: 2417–2426.
Linke R, Schroeder M, Helmberger T, Voltz R (2004). Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63: 282–286.
Mihara M, Sugase S, Konaka K et al. (2005). The “pulvinar sign” in a case of paraneoplastic limbic encephalitis associated with non-Hodgkin's lymphoma. J Neurol Neurosurg Psychiatry 76: 882–884.
Mitchell WG, Snodgrass SR (1990). Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 5: 153–158.
Mitchell WG, Davalos Y, Brumm VL et al. (2002). Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 109: 86–98.
Mitchell WG, Brumm VL, Azen CG et al. (2005). Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia. Pediatrics 116: 901–907.
Modrego PJ, Cay A, Pina A, Monge A (2002). Paraneoplastic subacute encephalitis caused by adenocarcinoma of prostate: a case report. Acta Neurol Scand 105: 351–353.
Moe PG, Nellhaus G (1970). Infantile polymyoclonia-opsoclonus syndrome and neural crest tumors. Neurology 20: 756–764.
Mori M, Kuwabara S, Yoshiyama M et al. (2002). Successful immune treatment for non-paraneoplastic limbic encephalitis. J Neurol Sci 201: 85–88.
Na DL, Hahm DS, Park JM, Kim SE (2001). Hypermetabolism of the medial temporal lobe in limbic encephalitis on FDG-PET scan: a case report. Eur Neurol 45: 187–189.
Nokura K, Yamamoto H, Okawara Y et al. (1997). Reversible limbic encephalitis caused by ovarian teratoma. Acta Neurol Scand 95: 367–373.
Ogata M, Kikuchi H, Satou T et al. (2006). Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 193: 68–79.
Okamura H, Oomori N, Uchitomi Y (1997). An acutely confused 15-year-old girl. Lancet 350: 488.
Overeem S, Dalmau J, Bataller L et al. (2004). Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62: 138–140.
Papero PJ, Pranzatelli MR, Margolis LJ et al. (1995). Neurobehavioral and psychological functioning of children with opsoclonus-myoclonus syndrome. Dev Med Child Neurol 37: 915–932.
Parisi MT, Hattner RS, Matthay KK et al. (1993). Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. J Nucl Med 34: 1922–1926.
Pelkofer H, Schubart AS, Hoftberger R et al. (2004). Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalitis in the rat. Brain 127: 1822–1830.
Petit T, Janser JC, Achour NR et al. (1997). Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody. Ann Oncol 8: 919.
Petruzzi MJ, Alarcon PA (1995). Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 127: 328–329.
Pittock SJ, Kryzer TJ, Lennon VA (2004). Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56: 715–719.
Pittock SJ, Lucchinetti CF, Parisi JE et al. (2005). Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58: 96–107.
Plonquet A, Gherardi RK, Creange A et al. (2002). Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol 122: 100–105.
Plonquet A, Garcia-Pons F, Fernandez E et al. (2003). Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol 142: 93–100.
Pohl KR, Pritchard J, Wilson J (1996). Neurologic sequelae of the dancing eye syndrome. Eur J Pediatr 155: 237–244.
Pozo-Rosich P, Clover L, Saiz A et al. (2003). Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 54: 530–533.
Pranzatelli MR, Hyland K, Tate ED et al. (2004a). Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin. J Child Neurol 19: 919–924.
Pranzatelli MR, Travelstead AL, Tate ED et al. (2004b). B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 62: 1526–1532.
Pranzatelli MR, Tate ED, Dukart WS et al. (2005a). Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 147: 372–378.
Pranzatelli MR, Tate ED, Travelstead AL et al. (2005b). Mycophenolate reduces CSF T-cell activation and is a steroid sparer in opsoclonus-myoclonus syndrome (abstract). Ann Neurol 58 [Suppl. 9]: S111.
Pranzatelli MR, Tate ED, Travelstead AL et al. (2005c). Cyclophosphamide therapy in pediatric opsoclonus-myoclonus syndrome [abstract]. Ann Neurol 58 [Suppl. 9]: S90.
Pranzatelli MR, Tate ED, Travelstead AL, Longee D (2005d). Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 115: e115–119.
Provenzale JM, Barboriak DP, Coleman RE (1998). Limbic encephalitis: comparison of FDG PET and MR imaging findings. AJR Am J Roentgenol 170: 1659–1660.
Ravizza SM, McCormick CA, Schlerf JE et al. (2006). Cerebellar damage produces selective deficits in verbal working memory. Brain 129: 306–320.
Rickman OB, Parisi JE, Yu Z et al. (2000). Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 75: 1321–1326.
Ridley A, Kennard C, Scholtz CL et al. (1987). Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 110: 1699–1709.
Roberts WK, Darnell RB (2004). Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 16: 616–622.
Rojas I, Graus F, Keime-Guibert F et al. (2000). Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55: 713–715.
Ronning C, Sundet K, Due-Tonnessen B et al. (2005). Persistent cognitive dysfunction secondary to cerebellar injury in patients treated for posterior fossa tumors in childhood. Pediatr Neurosurg 41: 15–21.
Rosenbaum T, Gartner J, Korholz D et al. (1998). Paraneoplastic limbic encephalitis in two teenage girls. Neuropediatrics 29: 159–162.
Rosenfeld MR, Eichen JG, Wade DF et al. (2001). Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50: 339–348.
Rostasy K, Behnisch W, Kulozik A et al. (2005). High-dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome [abstract]. Ann Neurol 58 [Suppl. 9]: S109.
Rousseau A, Benyahia B, Dalmau J et al. (2005). T-cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncology 71: 231–236.
Rudnick E, Khakoo Y, Antunes NL et al. (2001). Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies: a report from the Children's Cancer Group. Med Pediatr Oncol 36: 612–622.
Russo C, Cohn SL, Petruzzi MJ, Alarcon PA (1997). Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 29: 284–288.
Sahashi K, Sakai K, Mano K, Hirose G (2003). Anti-Ma2 antibody related paraneoplastic limbic/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry 74: 1332–1335.
Scheid R, Voltz R, Guthke T et al. (2003). Neuropsychiatric findings in anti-Ma2-positive paraneoplastic limbic encephalitis. Neurology 61: 1159–1160.
Scheid R, Honnorat J, Delmont E et al. (2004a). A new anti-neuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry 75: 338–340.
Scheid R, Lincke T, Voltz R et al. (2004b). Serial FDG positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 61: 1785–1789.
Shapiro B, Shulkin BL, Hutchinson RJ et al. (1994). Locating neuroblastoma in the opsoclonus-myoclonus syndrome. J Nucl Biol Med 38: 545–555.
Sheth RD, Horwitz SJ, Aronoff S et al. (1995). Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 10: 297–299.
Sillevis Smitt P, Grefkens J, de Leeuw B et al. (2002). Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 249: 745–753.
Solomon GE, Chutorian AM (1968). Opsoclonus and occult neuroblastoma. N Engl J Med 279: 475–477.
Stern RC, Hulette CM (1999). Paraneoplastic limbic encephalitis associated with small cell carcinoma of the prostate. Mod Pathol 12: 814–818.
Sutton I, Winer J, Rowlands D, Dalmau J (2000). Limbic encephalitis and antibodies to Ma2: a paraneoplastic presentation of breast cancer. J Neurol Neurosurg Psychiatry 69: 266–268.
Sutton RC, Lipper MH, Brashear HR (1993). Limbic encephalitis occurring in association with Alzheimer's disease. J Neurol Neurosurg Psychiatry 56: 808–811.
Tabarki B, Palmer P, Lebon P, Sebire G (1998). Spontaneous recovery of opsoclonus-myoclonus syndrome caused by enterovirus infection. J Neurol Neurosurg Psychiatry 64: 406–422.
Tattevin P, Schortgen F, Broucker T et al. (2001). Varicella-zoster virus limbic encephalitis in an immunocompromised patient. Scand J Infect Dis 33: 786–788.
Taylor RB, Mason W, Kong K, Wennberg R (1999). Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma. Can J Neurol Sci 26: 317–320.
Telander RL, Smithson WA, Groover RV (1989). Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg 24: 11–14.
Tersak JM, Safier RA, Schor NF (2005). Rituximab in the treatment of refractory neuroblastoma-associated opsoclonus-myoclonus syndrome [abstract]. Ann Neurol 58 [Suppl. 9]: S111.
Thieben MJ, Lennon VA, Boeve BF et al. (2004). Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62: 1177–1182.
Thuerl C, Muller K, Laubenberger J et al. (2003). MR imaging of autopsy-proven paraneoplastic limbic encephalitis in non-Hodgkin lymphoma. AJNR Am J Neuroradiol 24: 507–510.
Tomimitsu H, Arimura K, Nagado T et al. (2004). Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 56: 440–444.
Tsukamoto T, Mochizuki R, Mochizuki H et al. (1993). Paraneoplastic cerebellar degeneration and limbic encephalitis in a patient with adenocarcinoma of the colon. J Neurol Neurosurg Psychiatry 56: 713–716.
Veneselli E, Conte M, Biancheri R et al. (1998). Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol 30: 15–17.
Vernino S, Lennon VA (2000). New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 47: 297–305.
Vernino S, Lennon VA (2004). Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 10: 7270–7275.
Vernino S, Eggenberger ER, Rogers LR, Lennon VA (2002). Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma. Neurology 59: 929–932.
Vincent A, Buckley C, Schott J et al. (2004). Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127: 701–712.
Vitaliani R, Mason W, Ances B et al. (2005). Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 58: 594–604.
Voltz RD, Gultekin HS, Rosenfeld MR et al. (1999). A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. New Engl J Med 340: 1788–1795.
Wainwright MS, Martin PL, Morse RP et al. (2001). Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 50: 612–619.
Waragi M, Chiba A, Uchibori A et al. (2006). Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry 77: 111–113.
Wingerchuk DM, Noseworthy JH, Kimmel DW (1998). Paraneoplastic encephalomyelitis and seminoma: importance of testicular ultrasonography. Neurology 51: 1504–1507.
Wong AM, Musallam S, Tomlinson RD et al. (2001). Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189: 71–81.
Yiu VW, Kovithavongs T, McGonigle LF, Ferreira P (2001). Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 24: 72–74.
Younes-Mhenni S, Janier MF, Cinotti L et al. (2004). FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127: 2331–2338.
Yu Z, Kryzer TJ, Griesmann GE et al. (2001). CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49: 146–154.
Ziter FA, Bray PF, Cancilla PA (1979). Neuropathologic findings in a patient with neuroblastoma and myoclonic encephalopathy. Arch Neurol 36: 51.

Reference Title: REFERENCES

Reference Type: reference-list

Ahles TA, Saykin AJ (2002). Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3 [Suppl. 3]: S84–S90.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn. Text Revision edn. Washington, DC: American Psychiatric Association.
Anthony JC, LeResche L, Niaz U et al. (1982). Limits of the mini-mental state as a screening test for dementia and delirium among hospital patients. Psychol Med 12(2): 397–408.
Ballon JS, Feifel MD (2006). A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 67(4): 554–566.
Boutros NN, Struve F (2002). Electrophysiological assessment of neuropsychiatric disorders. Sem Clin Neuropsychiatry 7(1): 30–41.
Breitbart W, Cohen KR (1998). Delirium. In Holland JC (ed.) Psycho-oncology (pp. 564–573). New York: Oxford University Press.
Breitbart W, Marotta R, Platt MM et al. (1996). A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153(2): 231–237.
Breitbart W, Rosenfeld B, Roth A et al. (1997). The memorial delirium assessment scale. J Pain Symptom Manage 13(3): 128–137.
Breitbart W, Gibson C, Tremblay A (2002). The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/ caregivers, and their nurses. Psychosomatics 43: 183–194.
Brown TM (2000). Drug-induced delirium. Sem Clin Neuropsychiatry 5(2): 113–124.
Bruera E, MacMillan K, Hanson J, MacDonald RN (1989). The Edmonton staging system for cancer pain: preliminary report. Pain 37: 203–209.
Bruera E, Miller MJ, Macmillan K, Kuehn N (1992a). Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48(2): 163–166.
Bruera E, Fainsinger R, MacEachern T, Hanson J (1992b). The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 50(1): 75–77.
Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J (1992c). Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 7: 192–195.
Bruera E, Driver L, Barnes EA et al. (2003a). Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21(23): 4439–4443.
Bruera E, Strasser F, Shen L et al. (2003b). The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 26(5): 1049–1054.
Bruera E, Valero V, Driver L et al. (2006). Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24(13): 2073–2078.
Capuron L, Hauser P, Hinze-Selch D et al. (2002). Treatment of cytokine-induced depression. Brain Behav Immunol 16(5): 575–580.
Caraceni A, Nanni O, Maltoni M et al. (2000). Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 89(5): 1145–1149.
Carter GL, Dawson AH, Lopert R (1996). Drug-induced delirium. Incidence, management and prevention. Drug Safety 15(4): 291–301.
Cassem NH, Murray GB, Lafayette JM, Stern TA (2004). Delirious patients. In Stern T (ed.) Massachusetts General Hospital Handbook of General Hospital Psychiatry (5th edn.). Philadelphia, PA: Mosby.
Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994). Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12(3): 627–642.
Del Fabbro E, Dalal S, Bruera E (2006a). Symptom control in palliative care – Part III: Dyspnea. Dyspnea and delirium. J Palliat Med 9(2): 422–436.
Del Fabbro E, Dalal S, Bruera E (2006b). Symptom control in palliative care – Part II: Cachexia/anorexia and fatigue. J Palliat Med 9(2): 409–421.
Derogatis LR, Morrow GR, Fetting J (1983). The prevalence of psychiatric disorders among cancer patients. J Am Med Assoc 249: 751–757.
Dobie DJ (2002). Depression, dementia, and pseudodementia. Semin Clin Neuropsychiatry 7(3): 170–186.
Fadul N, Kaur G, Zhang T, Palmer JL, Bruera E (2007). Evaluation of the Memorial Delirium Assessment Scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals. Support Cancer Care 15(11): 1271–1276.
Fann JR, Roth-Roemer S, Burington BE et al. (2002). Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 95(9): 1971–1981.
Folstein MF, Folstein SE, McHugh PR (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189–198.
Franco K, Litaker D, Locala J, Bronson D (2001). The cost of delirium in the surgical patient. Psychosomatics 42(1): 68–73.
Gagnon B, Allard P, Masse B, DeSerres M (2000). Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 19: 412–426.
Gagnon B, Low G, Schreier G (2005). Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 30(2): 100–107.
Gaudreau JD, Gagnon P, Roy MA et al. (2005). Association between psychoactive medications and delirium in hospitalized patients: a critical review. Psychosomatics 46(4): 302–316.
Homsi J, Walsh D, Nelson KA (2000). Psychostimulants in supportive care. Support Care Cancer 8(5): 385–397.
Inouye SK (1998). Delirium in hospitalized older patients: recognition and risk factors. J Geriatric Psychiatry Neurol 11(3): 118–125.
Inouye SK (2000). Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 32(4): 257–263.
Inouye SK, van Dyck CH, Alessi CA et al. (1990). Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Int Med 113(12): 941–948.
Kelly KG, Zisselman M, Cutillo-Schmitter T et al. (2001). Severity and course of delirium in medically hospitalized nursing facility residents. Am J Geriatric Psychiatry 9(1): 72–77.
Lawlor PG (2002). The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer 94(6): 1836–1853.
Lawlor PG, Gagnon B, Mancini IL et al. (2000a). Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Int Med 160(6): 786–794.
Lawlor PG, Gagnon B, Mancini IL et al. (2000b). Delirium as a predictor of survival in older patients with advanced cancer. Arch Int Med 160: 2866–2868.
Leslie DL, Zhang Y, Holford TR et al. (2005). Premature death associated with delirium at 1-year follow-up. Arch Intern Med 165(14): 1657–1662.
Lipowski ZJ (1990). Delirium: Acute Confusional States. New York: Oxford University Press.
Ljubisavljevic V, Kelly B (2003). Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 25(5): 345–352.
Marcantonio ER, Juarez G, Goldman L et al. (1994). The relationship of postoperative delirium with psychoactive medications. J Am Med Assoc 272(19): 1518–1522.
Massie MJ, Holland J, Glass E (1983). Delirium in terminally ill cancer patients. Am J Psychiatry 140(8): 1048–1050.
Mayo-Smith MF, Mayo-Smith MF (1997). Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. J Am Med Assoc 278(2): 144–151.
Mazzocato C, Stiefel F, Buclin T, Berney A (2000). Psychopharmacology in supportive care of cancer: a review for the clinician: II Neuroleptics. Support Care Cancer (8)2: 89–97.
Mercadante S, Bruera E (2006). Opioid switching: a systematic and critical review. Cancer Treat Rev 32: 304–315.
Meyers CA, Valentine AD (1995). Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 3: 56–68.
Morita T, Otani H, Tsunoda J et al. (2000). Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 8(2): 134–137.
New P (2001). Radiation injury to the nervous system. Curr Opinion Neurol 14(6): 725–734.
O'Keeffe ST, Lavan JN (1999). Clinical significance of delirium subtypes in older people. Age Ageing 28(2): 115–119.
Olin J, Masand P (1996). Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 37(1): 57–62.
Pereira J, Bruera E (2001). Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants. J Palliat Med 4(1): 15–21.
Platt MM, Breitbart W, Smith M et al. (1994). Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci 6(1): 66–67.
Prieto JM, Blanch J, Atala J et al. (2002). Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 20(7): 1907–1917.
Raison CL, Demetrashvili M, Capuron L, Miller AH (2005). Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19(2): 105–123.
Reifler BV (2000). A case of mistaken identity: pseudodementia is really predementia. J Am Geriatr Soc 48(5): 593–594.
Reischies FM, Neu P (2000). Comorbidity of mild cognitive disorder and depression – a neuropsychological analysis. Eur Arch Psychiatry Clin Neurosci 250(4): 186–193.
Ross CA, Peyser CE, Shapiro I, Folstein MF (1991). Delirium: phenomenologic and etiologic subtypes. Int Psychogeriatr 3(2): 135–147.
Rozans M, Dreisbach A, Lertora JJ, Kahn MJ (2002). Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 20(1): 335–339.
Sarhill N, Walsh D, Nelson KA et al. (2001). Assessment of delirium in advanced cancer: the use of the bedside confusion scale. Am J Hospice Palliat Care 18: 335–341.
Schagen SB, Muller MJ, Boogerd W (2002). Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 9(13): 1387–1397.
Sood A, Barton DL, Loprinzi CL (2006). Use of methylphenidate in patients with cancer. Am J Hospice Palliat Care 23(1): 35–40.
Trzepacz PT (1994). A review of delirium assessment instruments. Gen Hosp Psychiatry 16(6): 397–405.
Trzepacz PT (1996). Delirium. Advances in diagnosis, pathophysiology, and treatment. Psychiatrics Clin North Am 19(3): 429–448.
Trzepacz PT, Baker RW, Greenhouse J (1988). A symptom rating scale for delirium. Psychiat Res 23(1): 89–97.
Tune LE, Damlouji NF, Holland A et al. (1981). Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet 2(8248): 651–653.
Valentine AD, Bickham JG (2005). Delirium and substance withdrawal. In Shaw A (ed.) Acute Care of the Cancer Patient (pp. 545–557). New York: Marcel Dekker.
Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003). Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15): 1549–1563.
Visser PJ, Verhey FR, Ponds RW et al. (2000). Distinction between preclinical Alzheimer's disease and depression. J Am Geriatr Soc 48(5): 479–484.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11): 2292–2299.

Reference Title: REFERENCES

Reference Type: reference-list

Alkon DL, Amaral DG, Bear MF et al. (1991). Learning and memory. Brain Res Rev 16: 193–220.
Anisman H, Zacharko RM (1982). Depression: the predisposing influence of stress. Behav Brain Sci 5: 89–137.
Ayada K, Tadano T, Endo Y (2002). Gnawing behavior of a mouse in a narrow cylinder: a simple system for the study of muscle activity, fatigue, and stress. Physiol Behav 77: 161–166.
Blanchard RJ, Yudko E, Dulloog L, Blanchard DC (2001). Defense changes in stress nonresponsive subordinate males in a visible burrow system. Physiol Behav 72: 635–642.
Blanchard DC, Griebel G, Blanchard RJ (2003). The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463: 97–116.
Borsini F, Meli A (1988). Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94: 147–160.
Carroll BJ (1978). Neuroendocrine function in psychiatric disorders. In Psychopharmacology: A Generation of Progress (pp. 487–497). New York: Raven Press.
Chance W, Von Meyenfeldt M, Fischer J (1983). Changes in brain amines associated with cancer anorexia. Neurosci Biobehav Rev 7: 471–479.
Chance WT, Cao L, Nelson JL, Foley-Nelson T, Fischer JE (1988). Reversal of neurochemical aberrations after tumor resection in rats. Am J Surg 155: 124–129.
Chao CC, DeLaHunt M, Hu S, Close K, Peterson PK (1992). Immunologically mediated fatigue: a murine model. Clin Immunol Immunopathol 64: 161–165.
Chermat R, Thierry B, Steru L, Simon P (1986). Adaptation of the tail suspension test to the rat. J Pharmacol 17: 348–350.
Chuluyan HC, Wolcott RM, Chervenak R, Dunn AJ (2000). Catecholamine, indoleamine and corticosteroid responses in mice bearing tumors. Neuroimmunomodulation 8: 107–113.
Crawley JN (2000). What's Wrong with My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice (pp. 1–368). Wilmington, DE: Wiley-Liss.
Cryan JF, Mombereau C (2004). In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9: 1050–1062.
Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238–245.
Dalakas MC, Mock V, Hawkins MJ (1998). Fatigue: definitions, mechanisms, and paradigms for study. Semin Oncol 25: S48–S53.
Davis JM, Weaver JA, Kohut ML, Colbert LH, Ghaffar A, Mayer EP (1997). Immune system activation and fatigue during treadmill running: role of interferon. Med Sci Sports Exerc 30: 863–868.
Dunn AJ, Berridge CW (1990). Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 15: 71–100.
Dunn AJ, Swiergiel AH (2004). Interferon effects on behavior, corticosterone, catecholamines and indoleamines in mice and rats. Neuropsychopharmacology 29[Suppl. 1]: S120.
Dunn AJ, Swiergiel AH (2005). Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 81: 688–693.
Dunn AJ, Swiergiel AH, Cork R, Newman RA (2004). Behavior, neurochemical and endocrine responses to leukemia in mice. In 2004 Abstract Viewer/Itinerary Planner (Vol. 462.13). Washington DC: Society for Neuroscience.
Dunn AL, Crnic LS (1993). Repeated injections of interferon-α A/D in Balb/c mice: behavioral effects. Brain Behav Immun 7: 104–111.
Geller A, Robustelli F, Jarvik ME (1970). Incubation and the Kamin effect. J Exp Psychol 85: 61–65.
Glaus A, Crow R, Hammond S (1996). A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4: 82–96.
Haug M, Whalen RE (1999). Animal Models of Human Emotion and Cognition (p. 341). Washington DC: American Psychological Association.
Katz RJ (1981). Animal models and human depressive disorders. Neurosci Biobehav Rev 5: 231–246.
Kaur G, Kulkarni SK (2000). Comparative study of antidepressants and herbal psychotropic drugs in a mouse model of chronic fatigue. J Chronic Fatigue Syndr 6: 23–34.
Kelly JP, Wrynn AS, Leonard BE (1997). The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74: 299–316.
Kent S, Bluthé R-M, Kelley KW, Dantzer R (1992). Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13: 24–28.
Maier SF, Seligman MEP (1976). Learned helplessness: theory and evidence. J Exp Psychol 1: 3–46.
Matthews K, Christmas D, Swan J, Sorrell E (2005). Animal models of depression: navigating through the clinical fog. Neurosci Biobehav Rev 29: 503–513.
McKinney WT, Bunney WE (1969). Animal models of depression. Arch Gen Psychiatry 21: 240–248.
Morris R (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.
Olton DS (1987). The radial arm maze as a tool in behavioral pharmacology. Physiol Behav 40: 793–797.
Ottenweller JE, Natelson BH, Gause WC et al. (1998). Mouse running activity is lowered by Brucella abortus treatment: a potential model to study chronic fatigue. Physiol Behav 63: 795–801.
Overmier JB, Seligman MEP (1967). Effects of inescapable shock on subsequent escape and avoidance responding. J Comp Physiol Psychol 63: 28–33.
Porsolt RD (2000). Animal models of depression: utility for transgenic research. Rev Neurosci 11: 53–58.
Porsolt RD, Bertin A, Jalfre M (1977a). Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn 229: 327–336.
Porsolt RD, Le Pichon M, Jalfre M (1977b). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730–732.
Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379–391.
Sachar EJ (1967). Corticosteroids in depressive illness: II. A longitudinal psychoendocrine study. Arch Gen Psychiatry 17: 554–567.
Sandman CA, Beckwith BE, Gittis MM (1974). Melanocyte-stimulating hormone (MSH) and overtraining effects on extradimensional shift (EDS) learning. Physiol Behav 13: 1631–1666.
Sandman CA, George JM, Nolan JD, van Riezen H, Kastin AJ (1975). Enhancement of attention in man with ACTH/MSH4–10. Physiol Behav 15: 427–431.
Schimanski LA, Nguyen PV (2004). Multidis